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Abstract 
 
 
Parkinson’s disease is an age related progressive neurodegenerative disorder 
affecting ~2% of the population over the age of 65. The aetiology of Parkinson’s 
disease is not fully understood and treatment limited. Hence, the goal of ongoing 
research is to understand and target the mechanisms underlying the disease process to 
halt or slow down its progression. Parkinson’s disease is pathologically characterised by 
the loss of dopaminergic neurons in the substantial nigra that leads to the loss of 
innervation to the striatum, subsequently leading to the motor complications observed in 
Parkinson’s sufferers. 
Recent clinical and experimental evidence suggests that inflammation, 
characterised by over activation of the brain’s resident immune cells such as 
microglia/macrophages, play a detrimental role in Parkinson’s pathology. This project, 
for the first time aims to explore the time course of microglial activation in association 
with dopaminergic neuronal cell death in the substantia nigra utilising the 6-hydroxy 
dopamine rat model of Parkinson’s. The dynamics of morphological, 
immunophenotypic and phagocytic properties of activated microglia in the substantia 
nigra was assessed immunohistochemically.  In addition we explored the cellular events 
between activated microglia and degenerating neurons in this model that had not been 
previously well defined.  The role of matrix metalloproteinases as signalling molecules 
that activate microglia were also studied. Finally the significance of local microglial 
activation in the substantia nigra was elucidated by modulation of the microglial 
response via activation of the gamma subtype of peroxisome proliferator activated 
receptors. This project provided evidence that microglial activation preceded 
dopaminergic neuronal cell death in the substantia nigra and inhibition of microglial 
response serves as a neuroprotective strategy in Parkinson’s disease.  
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1.1 Parkinson’s disease  
 
A textbook definition of PD is given as ‘ a progressive neurodegenerative disorder 
characterised by the clinical symptoms of muscle rigidity, resting tremor and bradykinesia 
due to the depletion of dopamine (DA) in the corpus striatum as a result of the degeneration 
of DA neurons in the Substantia Nigra Pars Compacta (SNc) (Zigmond et al., 1999). The 
clinical features of Parkinson’s disease (PD) were first described in 1817 by Dr. James 
Parkinson in an essay entitled, ‘An Essay of the Shaking Palsy’. The definition of PD given 
by James Parkinson’s described the disease as: 
 ‘‘Involuntary tremulous motion, with lessened muscular power, in parts not in action and 
even when supported; with a propensity to bend the trunk forwards, and to pass from a 
walking to a running pace: the senses and intellects being uninjured. ‘’ 
It was not until 1953 that the principal brain lesion in PD was identified as 
degeneration of DA neurons in the SNc (Greenfield and Bosanquet, 1953).  The 
biochemical and pharmacological understanding of the disease began in the 1960s. Ehringer 
and Hornykiewicz (1961) documented the dramatic loss of dopamine in the striatum of 
brains from patients dying with post-encephalitic and idiopathic Parkinson's disease.  Ever 
since its initial description by James Parkinson the aetiological mechanisms underlying the 
selective destruction of the nigrostriatal dopaminergic pathway have remained unknown 
(Langston 2002; Di Monte and Lawler 2001). Currently, clinical diagnosis of PD is based 
on movement-related behavioural abnormalities (Rao et al., 2003; Sethi, 2002). However, 
the absence of distinct biomarkers for the presymptomatic diagnosis of the disease, because 
of the lack of clear understanding of the disease process, has significantly hampered efforts 
to identify and treat PD patients early in the disease course. Therefore, the goal of ongoing 
research in this field is to identify the underlying mechanisms involved in the pathogenesis 
of PD to be able to stop or slow down its progression. Current pharmacological treatment of 
PD is focussed on DA replacement therapy, which aims to either replace the lost DA in the 
striatum or mimic the action of DA by the use of selective DA receptor agonists.  These 
strategies provide long-term symptomatic control of the cardinal motor features of PD and 
the use of these drugs significantly improves the motor function of PD patients and 
improves patient quality of life (Lang and Obeso, 2005). However, the long term use of 
  
 14
these drugs is associated with severe side effects that signifies the need for new therapeutic 
interventions that act as neuroprotective or neurorestoretive agents. 
1.2 Neuropathological features of idiopathic PD 
PD is characterised neuropathologically by the progressive and profound loss of 
neuromelanin containing dopaminergic neurons in the SNc with presence of eosinophillic, 
intracytoplasmic, proteinaceous inclusions termed as Lewy bodies (LB) and dystrophic 
Lewy neurites in surviving neurons throughout the central and autonomic nervous systems 
(Forno et al., 1996; Gelb et al., 1999) (Fig 1.1). Lewy bodies were first described by 
Friederich H. Lewy in the nucleus basalis of Meynert and the dorsal vagal nucleus in 
patients with PD (Lewy, 1912) and were named Lewy bodies in his honour. 
Morphologically LBs are classified to two types: The classical brainstem type and the 
cortical type. The classical type is intracytoplasmic, single or multiple, eosinophillic masses 
that are spherical or elongated, possessing a dense core and a peripheral halo. The cortical 
type is eosinophillic, irregular in shape, often without a conspicuous halo or central core 
(Takahashi and Wakabayashi, 2001). LBs are composed of several proteins, including 
ubiquitin, α-synuclein (Spillantini et al., 1997) and other ubiquitin-like proteins, such as 
torsinA (Wakabayashi et al., 2000; McNaught, et al, 2004). In PD, LB are found in many 
regions of the nervous system, including the substantia nigra, locus coeruleus, 
hypothalamus, nucleus basalis, cranial nerve motor nuclei, and the central and peripheral 
divisions of the autonomic nervous system (Iwanaga  et al., 1999). In addition, it has been 
reported that LB inclusions may form in glial cells, known as glial cell inclusions (GCI) that 
were found in the midbrain of PD patients and were immunoreactive for α-synuclein 
(Wakabayashi, et a., 1998). The precise role of LB in PD pathology is not fully known, 
however recent evidence suggest that  LB formation could be a cytoprotective phenomenon 
(Olanow et al., 2004). This hypothesis is based on studies showing LBs are made in a very 
similar way to aggrosomes (Kopito, 2000; McNaught et al., 2002). Aggresomes are 
proteinaceous inclusions formed at the centrosome that segregate and facilitate the 
degradation of excess amounts of damaged, mutated and cytotoxic proteins. These findings 
suggest that LBs could be cytoprotective by accumulating the damaging and toxic 
misfolded and mutant proteins. However, this could be a double edged sword, if LB 
formation represents a response to degrade the toxic proteins; the numbers of LBs continue 
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to increase as long as the host cells produce toxic proteins. Increase in LBs or their over-
load could on its own be cytotoxic and lead to further cell death.  
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Fig 1.1 Neuropathological features of Parkinson’s disease 
A: Substantia nigra from a control case, note the darkened, pigmented nuclei (black arrows). 
B: Substantia nigra from a PD case, note the substantia nigra has lost its pigmentation, 
indicative of nigral cell loss. C: Histological section from the substantia nigra of a PD case, 
illustrating a dopaminergic neurone containing Lewy Bodies (black arrows). Images kindly 
provided by UK PDS Tissue Bank, Hammersmith Hospital, Imperial College, London. 
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1.2.1 Dopaminergic neuropathology in PD 
The most prominent and consistent pathology in PD is the loss of the dopaminergic 
neurons in the SNc. The regional loss of SNc dopaminergic neurons results in the decrease 
of striatal dopamine concentrations in a regional pattern. Within the midbrain, three 
dopaminergic cell groups exist: the A8 group (retrorubral area) in the lateral reticular 
formation, the A9 group in the SNc and the A10 group in the ventral tegmental area 
(Pearson et al., 1983). The (A9) SNc neurons send projections along the medial forebrain 
bundle (MFB) to the putamen and caudate nucleus of the striatum to influence the basal 
ganglia pathway (Pollak et al., 2001). The striatum itself is divided into dorsal (caudate 
nucleus and the putamen) and ventral (nucleus accumbens). The dorsal and ventral parts of 
the striatum are segregated anatomically by the internal capsule. The pattern of SNc cell 
loss appears to correspond to the level of expression of the DA transporter (DAT) (Uhl et al., 
1994) and is consistent with the finding that depletion of dopamine is most pronounced in 
the dorsolateral putamen the main site of projection for these neurons (Bernheimer et al., 
1973). Within the SNc itself, cell loss follows a specific pattern, affecting ventral in 
preference to dorsal SNc cells (Damier et al., 1999). The cause of this brain regional 
vulnerability has remained unclear. However, a recent micro array study of PD and control 
brains indicated increased expression of genes encoding pro-inflammatory cytokines and 
subunits of the mitochondrial electron transport chain and decreased expression of several 
glutathione-related genes in the more vulnerable lateral tier region of the SN (Duke et al., 
2006). These factors have implicated in the pathogenesis of PD (see section 1.4). The onset 
of parkinsonian symptoms occurs when ~60% of putamenal dopamine is depleted and 
~80% of dopaminergic neurons in the SNc are lost. However, the adjacent mesolimblic 
dopaminergic neurons, with their cell bodies residing in the ventral tegmental area (VTA), 
are much less affected in PD. This is mirrored in significantly less depletion of dopamine in 
the caudate that is the main site of projection for these neurons (Price et al., 1978). It is not 
yet clear why the dopaminergic neurons in the VTA are less susceptible to degeneration in 
PD. Recent evidence suggests that genes potentially related to ‘neuroprotection’ are higher 
in VTA dopamine neurons, including four neuropeptide-related genes, and the calcium 
binding protein, calbindin. In fact, profiling experiments have confirmed that neuropeptide 
genes [e.g. Calcitonin gene related peptide (CGRP), Gastrin releasing peptitide (GRP) and 
Pituitary adenylate cyclase activating peptide (PACAP)] are more highly expressed in VTA 
dopamine neurons than in those from the SN (Chung et al., 2005; Greene et al., 2005) 
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.These findings potentially provides an explanation for why SN dopaminergic neurons are 
more susceptible to damaging factors that leads to their degeneration in PD.  
1.2.2 Non-dopaminergic neuropathology in PD 
 
The progressive degeneration of dopaminergic neurons in the SNc is the 
predominant pathologic feature of PD that leads to motor symptoms and diagnosis of this 
disease. Previously it was thought that the neuropathology of PD was solely confined to the 
lesions in the dopaminergic neurons of the SNc. However, evidence suggests that there is 
also non-dopaminergic pathology in PD. Indeed, neuronal cell loss in PD affects other 
neurotransmitter systems both in the periphery and the brain (Gerlach and Riederer, 1999; 
Goldstein et al., 2001, 2002). In the brain, the neurodegenerative process affects the 
noradrenergic system in the locus coeruleus (LC) with presence of LBs (Jellinger et al., 
1987), the serotonergic Raphe nuclei and the cholinergic nucleus basalis Meynert 
(Whitehouse et al., 1983). In addition, damage occurs to gamma aminobutyric acid 
(GABA)-ergic and peptidergic neurons in the cerebellum (Halliday et al., 1990). Another 
brain area which is affected in PD even before the symptoms of the disease manifest is the 
loss of neurons in the olfactory bulb and the anterior olfactory nucleus that could give rise 
to the disturbances in the sense of smell, which are a very common feature of idiopathic PD 
(Braak et al., 2003; 2004).  
It seems likely that Parkinson’s disease is not a single disease but a number of 
phenotypically similar illnesses. A variable range of genetic and environmental interactions 
may produce these conditions and it may be that any individual risk factor will only affect 
susceptible subjects.  
1.3 Current pharmacological treatments for PD and their limitations 
 
Current pharmacological treatment of PD is focussed on DA replacement therapy, 
which aims to either replace the lost DA in the striatum or mimic the action of DA by the 
use of selective DA receptor agonists.  These strategies provide relatively long-term 
symptomatic control of the cardinal motor features of PD and the use of these drugs 
significantly improves the motor function of PD patients, lowers morbidity and mortality 
and improves the patients quality of life ( Karlson et al., 2000; Rajput, 2005; Lang and 
Obeso, 2005).  
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One of most frequently used drugs for symptomatic control of PD is Levadopa (L-
DOPA). L-DOPA is DA precursor that provides effective relief of bradykinesia and rigidity 
(Yahr et al., 1968) of PD by replacing lost DA in the putamen (Agnati and Fuxe, 1980). 
However, prolonged L-DOPA treatment results in development of L-DOPA induced 
dyskinesias (LIDs), which are disabling involuntary movements (Brotchie et al., 2005). 
These complications occur in 90% of PD patients receiving L-DOPA, usually with 5-10 
years of the initiation of L-DOPA treatment (Ahlskog and Muenter, 2001).  
Alternative to L-DOPA is the use of DA D2 receptor agonists such as, pramipexole, 
which are effective at managing the motor symptoms of PD either as a monotherapy or as 
an adjunct to L-DOPA use, which allows lower doses of L-DOPA be to administered 
(Kondo, 2002). As a monotherapy, DA receptor agonists provide effective relief of motor 
symptoms over a prolonged period of time, thus delaying the need for L-DOPA therapy and 
onset of motor complications (Holloway et al., 2004). However, DA agonists are associated 
with side effects, which are also common to L-DOPA, including cognitive disturbances, 
hallucinations, confusion episodes, sleepiness and potentially oedema (Nutt et al., 2000). 
Another group of drugs which are prescribed in PD are Monoamine Oxidase inhibitors 
such as: rasagiline that also provide symptomatic relief of PD (Rabey et al., 2000). However, 
similar to DA agonists, patients will eventually require L-DOPA supplementation (Schapira, 
et al, 2006). 
Taken together, dopamine replacement therapy in PD provides a relatively long period 
of symptomatic control of PD which improves the  patients quality of life. However, long 
term use of these drugs is associated with severe motor complications. Importantly all 
current PD treatments are symptomatic in nature and do not halt the relentless progression 
of neurodegeneration in PD. Therefore, development of neuroprotective therapy for PD is 
one of the most important goals of research in this field. 
 
1.4 Epidemiology of PD 
Epidemiological studies suggest that the prevalence of idiopathic PD is estimated at 
0.3% of the general population and 1-2% of people aged over 60 (Nussabum and Ellis, 
2003). The prevalence of PD increases with age  since the idiopathic form is rare before 50 
years of age whilst the prevalence increases to up to 4% in people aged over 75 (deRijk et 
al., 2000), demonstrating that the primary risk factor for sporadic PD is aging. In support of 
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this, the incidence of PD is reported 1 in 1000 people below the age of 50, that increase 
dramatically to 1-2 in 100 people over the age of 60 (deLau and Bertler, 2006). In addition 
recent studies report a higher prevalence of PD in males compared to females (Swerdlow et 
al., 2001). The incidence of PD is reported to be approximately 1.5 times higher in men than 
in women (Elbaz et al., 2002); this finding may be related to risk factors more frequently 
found in men than in women (e.g., occupational risk factors), or to protective factors in 
women (e.g., hormonal factors). 
1.5 Aetiology and pathogenesis of PD 
 
The aetiology of PD is not yet fully known. The development of idiopathic PD 
might be the outcome of complex interplay between the innate vulnerabilities of the 
nigrostriatal dopaminergic pathway alongside genetic predisposition and environmental risk 
factors. The following section is an out line of some environmental risk factors that have 
been associated to developing idiopathic PD. 
 
1.5.1 Environmental risk factors for idiopathic PD 
To date a number environmental risk factors have been associated with development 
of PD later in life. The most compelling evidence for involvement of environmental risk 
factors in the development of PD came from the discovery of the neurotoxin, 1-Methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) (Langston et al., 1983). MPTP is a by-product 
of an illicit synthetic meperidine derivative developed by a group of young drug addicts that 
upon exposure to this drug developed clinical and pathological symptoms of idiopathic PD 
(Langston et al., 1983). The neuropathologic study of the brains of three MPTP-exposed 
subjects showed cell loss in the SNc and microglial activation with an ongoing 
inflammatory reaction 3–6 years after the toxic exposure (Langston et al., 1999). In addition, 
brain biopsy from non-human primates exposed to MPTP 5-14 years before death showed, 
cell loss in the SNc and reactive microglia and extracellular melanin in the SNc (McGeer et 
al., 2003). These findings indicate an active, ongoing neuronal loss, suggesting that toxic 
exposure happening at a single point in time many years before the onset of clinical 
symptoms of PD may result in a slowly progressive neurodegenerative process in  
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the SNc with a permanent inflammatory reaction in the brain of PD patients. The exact 
mode of action of MPTP is not fully known, however, MPTP is readily catalysed by 
monoamine oxidase type-B (MAO-B) in astrocytes to its active form the pyridinium ion 
MMP+. MPP+ is then taken up by dopaminergic neurons via the dopamine transporter 
(DAT). MPP+ then accumulates in mitochondria causing a profound inhibition of 
mitochondrial complex I that eventually leads to cellular energy failure and dopaminergic 
neuronal cell death (Blum et al., 2001).  
Epidemiological studies have shown that other environmental risk factors include 
exposure to pesticides and herbicides, increase the risk of PD (Gorrell et al., 1996; 
Priyadarshi et al., 2000).  The drinking of well-water that was shown to be contaminated 
with pesticides has also been investigated as an additional rural factor (Tanner et al, 1996). 
In agreement with these findings animal studies have also shown that chronic exposure of 
rodents to the pesticide, rotenone produces selective nigrostriatal degeneration and more 
importantly, the formation of LB-like inclusion bodies which are highly immunoreactive for 
α-synuclein. Rotenone treatment also induces microglial activation in the SNc of rodents 
(Betarbet et al., 2000; Sherer et al., 2003). Exposure to heavy metals such as iron, 
manganese, copper, lead, amalgam, zinc or aluminium have also been suggested as possible 
risk factors for the development of PD due to accumulation of metals in the SNc and 
increased oxidative stress (see section 1.4.3) (Olanow , 2004). Indeed, manganese is 
neurotoxic to the BG and individuals exposed to manganese dioxide ore have an increased 
risk of developing a parkinsonian-like syndrome, due to chronic inhalation of manganese 
dust (Huang et al., 2003). Additionally exposure to manganese fumes from welding has 
been suggested to increase the incidence of PD amongst welders, but this remains 
unsubstantiated (Jankovic, 2005). Interestingly, manganese is also a constituent of many 
pesticides, further suggesting a link between pesticide exposure and PD (Schapira, 2006).  
An interesting finding demonstrated that the herbicide paraquat which is structurally 
similar to MPTP (McCormack et al., 2002), causes nigrostriatal degeneration in rodents by 
inhibition of complex I (Richardson et al., 2005). Additionally, paraquat increases the rate 
at which α-synuclein forms fibrils in vitro (Uversky et al., 2001; 2004) and increases α-
synuclein expression in vivo leading to formation of inclusion bodies in nigral DA neurones 
(Manning-Bog et al., 2002). It is interesting to note that all of the environmental risk factors 
mentioned so far are either inhibitors of mitochondrial complex I or induce some form of 
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protein aggregation, suggesting a proteasomal deficit, both of which have been suggested to 
be involved in the pathogenesis of idiopathic PD (see section 1.4.3). Interestingly, 
compounds which inhibit proteasome activity appear to induce pathology and symptoms 
similar to PD in experimental models of PD (McNaught et al., 2002; 2004; Zeng et al., 
2006). The relevance of these findings to idiopathic PD is further confirmed by the 
observation of specific complex I and proteasomal deficits in post-mortem tissue from PD 
patients (Schapira et al., 1990; McNaught and Jenner, 2001; McNaught et al., 2001; 2002). 
 
1.5.2 Genetic risk factors 
 
Sporadic PD accounts for  90-95% cases and approximately 5-10% of cases are 
hereditary with clear genetic origins, which are termed familial PD (Farrer, 2006).  The 
discovery of genes linked to rare familial forms of PD during the last decade have confirmed 
the role of genetics in development of PD, and provided vital clues in understanding the 
molecular pathogenesis of the common sporadic illness. Studies have shown that relatives of 
PD patients have an approximate 2-3 fold higher risk of developing PD in comparison to 
age-matched controls (Gasser et al., 1998; Bonifati et al., 1995). Comparative studies on 
twins with age of PD onset before 50 years old demonstrated a significant concordance, 
suggesting that young-onset PD may have a genetic component (Schragg and Scott, 
2006 ;Tanner and Aston 2000). Additionally, imaging studies in both affected and 
unaffected mono- and dizygotic twin pairs revealed a significant concordance for PD in 
identical twins. Taken together, these findings suggest that genetics is important in PD 
aetiology (Farrer, 2006). Importantly, a major breakthrough in this respect involved large 
scale linkage analysis studies which have led to the mapping and cloning of several genes 
that cause monogenetically inherited forms of the disease in an autosomal dominant or 
recessive fashion. Namely PINK1, PTEN-induced kinase 1, SNCA, gene that encodes the 
protein α-synuclein, UCHL1, ubiquitin carboxyl-terminal esterase 1, PARK2, locus which 
encodes the protein Parkin, LRRK2, leucine rich repeat kinase 2, NFT, neurofibrillary 
tangles (Farrer et al., 2006). Interestingly, all the identified gene mutations which cause 
inherited PD are genes encoding proteins involved in DA synthesis and transmission, 
oxidative stress, protein accumulation and degradation, mitochondrial function, and 
xenobiotic metabolism, implicating these cellular processes in PD pathogenesis (see section 
1.4.3).  
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 Thus, taken together the current consensus is that sporadic PD may result from a 
combination of interacting genetic and environmental factors although the nature and time 
course of these interactions is debated (BenMoyal-Segal and Soreq, 2006; Allam et al., 
2005).  
 
1.5.3. Pathogenesis of PD  
 
Initially it was believed that neurodegeneration in PD was caused by necrotic cell 
death, but studies and use of modern techniques have shown that apoptosis (programmed 
cell death) is one of the main mechanisms of neuronal loss (Anglade et al., 1996; Tatton et 
al., 1998). There is a growing body of evidence suggesting that many factors are involved in 
PD pathogenesis such as: oxidative stress, protein handling dysfunction and inflammation. 
These factors participate in the cascade of events leading to neurodegeneration seen in PD 
(Jenner and Olanow, 1998; Olanow and Tatton, 1999; Jenner and Olanow, 2006). Below is 
a brief description of oxidative stress induced cell death and protein handling dysfunction 
leading to neuronal demise. However, the main focus of this thesis is on the role of 
inflammation in PD pathogenesis that is discussed in section 1.5. 
 
Oxidative stress and neurodegeneration in PD  
 
In the brain and specially the SNc the neurotransmitter dopamine, which is the main 
transmitter present in the SNc, normally, is subject to oxidative metabolism. It also has the 
potential to generate reactive oxygen species (ROS) and cytotoxic free radicals (Jenner, 
1996). Enzymatically, both the synthesis of dopamine by tyrosine hydroxylase (TH) and 
catabolism by monoamine oxidases (MAO) can lead to hydrogen peroxide (H2O2) 
production (Fig 1.2) (Jenner and Olanow, 1996). Under normal circumstances H2O2 is 
cleared by glutathione (GSH). GSH plays an important role in the adult brain by removing 
H2O2 formed during normal cellular metabolism which stops its further reaction with 
ferrous iron and formation of toxic hydroxyl radicals (Fig 1.2).  However, in the 
Parkinsonian brain there is a marked deficiency in chemically reduced glutathione levels 
and thus the brain’s capacity to clear H2O2 is diminished (Sian et al., 1994). This becomes 
important since the nigra has high iron content, and further the iron levels are increased in 
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the brains of PD patients (Dexter et al., 1989). Iron might then react with excess H2O2 
leading to production of toxic hydroxyl radicals (Fig.1.2) and potentially lead to oxidative 
damage and neuronal cell death (Perry and Yong, 1986).  
Toxic free radicals are also generated during non-enzymatic oxidation of dopamine. 
These free radicals include: quinone, semiquinone (SQ) molecules and reactive oxygen 
species (ROS) that lead to oxidative damage of different neuronal components and 
eventually cell death (Fig. 1.2) (Adapted from Jenner & Olanow, 1998). 
 Evidence suggesting that the SN is in a of  state of oxidative stress came from post-
mortem studies on human PD brain tissue that showed increased iron, decreased GSH levels 
and evidence of lipids peroxidation and oxidation of proteins and DNA (reviewed in Jenner 
and Olanow, 2006). Therefore in recent years anti-oxidant compounds have received 
considerable attention for their potential neuroprotective properties. 
 
a) Enzymatic dopamine oxidation 
 
1. DA+O2+H2O  Æ  3,4DHPA+NH3+H2O2 
2. H2O2+2GSH  Æ GSSG+2H2O 
3. H2O2+Fe+2 Æ OH·+OH-+Fe+3 
 
 
       b) Auto-oxidation of dopamine 
4. DA+O2   Æ  SQ· +·O2- +H+ 
   5. DA+·O2+2H+ Æ  SQ· +H2O2 
 
Fig 1.2: a) The enzymatic metabolism of dopamine. b) Dopamine auto-oxidation. 
Under normal circumstances hydrogen peroxide generated during dopamine metabolism by 
MAO (1)is cleared by glutathione (GSH) (2) this  stops its further reaction with ferrous iron 
and formation of hydroxyl radicals (3).  
 
 Ubiquitin-proteasome system dysfunction  
 
One of the main consequences of oxidative stress is the resultant dysregulation of 
protein metabolism in the cells (Berlett and Stadtman, 1997). Under normal circumstances 
MAO 
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damaged intracellular proteins and cell fragments are tagged, usually by ubiquitin, which 
triggers their breakdown and clearance by the proteasome. This will enable cell function to 
continue and provides a balance between the rate of damage and clearance of these proteins 
inside the cell. Once cell death occurs in the brain, the levels of unwanted cell fragments 
and damaged proteins increase. The ubiquitin-proteasome system (UPS) is the primary non 
lysosomal system, responsible for degradation and clearance of mis-folded, short-lived, 
mutant, damaged by oxidative or excitotoxic injury or misplaced proteins in eukaryotic cells 
(Sherman and Goldberg, 2001).  
Evidence for involvement of UPS dysfunction in PD came from familial cases of PD 
where specific gene defects were linked to inhibition of the UPS resulting in aggregation of 
abnormal proteins and associated loss of biological function (Jenner & Olanow, 1998). In 
sporadic PD, quantitative western blot analyses have shown a marked increase in the levels 
of aggregates of α-synuclein in the SNc (Baba et al., 1998). Many other proteins in addition 
to α-synuclein have also been demonstrated to accumulate in the SNc and other brain 
regions in PD. For example, a several-fold increase in the levels of ubiquitin–protein 
conjugates and phosphorylated proteins in the SNc has also been demonstrated (McNaught 
et al., 2002; and Zhu et al., 2002). In vitro and in vivo studies of McNaught et al., (2001) 
have shown  that build up of un-processed proteins resulting from compromised UPS can 
lead to initiation of an inflammatory response that may lead to the death of dopaminergic 
neurones (Wyss-Coray and Mucke, 2002; Jenner et al.,2006) .   
 
1.6 Inflammation in the brain 
 
Inflammation is the first line of defence against injury and infection. However, an 
excessive inflammatory response can be a source of additional injury to host cells (Wyss-
Coray and Mucke, 2002).The brain has a relatively low adaptive immune response but is 
vulnerable to innate immune reactions. Neurons, owing to a lack of ability to divide and 
little ability to recover from injury, are extremely vulnerable to auto destructive immune 
and inflammatory processes (Carson et al., 2006).This might hinder the recovery of 
neurological function at sites of inflammation or even exacerbate neuronal injury. 
Conventionally, it was believed that the brain is an immune privileged organ following a 
number of observations including the absence of professional antigen presenting dendritic 
cells in the brain that act as primary immune-surveyors in other tissues (Aloisi et al., 2001). 
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In addition, the lymphatic system that delivers antigen to lymph nodes and organs, and thus 
to the attention of general immune surveillance; is absent in the brain, although slow 
circulation of soluble antigens does occurs towards cervical lymph nodes (Aloisi et al., 
2001).  Moreover, there is a very low level of constitutive expression of major 
histocompatibility complex (MHC) molecules within the brain, and in particular MHC I 
expression which is required in order to present either self or foreign antigen to T cells, to 
initiate the adaptive immune response (Chew et al., 2006). However, the notion of the brain 
being an immune privileged organ was challenged by number of studies and observations. 
One of the main studies that challenged this idea demonstrated that transplanted tissue did 
not elicit a primary immune response when inoculated directly into the brain; however, 
upon peripheral challenge with the same antigen, a robust immune response was induced 
both in the periphery and to the previously tolerated inoculum in the brain (Perry et al., 
1998). This and similar observations initiated a change in the concept of the brain as being 
entirely separate from immune surveillance, and over the last few years, it has become clear 
that the immune system and the central nervous system do indeed interact, but the immune 
response in the brain is much more tightly regulated than in the periphery.  Furthermore, it 
was demonstrated that the BBB is not a completely impenetrable barrier, and that in health 
activated T cells do continuously, albeit in low numbers, circulate throughout the brain from 
the blood vessels and meninges towards cervical lymph nodes (Aloisi et al., 2000). Antigen 
presentation within the healthy brain does occur but is mediated exclusively through 
microglia, which have inducible antigen presenting ability, rather than through professional 
antigen presenting cells like dendritic cells found in the periphery (Kreutzberg et al., 1996). 
The antigen presenting ability of microglia is considerably suppressed however with very 
little or no constitutive MHC expression in the healthy brain. The microenvironment of the 
brain has developed specialised properties that limit potentially harmful inflammatory 
reactions which are to protect the largely irreplaceable post mitotic neurons. However under 
pathological conditions inflammatory reactions takes place that are characterised by 
activation of the microglia. Pro-inflammatory cytokines, released by microglia act on the 
endothelium to induce up-regulation of cell adhesion molecules including vascular cell 
adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) 
(Neumann and Wekerle, 1998). This up-regulation recruits passing T cells and monocytes 
expressing the counter receptors such as leukocyte function antigen-1 (LFA-1 or CD54) 
(Neumann and Wekerle, 1998).  Activated T cells themselves release further pro-
inflammatory cytokines like IFNγ and TNFα, which induce expression of MHC class II and 
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co-stimulatory molecules on the microglial cells (Gebicke-Haerter, 2001). When these 
activated microglial molecules bind to their respective receptors on T cells, they can then 
cause the transformation of the activated T cells into effector cells. Activated CD8 T 
lymphocytes can then mediate the direct cytotoxic lysis of target cells, recruit and activate 
accessory cells via pro-inflammatory mediators, while activated CD4 T lymphocytes 
instruct B cells to produce high affinity antibodies (Raivich et al., 1999).  These functions 
are controlled and balanced by the production of an array of pro-inflammatory cytokines 
such as IL1, TNFα and IFNγ, and anti-inflammatory cytokines including IL10 and 
transforming growth factor-β (TGFβ) by the T cells and the microglia.  The cascade of 
events during an inflammatory reaction in the brain suggests that microglia play a 
significant role in this process therefore, the following section is an outline of the main 
functions of microglia during homeostasis and pathological conditions such as PD. 
 
1.6.1 Microglia and their function 
 
Microglia, initially identified by Del Rio Hortega, constitute about 10% of all glial 
cells in the brain.  They are found throughout the brain parenchyma and are the resident 
macrophage population of the brain. In healthy brain they usually display a ramified 
morphology signifying their non-activated state but recent in vivo imaging by   Nimmerjahn, 
et al (2005) demonstrated that microglia even in their resting state are in constant activity 
and surveillance of the extracellular environment by extending and retracting their 
ramifications. As demonstrated by Nimmerjahn, et al (2005), following a laser beam injury 
to a blood vessel the surrounding microglia were activated as their processes thickened and 
retracted. Their phenotypic characteristic underwent a dramatic transformation as they 
migrated to the site of injury and accumulated around the injured vessel that was followed 
by phagocytosis of the injured vessel. Over the past few years an increasing body of 
evidence has emerged suggesting that microglia are the key components in immune 
surveillance of the brain. Traditionally, microglia were considered merely to have a 
housekeeping function where it was believed that they were principally involved in the 
removal of cellular debris (Barron et al., 1995). Microglia, not only act as phagocytic cells 
but also perform other roles in tissue repair and cellular homeostasis. During homeostasis 
microglial cells monitor the physiological integrity of their microenvironment to promote 
tissue repair by secreting growth factors, acquisition of macrophage differentiation markers 
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and effector properties thus, maintain the homeostasis of the brain parenchyma (Kreutzberg 
et al., 1996).  In normal, healthy brain microglia have a ramified morphology and do not 
display an activated macrophage array of receptors. There is low expression of the 
membrane ligands and receptors that are essential for mediating typical macrophage 
functions, such as leukocyte common antigen (LCA/CD45), CD14, and mac-1 (Kreutzberg 
et al., 1996). Under conditions of brain infection, exposure to inflammatory stimuli or 
interaction with blood-derived cells, microglia become activated to perform several innate 
immune functions including production of pro-inflammatory cytokines, cytotoxicity and 
regulation of T cell responses through antigen presentation (Aloisi et al., 2001). Microglial 
activation involves an increase in a range of molecules with immune function (Raivich et al., 
1999). There is increased microglial IgG reactivity and up-regulation of complement 
receptors and cell adhesion molecules like LFA-1, ICAM-1 (CD54), VCAM-1 (CD106) and 
CD1 (Kreutzberg et al., 1996). This is considered to represent a state of alert (Kreutzberg et 
al., 1996). If the inducing stimulus persists, microglial morphological and functional 
transformation continues with the up-regulation of MHC molecules alongside changes in 
the internal cytoskeleton of the microglial cell, enlarging the cell body and withdrawing 
processes to a more macrophage-like phenotype. Fully activated microglia then release 
large amounts of pro-inflammatory cytokines and cytotoxic factors including reactive 
oxygen and nitrogen species (Aloisi et al., 2001). Production of these neurotoxic factors 
causes neurodegeneration which in-turn could lead to further microglial activation and 
inflammation. When neuronal death occurs, microglia can recognize the expression of 
phosphatidylserine on the surface of apoptotic cells and will remove cellular debris from 
region by phagocytosis (Witting et al., 2000; Hirt and Leist, 2003). In Parkinson’s disease 
the localisation of activated microglial cells in areas of neurodegeneration is indicative of 
their role in perpetuating the disease process that could lead to further damage to neurons. 
Recent evidence suggests a pivotal role of inflammation that is characterised by microglial 
activation in the initiation and progression of PD (Nguyen et al., 2002).  Moreover, several 
studies have demonstrated that neuronal cell loss in the SNc in PD is accompanied by an 
inflammatory response with a dramatic proliferation of reactive microglial cells (McGeer et 
al., 1988; Forno., 1992; Forno, 1996; Knott et al., 2000).  In such PD patients, higher levels 
of pro-inflammatory cytokines such as, TNF-α, IL-1ß and INF-γ were detected in the 
striatum and cerebrospinal fluid (Mogi et al., 1994, 1996). It is not yet known what factors 
are involved in the induction of the inflammatory response and over-activation of microglia. 
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However, a number of inflammation inducing risk factors in developing PD have been 
studied that are discussed in the following section (see section 1.6.2 ). 
1.6.2 Inflammation inducing risk factors and development of PD 
 
Epidemiological case control studies have demonstrated that some cases of PD are 
associated with head trauma or certain viruses or infections, suggesting that microglial 
activation caused by preceding brain inflammation may trigger the onset of a cascade of 
events leading to progressive degeneration of DA neurons (Liu and Hong 2003, Herrera et 
al., 2005). The correlation between closed head injury and development of PD later in life 
has been studied by many groups.  Analysis of the medical histories of a large group of 
World War II veterans pointed to an association between the occurrence of severe head 
injuries and the development of PD in later life (Plassman et al., 2000). This notion is 
supported by several other studies, including several case–control studies that have 
identified head injury as a major risk factor for the development of PD (Stern et al., 1991; 
Taylor et al., 1999; Tsai et al., 2002). A very recent study demonstrated a significant 
increase in the risk of developing PD in twins with a history of prior head injury (Goldman 
et al., 2006). This study in accordance with the previous studies reported a long latency 
between injury and disease manifestation. This offers a long window for implementation of 
protective or preventive strategies, such as the use of anti-inflammatory agents. In support 
of the notion of head injury being a risk factor in development of PD later in life it is worth 
noting the so called  ‘ Boxer’s parkinsonian syndrome’’ that suggests  a higher incidence of 
PD-like movement disorders in boxers, due to their profession that is related to higher 
chance of suffering head injuries (Friedman et al., 1989). Although the mechanism 
underlying this head trauma–related development of permanent damage to the nigrostriatal 
pathway remains unclear, it is possible that the initial neuronal damage leads to the 
activation of glial cells that may exacerbate the neurodegenerative process. A number of 
biologically plausible mechanisms could explain the reason that head injury may lead to a 
neurodegenerative process such as PD.  Mild-to-moderate closed-head injury induces an 
inflammatory cascade that begins within minutes of the injury and may persist for months. 
In addition the break down of the blood-brain barrier is an early response to traumatic brain 
injury, followed rapidly by oedema, leukocyte infiltration, and microglial activation 
(Schmidt et al., 2005). A number of animal studies also support the deleterious role of 
inflammation following head injury. Shohami et al., (1997) have demonstrated significant 
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elevations in the levels of a number of cytokines (including IL-1, IL-6, and TNF-α) after 
head injury in rats. The production and accumulation of such pro-inflammatory factors may 
exacerbate the neuronal damage initially induced by the head injury. In addition 
epidemiologic studies have shown an association between early-life viral or bacterial 
infections to postencephalitic PD; case reports have shown development of acute 
Parkinsonism following viral infections (Tsui et al., 1999; Ghaemi et al., 2000). The 
possibility that viruses can induce PD is also suggested by studies in rodents where rats 
infected with Japanese encephalitis virus exhibited neuronal loss with microglial activation 
which was confined mainly to the SNc (Ogata et al., 1997).   In addition to viruses certain 
bacterial infections have also been associated with development of PD. Evidence suggests 
that peptic ulcer is more frequent in PD patients and one bacteria that is known to cause 
peptic ulcers is the Helicobacter pylori. Therefore, a study was performed to determine 
whether H. pylori seropositivity was associated with development of PD. Interestingly it 
was shown that siblings of PD patients had an increased probability of H. pylori 
seropositivity compared to control subjects (Charlett et al., 1999). Taken together, these 
studies suggest that early life incidences that are linked to an inflammatory component, 
increase the risk of developing PD in later life. Therefore, the following section focuses on 
the role of microglia in PD and the evidence suggesting that  inflammation plays a 
significant role  in PD pathogenesis.  
 
1.6.3 Inflammation in PD 
 
1.6.3.1 Atypical glial pathology in PD 
The glial cells in the brain are composed of two major types. Macroglia, which 
include astrocytes and oligodendrocytes, and the microglia. So far evidence suggests that 
oligodendrocytes, which are involved in the process of myelination, are not implicated in 
Parkinson's disease pathology, whereas both astrocytes and microglial cells are involved 
(Wilkin and Knott, 1999). Astrocytes provide homeostatic control of the neuronal 
extracellular environment and respond to a diversity of damaging insults, including physical 
damage, disease or chemicals. Even damage to astrocytes themselves elicits reactive 
changes such as hypertrophy and proliferation of surviving astrocytes (Wilkin and Knott, 
1999). An accumulating body of evidence suggests that there is a significant glial reaction 
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in the SNc in PD (Vila et al., 2001) but the gliosis observed in PD is an atypical form in 
which reactive astrocytes are largely absent in the SNc of post mortem parkinsonian brain 
tissue (Banati et al., 1998). However, only one type of glial cells seems to be highly 
activated in the SN of parkinsonian brains and that is microglia (Vila et al., 2001).  
1.6.4 Evidence for involvement of inflammation in PD pathology 
 
1.6.4.1 Evidence from human studies 
 
 A glial response has been observed in the vicinity of dying dopamine-containing 
neurons in human post-mortem SN from PD patients (McGeer et al., 1988) and MPTP-
intoxicated individuals (Langston et al., 1999). Markers of elevated accumulation of NO, 
ROS and pro-inflammatory cytokines such as TNF-α, IL-1b and IFN- γ in the SN of PD 
patients have been demonstrated (Liu et al., 2003) indicating a state of chronic 
inflammation in the PD brain.  In addition IgG from patients with PD can induce injury of 
dopaminergic neurons following stereotaxic injection into rat SNc (Chen et al., 1998). 
Furthermore, recent in vivo positron emission tomography (PET) studies demonstrated 
microglial activation using the peripheral benzodiazepine receptor binding ligand [11C]-(R) 
PK11195. This study revealed that patients with idiopathic PD have markedly elevated 
neuroinflammation in the pons, basal ganglia, striatum, and frontal and temporal cortical 
regions compared to age-matched healthy controls irrespective of the number of years with 
the disease. These observations indicated that changes in microglia activation in the affected 
nigrostriatal pathway in early PD are likely to occur in parallel or prior to the loss of 
dopaminergic terminals (Gerhard et al., 2006). Moreover, epidemiological studies 
demonstrated that regular users of non-steroidal anti-inflammatory drugs (NSAIDs) are at 
lower risk of developing PD (Wahner et al., 2007; Ton et al., 2006; Chen et al., 2005). 
Taken together, these findings are indicative of an ongoing inflammatory process in 
the brain of PD patients suggesting that inflammation plays a significant role in the 
pathogenesis of this disease. 
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1.6.4.2 Evidence from animal models of PD 
Involvement of inflammation in PD is also evident from toxin induced experimental 
animal models of this disease. The neurotoxins employed include, 6-hydroxydopamine (6-
OHDA), 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), and the inflammogen 
Lipopoysaccharide (LPS) that have suggested an aetiological mechanism that involves 
inflammatory processes (Kurkowska-Jastrzebska et al., 1999; Carvey et al., 2005 and 
Iravani et al., 2001). 
Inflammation in MPTP model of PD 
As mentioned earlier MPTP is a neurotoxin that selectively injures the nigrostriatal 
system and post-mortem examination of MPTP-intoxicated humans years after exposure 
revealed dopaminergic cell loss without Lewy body formation and a marked microglial 
reaction in the SNc (Langston et al., 1999). The presence of this ongoing inflammatory 
reaction years after the original toxic exposure supports the idea that an environmental 
insult to the brain can set in motion a self-perpetuating process of neurodegeneration 
mediated by focal inflammatory processes. Following systemic administration, MPTP 
readily enters the brain and is metabolised by astroglia to the active metabolite 1-methyl-4-
phenylpyridinium (MPP+). MPP+ enters cells via the dopamine transporter, and inhibits 
complex I of the mitochondrial electron transport chain (Murphy et al., 1995) leading to 
SNc cell death, depletion of striatal dopamine and interestingly  early activation of 
microglia in both regions (Liberatore et al., 1999). Following MPTP administration to mice 
microglia not only activate, as evidenced by altered morphology from ramified to 
macrophage-like, but also increase in their number suggesting recruitment and/ or 
proliferation. There is markedly increased expression of both MHC class I and II antigens 
and the up regulation of inducible nitric oxide synthase (iNOS) expression (Liberatore et al., 
1999). Inflammation is also a noted contributor to direct neuron damage, as MPTP toxicity 
is significantly reduced in mutant mice deficient in pro-inflammatory factors, such as 
superoxide  (Zang et al.,2000; Wu et al., 2003)  myeloperoxidase (Choi et al., 2005), 
prostaglandins (Feng et al., 2002; Vijitruth et al.,  2006; Wang et al.,  2005), NO (Wu et al., 
2002) and TNFα  (Sriram et al., 2002; Sriram et al., 2006). The effects of microglial 
inhibitors and anti-inflammatory drugs on MPTP administered mice provide further 
evidence for an active role of the microglial immune response in pathogenesis of PD. 
Minocycline, a semisynthetic tetracycline, is a potent inhibitor of microglial activation. 
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Minocycline acts on MPTP-activated microglia to prevent iNOS up regulation, inhibit 
phosphorylation of p38 mitogen activated protein kinase (Du et al., 2001) and reduce 
production of IL1β (Wu et al., 2002).  Other anti-inflammatory agent and a preferential 
cyclooxygenase-2 inhibitor, also significantly attenuates dopaminergic cell loss in the 
MPTP mouse model of PD (Teisman and Ferger, 2001). 
Inflammation in 6-Hydroxydopamine (6-OHDA) model of PD 
6-OHDA is another neurotoxin capable of inducing regional degeneration of 
dopaminergic neurons in the SNc and depletion of dopamine in striatum very similar to 
idiopathic PD when injected intracranially in rodents (Rodriguez et al., 2001). There is also 
evidence that 6-OHDA toxic effects are in part mediated via the activation of microglia. 
Intra-striatal administration of 6-OHDA into mice causes microglial cells to activate and 
increase in number in the SNc   post-injection. Dopaminergic cell loss follows and is 
accompanied by a further increase in microglial cell numbers (He et al., 2001). Analogous 
to the MPTP findings, co-administration of the microglial inhibitor minocycline protects 
dopaminergic cells, strongly favouring a pathogenic role for microglia (He et al., 2001). 
Activation of microglial cells is also shown to lead to production of pro-inflammatory 
cytokines such as: TNF-α in rats following 6-OHDA lesion induction. 
These observations further emphasise the possible deleterious role of inflammation 
characterised by activation of microglial cells in the SNc in PD pathogenesis. 
Inflammation in Lipopolysaccaride (LPS) model of PD 
The bacterial endotoxin LPS is a potent microglial activator that binds to the LPS 
cell membrane receptor complex on microglia, triggering nuclear localisation of 
transcription factor NFκB, and subsequent activation of genes in the pro-inflammatory 
pathways (Kim et al., 2000). Injection of LPS into rat SNc produces a strong microglial 
response followed by death of dopaminergic neurons, whereas the same injection into rat 
hippocampus or cortex does not cause any cell death (Kim et al., 2000; Iravani et al., 2002). 
Interestingly, the midbrain dopaminergic neurons are not affected by midbrain injections of 
LPS, analogous to the sparing of these neurons by other neurotoxins including MPTP and 6-
OHDA in animal models, and in human PD (Iravani et al., 2002). One possible explanation 
for this observed regional specificity of response to LPS is suggested to be a higher 
population of microglia in the SNc compared to other regions of the brain (Lawson et al., 
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1990). Moreover even systemic injection of LPS in female rats led to reduced striatal 
dopamine, increased TNFα, and reduced dopaminergic cell count in the mesencephalon in 
their 21-day-old pups (Ling et al., 2002). Indicating that even a systemic inflammatory 
insult could lead to a localised degeneration of dopaminergic neurons in the SNc.   The 
cellular events that leads to  inflammation mediated dopaminergic neuronal cell death 
following LPS administration involves the activation of microglial cells, concomitant with  
up regulation of iNOS in SNc (Iravani et al., 2002; Gao et al., 2002) production of NO (Kim 
et al., 2000) and peroxinitrite which is toxic to dopaminergic neurons. Moreover production 
of pro-inflammatory cytokines such as, TNFα and IL1β from activated microglia (Kim et 
al., 2002) leads to further damage and cell death in the SNc.   The production of these 
microglial derived neurotoxic factors precedes the death of dopaminergic neurons (Gao et 
al., 2002). 
Taken together, these findings, from both human and animal studies strongly 
suggest that activated microglia play an important role in the pathogenesis and progression 
of PD.  Moreover, DA neurons in the SN appear to be easily affected by microglial-derived 
neurotoxic factors, because the SN region is particularly rich in microglia and DA neurons 
are particularly sensitive to pro-inflammatory stimuli in the brain, such as LPS. Such 
evidence also indicates a possible role of activated microglia in the early stage of disease 
pathogenesis. More importantly, several studies have confirmed that microglia can play a 
causal role in DA neuron death. For example, LPS, is toxic to neurons but only in the 
presence of microglia (Gao et al., 2002; Gibbons and Dragunow, 2006). Also, an increasing 
number of experimental observations in animal models of PD indicate that inhibition of the 
inflammatory reaction could attenuate degeneration of nigrostriatal dopaminergic neurons 
(Liu et al., 2000; Teismann and Ferger et al., 2001; Wu et al., 2002). As such, 
pharmacological inhibition of iNOS (Iravani et al., 2002) or inhibition of microglial 
production of superoxide in vivo (Liu et al., 2000) reduces the LPS-induced SNc cell death. 
Naloxone, an opioid receptor antagonist, interferes with LPS binding to the LPS cell 
membrane receptor complex, CD14, on microglia preventing LPS from binding to its 
receptor complex inhibits activation of microglia and subsequent production and release of 
the pro-inflammatory factors, protecting the neuron-glia cell culture (Liu et al., 2000). 
These studies further support the concept that environmental insults can trigger prolonged 
microglial activation inducing pro-inflammatory cytokine production, lymphocyte 
recruitment, and alterations in cellular metabolism. This leads to the death of SNc neurons, 
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and can be a prolonged process mimicking idiopathic PD. The anti-inflammatory 
medications that down-regulate the microglial response and reduce neuronal loss strongly 
suggest that localised inflammation is pathogenic in the SNc rather than merely a late 
response to neuronal death.  
1.7 Triggers for microglial activation 
Post-mortem and experimental evidence indicates that microglial activation is 
indeed involved in PD pathogenesis. However, very little is known about the signals and 
triggers that leads to reactive gliosis. A number of studies have demonstrated that microglia 
are influenced primarily by direct neuronal-microglial interactions. Microglia are kept in a 
quiescent state in the intact CNS by local interactions between the microglia receptor 
CD200 and its ligand among other factors, which is expressed on neurons (Neumann et al., 
2001). Indeed damage to neurons by neurotoxins led to the induction of MHC molecules on 
microglia and astrocytes. Thus, over-activation of microglial cells in the CNS is inhibited 
by the local microenvironment, in particular by physiologically active neurons, to prevent 
unwanted immune mediated damage of neurons. Other signalling molecules involved in 
glial activation are Matrix metalloproteinases (MMPs) such as: MMP-3. As demonstrated 
by Kim, et al, (2005) MMP-3 may be a microglia-activating signalling molecule released 
from neurons in early apoptosis. 
 
1.8 Aims of the study  
The working hypothesis in this project is that the microglial response associated 
with neurodegenerative process in PD is detrimental to remaining neurons and targeted 
immune modulators may act as neuroprotective agents. The presence of activated microglia 
in the SNc of post-mortem brain tissue signifies their association with dopaminergic 
neuronal cell death in PD. However, it only reflects their state in the terminal hours of the 
patient's life. What their activity was in previous days, months, or years remains completely 
unknown. Considering the evidence for the involvement of inflammation and microglial 
activation in PD pathology, a crucial factor in determining the fate of activated microglia 
following an insult is time. To date limited information is available on the time frame of 
activation of microglia in PD and whether inflammation precedes dopaminergic cell loss or 
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is it a consequence of it?  The mechanism by which activated microglia might specifically 
target dopaminergic neurons and the cell to cell interaction between activated microglia and 
degenerating dopaminergic neurons in the in vivo models of PD also remains a critical 
missing link. Therefore the aims of this project were to address the following questions:  
 
1) What are the kinetics (time course) of the immunophenotypic changes of 
activated microglia and the subsequent fate of activated microglial cells during the initiation 
and progression of dopaminergic neuronal loss in the SNc of 6-hydroxydopamine (6-OHDA) 
rat model of PD? 
2) What signal(s) are released from neurons and how do these signal(s) modulate 
microglial activation in the 6-OHDA model of PD.  What is the kinetic of signalling 
molecules such as: matrix metalloproteinases during the progression of dopaminergic lesion 
in the SNc? How does the expression of these signalling molecules correlate with the degree 
of microglial activation and what are the neuron-microglia interactions, with focus on the 
role of CD200R in dopaminergic cell death in the SNc after 6-OHDA lesion induction.  
3) Finally, whether modulation of glial activity by anti-inflammatory compounds 
namely peroxisome proliferator activated gamma receptor (PPAR-γ) agonists leads to 
dopaminergic neuroprotection in 6-OHDA model of PD. 
In order to satisfy these aims, the classical 6-OHDA rat model of PD will be 
employed, which produces selective degeneration of the rodent nigrostriatal system 
(Betarbet et al, 2002; Deumens et al, 2002). The effect of focal unilateral 6-OHDA lesion 
induction into the medial forebrain bundle (MFB) will be assessed on both the integrity and 
functionality of the nigrostriatal tract. Nigrostriatal integrity will be assessed by 
immunohistochemical studies quantifying the number of dopaminergic neuronal cells 
utilising the antigen Tyrosine hydroxylase (rate limiting  enzyme in dopamine synthesis) in 
the SNc. Additionally, to quantify the effects of the 6-OHDA lesion on nigrostriatal 
functionality, the concentrations of DA and its metabolites dihydroxyphenylacetic acid 
(DOPAC) and homovanillic acid (HVA) in the corpus striatum will be quantitatively 
measured by High Performance Liquid Chromatography with Electrochemical Detection 
(HPLC-ECD). The relative amount of striatal DA metabolism will also be calculated. 
Furthermore to investigate the time course of microglial activation following 6-OHDA 
lesion induction in relation to dopaminergic neuronal cell death, animals will be sacrificed 
on days 1,3,5,7,9,13 and 15 after lesioning. To detect nigral microglial/macrophage 
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activation following 6-OHDA lesion induction, immunohistochemistry will be performed 
with OX-6 antibody targeted against MHC class II expressing activated microglia, OX-42,  , 
antibody that is a general marker for microglial activation and CD-68 antibody that detects 
phagocytic macrophages. To study the potential signalling molecules that are involved in 
the initiation of microglial activation in the SNc after 6-OHDA lesion induction, 
immunohistochemistry will be performed for the active forms of MMP-3 and MMP-9 in 
addition to CD200R+ve cells. Finally, the significance of microglial response will be 
assessed by orally treating animals with different PPAR- γ agonists using different 
treatment regimes. The effect of each treatment on microglial activation and nigrostriatal 
functionality and integrity will be assessed as mentioned above.  
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2.1 In vivo methods 
2.1.1 6-hydroxydopamine (6-OHDA) experimental model of Parkinson’s disease 
 
2.1.1.1 Overview 
 
Experimental models of neurodegenerative diseases including PD are valuable tools 
that enable us to study the underlying pathophysiological mechanisms involved in the 
neurodegenerative processes observed during the course of these diseases. Research into the 
pathogenesis of PD has advanced very rapidly using animal models that are indispensable 
for the testing of novel therapeutic and neuroprotective strategies.  However, up to date 
none of these models can mimic all the pathophysiological and clinical aspects of the 
disease as it is observed in humans. A model that utilises the toxin 6-OHDA in vivo is used 
in this project to replicate certain aspects of PD. 6-OHDA was the first chemical toxin 
discovered that destroyed catecholaminergic neurons both in vivo and in vitro. 6-OHDA 
that was originally isolated by Senoh and Witkop (1959) is a hydroxylated analogue of the 
neurotransmitter dopamine (Axlerod et al., 1998).  The biological effects of 6-OHDA were 
first demonstrated by Porter et al,( 1963), who showed that 6-OHDA induces efficient and 
long lasting noradrenalin depletion in sympathetic nerves to the heart (Porter et al., 1963). 
6-OHDA is mainly used in rodents, to induce nigrostriatal damage and replicate the loss of 
striatal dopamine as seen in PD patients. 6-OHDA induced neuronal death is shown to be by 
both apoptotic (Silva et al., 2005; Vila and Przedborski, 2003) and non-apoptotic pathways 
(Jeon et al., 1995). If administered systemically 6-OHDA does not cross the blood-brain 
barrier (BBB) except in neonatal rats when the BBB is still permeable (Podkletnova et al., 
1998; 2001). Hence to mimic the pathological changes observed in the nigrostriatal pathway 
in PD, 6-OHDA must be stereotaxically injected into one of the following distinct structures 
in the brain, corpus striatum, substantia nigra and the medial forebrain bundle (MFB) that 
comprises the nigrostriatal tract. In rodents, 6-OHDA injection into the substantia nigra 
directly, produces a rapid degeneration of dopaminergic neurons, within 24 h with 
subsequent depletion of striatal dopamine levels (Faull and Laverty, 1969).  Intrastriatal 
injection of 6-OHDA causes a retrograde neuronal cell death in the SNc that (Berger et al., 
1991; Sauer and Oertel, 1994; Przedborski et al., 1995) was shown to be progressive up to 5 
weeks post lesion (Yuan et al., 2005). However, striatal injections of 6-OHDA results in the 
small focal losses of dopaminergic cells in the SNc and multiple injections of 6-OHDA are 
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required to create a model mimicking the early stages of clinical PD. Such multiple 
injections can induce unwanted mechanical damage. Whereas, 6-OHDA injection into the 
MFB leads to the loss of dopamine content in the striatum as early as 3 days after lesion 
induction followed by progressive loss of dopaminergic neurons in the SN up to 8 weeks 
(Yuan et al., 2005). This closely mimics the progressive nature of PD in humans. Injections 
of 6-OHDA into the MFB also allow the investigation of the effect of 6-OHDA on the 
nigrostriatal and the mesolimbic system. The magnitude of the lesion depends on the 
concentration of 6-OHDA injected, the site of the injection, the species used (Betarbet et al., 
2002) and whether noradrenalin uptake blockers such as desipramine are employed 
(Luthman et al., 1989). In mice, rats and cats, 6-OHDA is a highly effective toxin for 
dopaminergic (DAergic) neurons (Beal, 2001).  
 
Since PD pathology is observed bilaterally in the human brain, bilateral PD models 
are considered more appropriate. Bilateral 6-OHDA lesions induce, in part, parkinsonian 
motor symptoms; however, the bilateral lesion does not represent the most frequently used 
model, due to the fact that bilaterally affected animals  are associated with high morbidity 
rate due to aphagia caused by the severity of the lesion, therefore these animals require 
intensive nursing care (Cenci ,et al., 2002). Hence, unilateral lesions with 6-OHDA are the 
most reproducible and commonly used method to model PD with the un-lesioned 
hemisphere of the brain serving as internal control. Taken together, to be able to replicate 
the progressive and partial lesion of the nigrostriatal system, unilateral 6-OHDA injection 
into the MFB was employed as the animal model of PD in this project. 
 
Benefits and limitations of 6-OHDA rat model  
 
The clinical and widespread neuropathological alterations seen in PD patients are 
not entirely replicated in any animal model including the intra-cerebral injection of 6-
OHDA in rodents. Although, 6-OHDA induces a significant decrease in dopamine and 
dopaminergic fibres in the striatum and leads to degeneration of dopaminergic neurons in 
the SNc with preservation of non-dopaminergic neurons 6-OHDA does not affect other 
brain regions that are affected in human PD such as:  anterior olfactory structures, lower 
brain stem areas or the locus coeruleus (Betarbet et al., 2002). In addition formation of 
cytoplasmic inclusion bodies known as Lewy bodies that are hallmarks of PD pathology is 
not observed in 6-OHDA lesioned animals. However, in vivo the 6-OHDA partial lesion 
  
 41
model has been used routinely for the purpose of screening potential therapeutic (Lundblad 
et al., 2002; Asin et al., 1995) and neuroprotective drugs (Zbarsky et al., 2005). 6-OHDA 
robustly mimics and reflects the molecular changes such as, oxidative stress, accumulation 
of iron in the SNc as observed in human PD and it is a suitable model for studying the 
underlying mechanisms involved in the process that leads to dopaminergic neuronal loss 
including the involvement and role of inflammation (Cicchetti et al., 2002; Depino et al., 
2003) in the course of the disease. Despite the mentioned limitations of this model it is one 
the most reliable, reproducible and widely used models of PD. 
 
2.1.1.2 Medial forebrain bundle lesions 
 
In order to study the role of inflammatory processes in the early phases of PD 
pathology, at which time point use of neuroprotective treatments would be most beneficial, 
it was decided that a partial lesion model of PD was the most suitable approach.  To create a 
model that mimics the early phases of PD pathology, a unilateral partial lesion in the 
nigrostriatal system was induced by injection of 6-OHDA into the MFB rather than SN or 
the striatum (Fig 2.1). MFB comprises the dopaminergic axon projections from substantia 
nigra (SN) pars compacta and the ventral tegmental area (VTA) to the dorsal striatum 
(Fallon et al., 1978). These cells release dopamine at the somatodendritic level as well as at 
the terminal region. Studies by other colleagues in this laboratory have shown that 7 days 
after unilateral 6-OHDA injection into the MFB 60-70% of dopamine content in the 
striatum is lost with retrograde loss of 40-50% of dopaminergic neurons in the SN (Datla et 
al., 2001; 2003; 2004; Zbrasky et al., 2005) sparing the ventral tegmental area (VTA). 
These observations reflect the nigrostriatal pathology of PD as seen in human cases (Damier 
et al., 1999; Braak et al., 2004). As mentioned earlier the partial lesion model not only 
enables us to study the pathological mechanism involved in early phases of PD but it is also 
a suitable model for testing potential neuroprotective compounds that exert their beneficial 
effects when administered early in the degenerative process. In addition, 6-OHDA lesion 
induction to the MFB avoids local mechanical trauma to the SNc or the striatum and 
initiates degeneration at the axon terminals leading to retrograde damage of the DA neurons 
in the SN.  
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Fig 2.1 Schematic diagram of the nigrostriatal pathway  
 
Shaded areas in the left striatum indicate the loss of DA due to a MFB injection of 6-
OHDA. Abbreviations: RS, right striatum; LS, left striatum; R MFB, right medial forebrain 
bundle; L MFB, left medial forebrain bundle; 6-OHDA, 6-hydroxydopamine; R SN, right 
substantia nigra; L SN, left substantia nigra. 
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2.1.1.3 Mechanism of 6-OHDA neurotoxicity 
  
One of the potential mechanisms by which 6-OHDA is shown to cause neurotoxicity 
to dopaminergic neurons is oxidative stress (Heikkila and Cohen, 1971; Sachs and Jonsson, 
1975). 6–OHDA undergoes auto-oxidation very rapidly and generates hydrogen peroxide 
and para-quinons that leads to generation of reactive oxygen species (ROS).In addition 
evidence shows that 6-OHDA disturbs the endogenous antioxidant mechanisms in the basal 
ganglia by depleting the reduced glutathione (GSH) and reducing the activity and the 
mRNA levels of super-oxide dismutase (SOD) (Perumal et al., 1992), which results in 
production of high levels of hydrogen peroxide (H2O2). H2O2   reacts with iron via the 
Fenton reaction leading to production of toxic hydroxyl radicals (OH·) (Ben-Shachar and 
Youdim, 1991). 6-OHDA also leads to iron accumulation in the SN and directly stimulates 
the release of Fe2+ from ferritin (Ben-Shachar and Youdim, 1991; Youdim et al., 1993). 
These observations suggest that 6-OHDA renders the basal ganglia to the state of an on-
going oxidative stress that is measured by increased levels of malondialdehyde indicative of 
lipid peroxidation in the SNc (Kumar et al., 1995). The biochemical defects in the brain, 
specifically the SNc caused by 6-OHDA are similarly observed in post-mortem brain tissue 
of PD patients. These defects include, increased membrane peroxidation in the SNc and 
widespread ROS-induced protein modification  (Dexter et al., 1989; Dexter et al., 1994). In 
addition evidence shows  that 6-OHDA acts as a direct inhibitor of mitochondrial electron 
transport chain enzymes, the complex IV (cytochrome c) and the complex I (NADH 
dehydrogensae) resulting in cellular energy failure and depletion of adenosine triphosphate 
(ATP) subsequently cell death (Glinka et al., 1996; 1997; Youdim  et al., 1995). 
Mitochondrial Complex I defects have similarly been observed in the SNc from post-
mortem brain tissue of PD patients (Schapira et al., 1990 and 2006). Evidence shows that 
oxidative stress and mitochondrial dysfunction are not the only mechanisms involved in 6-
OHDA induced neurotoxicity; activation of microglia has also been shown to play a key 
role in neuronal death after 6-OHDA lesion induction. Direct administration of 6-OHDA 
into the SNc of mice activates microglia and increases the number of activated microglia in 
the SNc with the subsequent loss of dopaminergic neurons 1 week after 6-OHDA 
administration (He et al., 2001). Furthermore, 6-OHDA-lesioned rats have been 
demonstrated to have increased levels of TNFα in both the SNc and the striatum (Mogi et 
al., 1999). These observations are in accord with evidence from post-mortem brain tissue 
from the SNc of PD patients showing the presence of similar inflammatory response 
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characterized by activated microglia (McGeer et al., 1988; Mogi et al., 1995). 
Mitochondrial inhibition, oxidative stress and inflammatory response induced by 6-OHDA 
are mechanisms that could work synergistically in vivo leading to neuronal cell death in the 
SNc (Rodriguez-Pallares et al., 2007). 
 
2.1.1.4 Motor impairments in 6-OHDA lesion induced model of PD 
 
Rats with severe unilateral 6-OHDA lesions including lesions to the MFB show 
significant signs of motor impairments similar to akinesia and bradykinesia observed in 
human cases of PD when 80-90% of the striatal dopamine is lost and more than 80% of 
dopaminergic neurons in the SN have degenerated. Akinetic movements are observed in 
rats in their reaction time to challenges such as: adjusting step test and paw retraction test 
(Barneoud et al., 1995). In addition severe 6-OHDA lesions cause an asymmetric and 
quantifiable rotating motor behavior in the longitudinal axis of the body, which can be 
quantified in a rotation-box (Hefti et al., 1980). This rotational asymmetry is induced by 
systemic administration of drugs that have direct or indirect agonistic effect on dopamine 
release (Hefti et al., 1980). For example, systemic administration of apomorphine (APO), a 
dopamine agonists, induces contralateral turning behavior to the side of the lesion in rats 
with severe 6-OHDA lesions. APO stimulates both classes of dopamine receptors (D1, D2). 
The degeneration of the nigro-striatal dopaminergic neurons leads to super-sensitivity of 
post-synaptic dopamine receptors in the striatum. Thus receptors on the lesioned side are 
more sensitive to dopamine agonists than those on the intact side. Consequently when 
challenged with APO contralateral response is attributed to the stimulation of supersensitive 
D1-receptor and D2-receptors (Schwarting and Huston, 1996). Another class of dopamine 
releasing drugs are the indirect agonists that include amphetamines. Amphetamines are 
considered indirect dopamine agonists, since they bind to the monoamine transporters and 
increase extracellular levels of endogenous striatal dopamine (Schwarting and Huston, 
1996). Systemic amphetamine treatment after 6-OHDA lesion induction induces a dose 
dependent ipsilateral turning behavior to the side of the lesion that could be explained by 
stimulation of post-synaptic dopamine receptors on the contralateral un-lesioned side. It is 
noteworthy however to mention that shortly after 6-OHDA lesion, amphetamine treatment 
can induce contralateral turning that is in response to the release of non-functional 
dopamine pools in the lesioned hemisphere. When dopamine pools are depleted, the 
direction of turning switches to the contralateral side. This phenomenon could be explained   
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by the release of dopamine in the unlesioned hemisphere after amphetamine injection 
(Schwarting and Huston, 1996). The characteristic rotating behaviour is often used as a 
measure for the degree of lesion induced by 6-OHDA and to test potential beneficial effects 
of the anti-parkinsonian therapeutic agents.  
It should be emphasised that such testing is not suitable in the partial lesion model 
employed in this project, since degree of dopamine depletion in the striatum and 
dopaminergic neuronal loss in SNc are not sufficient enough to be able to observe sever and 
significant rotational behaviour. 
 
2.1.2 Stereotaxic surgery  
 
2.1.2.1 Animals 
 
Male (Sprague-Dawley (SD) rats (Harlan, UK) weighing 200-210(g) on arrival were 
housed in groups of three per cage at a temperature of 21± 1ºC on a 12hr light: dark cycle 
(lights on 07:00 am, lights off 07:00 pm). Rats had free access to standard rat chow and 
water ad libitum. Animals were allowed to acclimatize for 7 days in the Charing Cross 
Central Biomedical Unit (CBU) before any experiments were carried out. During this time 
the weight of the animals increased to the most suitable weight of 220-250g for sterotaxic 
surgery. The stereotaxic surgical coordinates adapted from Paxinos and Watson rat brain 
atlas are calculated for rats weighing up to 290g.  Male rats were used through out this 
project because recent evidence shows; the incidence of PD is greater in males than females 
(Scharg et al., 2000; Swerdlow et al., 2001). In addition evidence from experimental models 
of PD also support this observation and suggests that oestrogen might have neuroprotective 
properties on dopaminergic neurons after 6-OHDA lesion (Gillies et al., 2004; Murray et al., 
2003; Dluzen, 1997; Dubal et al., 1998). 
 
2.1.2.2 Stereotaxic injection of 6-OHDA into the MFB 
 
Groups of rats (n=6) received unilateral injection of 6-OHDA into the MFB 
according to the protocol of Datla and colleagues, (2001). Rats were weighed on the day of 
surgery and pre-operative weight was recorded. Generalised anaesthesia was induced using 
5% Isoflurane (Abbott, U.K.) in oxygen (2l/min) (BOC, U.K.) in an induction chamber. 
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Once stable anaesthesia was established by testing the loss of paw pinch reflex, animals 
were then placed into a stereotaxic frame (David Kopf instrument, USA) with incisor bar 
set at 5mm below the interaural line. To maintain their body temperature at 37 ºC rats were 
kept on a thermostatically controlled heated mat. Anaesthesia was maintained thereafter 
with isoflurane (1-3%) in oxygen (1l/min). The scalp area was shaved and swabbed with 
iodine solution (Betadine, Seton Healthcare Group Plc, Oldham, UK) to sterilise the skin. 
0.1 ml bupivacain hydrochloride (Marcain, AstraZeneca, Chester, UK) was then 
administered by subcutaneous (s.c.) injections at four sites on the scalp as local anaesthetic 
and 5ml 4% glucose in 0.18% saline intraperitoneal (i.p.) was given to prevent dehydration. 
A single incision was made sagittally along the scalp starting from behind the eyes and 
going up to the ears to expose the skull. The skin was retracted and the periosteum removed, 
the cranium was then dried to ensure clear view of the bregma. All subsequent stereotaxic 
coordinates were measured in millimetres with anterior and lateral coordinates made 
relative to bregma and ventral coordinates made relative to the dura. A small hole was made 
in the skull with a sterile dental drill above the level of the MFB (2.2mm posterior, 1.5mm 
lateral from bregma and 7.9mm ventral to the dura, according to Paxinos and Watson, 1986) 
(Fig 2.2). 6-hydroxydopamine hydrobromide (dissolved in 0.1% ascorbic acid in 0.9% 
sodium chloride solution; Sigma, U.K.) was injected into the left MFB, delivered in 4min 
using a 10µl manual, microinjection syringe (Hamilton, USA) and the needle left in situ  for 
4min to prevent reflux along the injection needle. The concentration of 6-OHDA was 
calculated from its free base in an injection volume of 4µl. Post-surgery, animals were 
placed in a heated recovery chamber for 1 hour to recover from the anaesthetic. Post-
operative care included individual caging and a mashed diet.  
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Fig 2.2 Diagrammatized coronal brain section (plate 37 of the standard rat brain atlas, 
Paxinos and Watson, 1986) to illustrate the stereotaxic coordinates used to inject 12μg 6-
OHDA into the left MFB. Coordinate 1 is equal to 1.5 mm lateral to the midline and 
coordinate 2 is equal to –7.8mm ventral to dura.  The anterior coordinate is not shown, but 
is equal to –2.2 mm anterior to bregma. These co-ordinates were measured with the incisor 
bar set 5 mm above the interaural line. The Paxinos and Watson atlas (1986) diagrams are 
based on incisor bar set 3 mm above the interaural line, hence these markers are purely 
illustrative and not intended to be to exact scale.  
 
 
1
 
2 
1 
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2.1.3 Post-mortem procedures and brain tissue collection 
 
At the end of each individual experiment animals were sacrificed by CO2 over dose. 
Brains were quickly removed and cut coronally at the level of infundibular system (-4.16 
mm from bregma) on a chilled platform using a rodent brain matrix. Hindbrain and 
forebrain blocks were then separated. Hindbrain blocks containing the SNc were transferred 
to 4% paraformaldehyde solution made up in 0.1M PBS (pH 7.4) and kept for 6-7 days for 
fixation. Then the brains were cryoprotected in 30% sucrose solution containing 0.1% 
sodium azide as preservative until the block had sunk (48-72 hours). The brains were then 
stored at -800C freezer until subsequent cryostat sectioning. From the forebrain block 
corpus striata were dissected out on ice and flash frozen on dry ice, the striata were stored at 
-800C until processed for measurement of the monoamine content by High Performance 
Liquid Chromatography with Electrochemical detection (HPLC-ECD) ( see section 2.2.4.1 ). 
 
 
2.2 Ex-vivo methods 
 
2.2.1 Avidin-Biotin Immunohistochemistry  
 
2.2.1.1 Overview 
 
Immunohistochemistry is the process of localizing proteins (antigens) in cells of 
tissue sections exploiting the principle of antibody binding specifically to antigens.  The 
antigen-antibody interaction can then be visualized by markers such as: dye, enzyme, 
fluorescent dye, radioactive element and colloidal gold. Albert H. Coons and his colleagues 
(Coons et al., 1955) were the first to label antibodies with fluorescent dye and use it to 
identify antigens in tissue sections. With the expansion and development of 
immunohistochemistry technique, enzyme labels were introduced such as peroxidase 
(Nakane and Pierce, 1966). Other methods included colloidal gold (Faulk and Taylor, 1971) 
label that was used to identify immunohistochemical reactions at both light and electron 
microscopy level.  
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One of the immunohistochemical methods employed in this project to analyse 
antigen localisation is standard avidin-biotin complex (ABC) immunoperoxidase technique. 
Avidin is a large glycoprotein, with 68kDa molecular weight that has a very high affinity 
for biotin. Biotin, a low molecular weight vitamin, can be conjugated to a variety of 
biological molecules such as antibodies. In addition to the high affinity between avidin and 
biotin, avidin has four binding sites for biotin thus several molecules of biotin could be 
conjugated to proteins including enzymes and antibodies. Exploiting these properties 
provides potential for formation of molecular complexes between biotinylated proteins and 
avidin hence, immunoperoxidase method was developed to localise antigens in tissue 
sections. The technique builds three layers of macromolecules, the first layer is the addition 
of the unlabeled primary antibody to the tissue, second layer is biotinylated secondary 
antibody and the third layer is a complex of avidin-biotin peroxidase. The binding can be 
visualised by addition of the substrate for the peroxidase. The traditional substrates include 
diaminobenzidine tetrachloride (DAB) and 3 –amino-9-athyl carbazole (AEC). DAB 
produces a brown precipitate in tissue sections or purple/grey colour in the presence of 
divalent cations such as nickel or cobalt that are insoluble in alcohol (Fig 2.3 ). ABC is a 
simple and rapid method that has several advantages over other methods such as: directly 
coupling a marker to an antibody or using nucleic acid probes and lectins. The high affinity 
constant (>10 15 M-1), between avidin and biotin leads to rapid formation of an irreversible 
stable complex of avidin conjugate and biotinylated secondary antibody. In addition, since 
avidin has more than one binding site for biotin, a large amount of peroxidase can bind to a 
single antigen site. This leads to a very high sensitivity of the staining performed, allowing 
lower concentration of primary antibody to be used. 
The general protocol for ABC immunohistochemistry technique for detection of 
specific proteins is out-lined in the following section. Modifications to this standard 
immunohistochemistry protocol are covered in the individual experiments.  
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Fig 2.3 Illustration of the avidin-biotin immunoperoxidase immunohistochemistry 
technique.  
In brief, the unlabelled primary antibody is applied to the tissue sections followed by 
biotinylated secondary antibody. A preformed avidin-biotin-horseradish peroxidase 
macromolecular complex is then applied to form a molecular scaffold bound to the 
secondary antibody. Antibody binding is then visualised by the addition of the chromagen 3, 
3’-diaminobenzidine (DAB) which, in the presence of the peroxidase substrate hydrogen 
peroxide, forms an insoluble brown precipitate. 
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2.2.1.2 General standard protocol for ABC immunohistochemistry 
 
All primary and secondary antibodies were titrated to obtain the optimum working 
dilution (Table 2.1). Coronal sections of the entire SNc, that expands from  -4.80 to 6.30 
mm from bregma, was cut at 20µm thickness  on a cryostat (Bright Instruments, UK) 
maintained at -20 ºC. Sections were collected and free floated in 24 well plates (Beckton 
Dickenson, UK) and were stored at 4°C in 0.1M phosphate buffered saline (PBS) 
containing 0.05% sodium azide as preservative, pH 7.4. Prior to staining minimum three 
and maximum six tissue sections were transferred to individual wells in 2mls of  0.1M PBS. 
Excess sodium azide was washed out by rinsing section 3x 5min in 0.1M PBS on a shaking 
platform. Endogenous peroxidase activity was then quenched by incubating tissue section in 
1% H2O2 for 30-50min. To facilitate antibody penetration sections were incubated for total 
of 15min in 0.1 M PBS containing 0.05% Triton X-100 (Sigma-Aldrich-UK). In order to 
eliminate any non-specific antibody binding tissue sections were blocked for 1 hour in the 
appropriate non-immune  serum diluted in 0.1M PBS. Normal goat serum (Vector Labs, 
Peterborough, UK) was used when the secondary antibody was raised in goat and normal 
horse serum (Vector Labs, Peterborough, UK) was used when the secondary antibody was 
raised in horse, this information may be found in Table 2.1. After blocking, tissue sections 
were incubated in appropriate primary antibody, diluted in 0.1M PBS Triton X-100 at room 
temperature (20-21°C) over night (~ 18 hours). This was followed by 60-90 min incubation 
in the appropriate biotinylated secondary antibody diluted in 0.1M PBS Triton X-100. 
Secondary antibodies were chosen according to the host in which the primary antibody was 
raised, the list of primary and corresponding secondary antibodies may be found in Table 
2.1. Sections were then incubated in a pre-formed avidin conjugated horseradish peroxidase 
macromolecular complex (Vactastain Elite ABC kit PK-6100, Vector Labs, UK) for 45min. 
ABC was prepared according to the manufacturer’s instructions, diluted in 0.1M PBS Triton 
X-100 30min before use. Antibody binding was then visualised by incubating sections in 
DAB, using a DAB peroxidase kit [(DAB peroxidase kit SK-4100), Vector Labs, UK], as 
per manufacturer’s instructions. DAB incubation time was optimised depending on the 
specific protein under study. DAB reactivity was visually determined by characteristic DAB 
brown precipitate. To terminate DAB reaction tissue sections were rinsed in distilled water 
for 5min. Where appropriate Nickel/DAB staining enhancer was used as per manufacturer’s 
guide in order to enhance the density of the staining [(DAB peroxidase kit SK-4100), 
Vector Labs, UK]. 
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 For each immunostaining a negative control was added in which the primary 
antibody was omitted. In none of the cases immunoreactivity was observed (data not 
shown). Tissue sections were then mounted onto poly-L-lysine coated slides and left to dry 
at room temperature before being dehydrated in ascending concentration of ethanol for 3 
min each. Sections were then immersed into two changes of xylene for 3min each to de-fat 
the tissue. DPX mounting medium was used to cover-slip the tissues sections on slides. All 
dehydration stages including cover slipping was performed in a fume hood and slides were 
allowed to dry overnight before being analysed.  
 
2.2.1.3 Tyrosine hydroxylase (TH) immunohistochemistry protocol 
 
To visualise dopaminergic neurons in the SN, TH immunohistochemistry was 
utilised. TH is cytosolic rate limiting enzyme which is involved in dopamine synthesis by 
catalyzing the conversion of the amino acid L-tyrosine to dihydroxyfenilalnine (DOPA). 
DOPA is a precursor for dopamine which in turn is a precursor for noradrenalin and 
adrenaline. Hence, TH antibody labels both dopaminergic and noradrenergic neurons. 
However, in the SNc the only chatecholaminergic neurons present are dopaminergic (Pickel 
et al., 1977; Wassef et al, 1981) thus, TH is a suitable marker for quantification of 
dopaminergic neurons in the SN. TH immunostaining is an accurate and rapid method to 
assess the integrity of the SN after 6-OHDA lesion induction and /or to asses the effect of 
potential neuroprotective/neurorestorative treatments on the integrity of dopaminergic 
neurons. The staining was performed on 20µm thick, free-floating nigral sections as 
described in (see section 2.2.1.2). The details of primary and secondary antibodies and their 
working dilution may be found in (Table 2.1). The staining was performed on 6-OHDA 
lesioned, sham operated and/or drug treated animals. Once the immunostaining was 
completed sections were analysed under a light microscope (Nikon Eclipse E400) and the 
number of TH+ve dopaminergic neurons was counted at both ipsi and contralateral sides of 
the 6-OHDA lesion or sham operated animals.  
2.2.1.4 Immunostaining for markers of glial cell activation in the SNc 
To monitor the effect of 6-OHDA and/or drug treatments on the activational state of 
microglial cells in the SNc, resident microglia and macrophages were detected using three 
different antibodies outlined below. The working dilution and secondary antibodies used 
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may be found in Table 2.1. Staining was performed on 20μm thick consecutive free floating 
sections of the SNc of 6-OHDA lesioned, sham operated and/or drug treated animals as 
previously described (see section 2.2.1.2). The immunostained sections were analysed 
microscopically and were assessed both quantitatively and qualitatively, the details of the 
criteria used for their analysis are outlined in section 2.2.3.1 and 2.2.3.2. 
OX-6: to detect the activation of a population of microglial cells that express major 
histocompatibility complex II (MHC II) surface receptor. 
OX-42 (CD11b): to monitor the activation of brain resident monocytes/microglial cells. 
This antibody recognises the presence of leukocyte integrin complement receptor type 
3 (CR3) on microglia. 
CD-68: to detect the presence of macrophages with phagocytic function, this antibody 
recognises a glycoprotein that is expressed predominantly on the lysosomal membrane of 
myeloid cells. 
2.2.1.5 Immunostaining for matrix metalloproteinase 3 (MMP3) expression in SNc  
 
MMPs belong to a family of zinc-dependent proteases. The main function associated 
with MMPs is degradation and remodeling of extracellular matrix proteins. They are known 
to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands and 
chemokine activation. Immunostaining for MMP-3 and MMP-9 was performed to monitor 
the effect of 6-OHDA on the number of MMP-3 and MMP-9 expressing cells in the SNc.  
The working dilutions and secondary antibodies used may be found in Table 2.1. Staining 
was performed on 20µm thick consecutive free floating sections from the SNc of 6-OHDA 
lesioned and sham operated animals as described in section 2.2.1.2. The immunostained 
sections were analysed microscopically. MMP-3 and MMP-9 positive cells were analysed 
morphologically and quantitatively, the details of the criteria used for their analysis are 
outlined in section 2.2.3.3. 
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    Epitope 
Antibody 
and its 
working 
dilution 
Source Secondary antibody 
Secondary 
antibody 
working 
dilution 
      Source 
Tyrosine 
Hydroxylase 
(TH) 
Polyclonal 
rabbit α-rat 
TH 
1:000 
Pel-
freez 
(USA) 
Biotinylated 
rabbit α-rat 
made in goat 
1:200 
Vectorlabs 
Peterborough, 
UK 
 
OX42 
Monoclonal 
mouse α-rat 
OX42 
1:750 
Serotec 
(UK) 
 
Biotinylated 
mouse α−rat 
made in horse 
 
1:100 
Vectorlabs 
Peterborough, 
UK 
 
OX6 
Monoclonal 
mouse α−rat 
OX6 
1:750 
Serotec 
(UK) 
 
Biotinylated 
mouse α−rat 
made in horse 
 
1:100 
 
Vectorlabs 
Peterborough, 
UK 
 
CD68 
Monoclonal 
mouse α-rat 
CD68 
1:750 
Serotec 
(UK) 
 
Biotinylated 
mouse α-rat 
made in horse 
 
1:100 
 
Vectorlabs 
Peterborough, 
UK 
 
MMP-3 
Polyclonal 
rabbit α-rat 
MMP-3 
1:100 
Santa-
Cruz 
(USA) 
Biotinylated 
rabbit α-rat 
made in goat 
1:200 
 
Vectorlabs 
Peterborough, 
UK 
 
MMP-9 
Polyclonal 
rabbit α-rat 
MMP-9 
1:100 
Santa-
Cruz 
(USA) 
Biotinylated 
rabbit α−rat 
made in goat 
1:200 
 
Vectorlabs 
Peterborough, 
UK 
 
Table 2.1 Details of all primary and secondary antibodies utilised in ABC  
 immunohistochemistry. Sources as well as optimal working dilutions are also shown. 
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2.2.2 Double immunofluorescence 
 
Double-labelling immunofluorescence techniques detect the localization of a protein 
relative to another protein and allow analysis of co-localization at a cellular and sub-cellular 
level. Immunofluorescence staining methods can also be used successfully for labelling 
multiple antigens in the same preparation. Such methods are especially useful for co-
localization of antigens in the same compartment of a cell, and in this regard offer a distinct 
advantage over enzyme-based detection systems. In this project the traditional approach to 
double fluorescent labelling has been used in which fluorescently conjugated secondary 
antibodies are targeted against primary antibodies from different species. Although this 
technique in general tends to be less sensitive than enzymatic staining, the sensitivity of the 
fluorescent stain can be increased by using a (strept) avidin-biotin system for amplification 
of the label. The dyes chosen for immunofluorescence are excited by a specific wavelength 
of light, usually blue or green, and emit light of a different wavelength in the visible 
spectrum.  By using selective filters, only the light coming from the dye or flurochrome 
used is detected in the fluorescence microscope.  By attaching different dyes to different 
antibodies, the distribution of two or more molecules can be determined in the same cell or 
tissue section. The general protocol for double fluorescence immunostaining is out-lined in 
the following section (see section 2.2.2.1). 
 
2.2.2.1 General immunofluorescence protocol 
 
One of the immunohistochemical methods used throughout this project was double 
immunofluorescence technique. All primary and secondary antibodies were titrated to 
obtain the optimum working dilution (Table 2.2). Any modifications made to this protocol 
are mentioned in individual experiment. Coronal sections of the entire SN that expands 
from  -4.80 to 6.30 mm from the bregma were cut at 20µm thickness on a cryostat (Bright 
Instruments, Cambridge, UK) maintained at -20 ºC. Free floating sections were collected in 
a 24 well plates (Falcon, Beckton Dickenson, Cowley, UK) and were stored at 4°C in 0.1M 
phosphate buffered saline (PBS) containing 0.05% sodium azide as preservative, pH 7.4. 
Prior to staining  minimum three and maximum six tissue sections were transferred to 
individual wells in 2mls of  0.1M PBS. Excess sodium azide was washed out by rinsing 
section 3x 5min in 0.1M PBS on a shaking platform. To facilitate antibody penetration 
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sections were incubated for total of 15min in 0.1 M PBS containing 0.05%. Triton X-100. 
In order to eliminate any non-specific antibody binding tissue sections were blocked for 1 
hour in the appropriate non-immune  sera diluted in 0.1M PBS. Normal goat serum (Vector 
Labs, Peterborough, UK) was used when the secondary antibody was raised in goat and 
normal horse serum (Vector Labs, Peterborough, UK) was used when the secondary 
antibody was raised in horse (Table 2.2). Sections were then incubated for 18 hours (over-
night) with two different primary antibodies that recognise two different antigens of interest, 
for the purpose of determination of co-localisation. The primary antibodies that were co-
incubated were not made in the same animal species to eliminate cross-reactivity. In all 
cases negative controls were included and non showed immunoreactivity (Data not shown).  
Tissue sections were then incubated in appropriate secondary antibodies in the dark for 60 
minutes. Secondary anti-bodies had fluorescent dye attached to the antibody so that they are 
detected by UV light. Sections were then wet mounted onto Poly-l-lysine coated slides in 
dark and left to dry at room temperature. Once dry sections were cover-slipped using 
Vectasheild Hard Set mounting medium with DAPI with is a marker for cell nucleus 
(Vector Laboratories, Peterborough, U.K.) before being examined on a Nikon Eclipse 
E1000 fluorescence microscope using appropriate filter sets. DAPI (4’, 6-diamidino-2-
phenylindole) bind to the DNA and is used to mark cell nucleus. DAPI produces a blue 
fluorescence with excitation emission at about 460 nm when bound to DNA. The details of 
all primary antibody co-incubations, working dilution, secondary antibodies and their 
working dilution and the wavelength at which the fluorescent dyes attached emit light that is 
in visible spectrum may be found in (Table 2.2). Table 2.2 provides details of co-
localisation studies that were performed through out this project, specificity and choice of 
each marker is discussed in individual studies and experiments.  
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Table 2.2 Details of all antibody co-localisation experiments and working dilutions in 
addition to their relevant secondary antibodies.  
1st AB Source 2nd AB source 1
st secondary 
AB 
Emission 
 (nM) 
2nd secondary 
AB 
 
Emission 
(nM) source 
Polyclonal 
rabbit α-rat 
TH 
1:500 
Pel-freez 
(USA) 
Monoclonal 
mouse α-rat 
OX6 
1:750 
Serotec 
(UK) 
Alexa fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
TH 
1:500 
Pel-freez 
(USA) 
Monoclonal 
mouse α-rat 
CD68 
1:750 
Serotec 
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
TH 
1:500 
Pel-freez 
(USA) 
Monoclonal 
mouse α-rat 
NeuN 
1:2000 
Chemico
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
Ki67 
1:200 
Clone TEC-3
Dako  CA 
(USA) 
Monoclonal 
mouse α−rat 
OX-6 
1:750 
Serotec 
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
iNOS 
1:400 
Calbiochem
(UK) 
Monoclonal 
mouse α-rat 
OX-6 
1:750 
Serotec 
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
MMP-3 
1:200 
Santa-Cruz 
(USA) 
Monoclonal 
mouse α-rat 
GFAP 
1:500 
Sigma 
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
MMP-9 
1:200 
Santa-Cruz 
(USA) 
Monoclonal 
mouse α-rat 
GFAP 
1:500 
Sigma 
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
MMP-9 
1:200 
Santa-Cruz 
(USA) 
Monoclonal 
mouse α-rat 
NeuN 
1:2000 
Chemico
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
MMP-3 
1:200 
Santa-Cruz 
(USA) 
Monoclonal 
mouse α-rat 
NeuN 
1:2000 
Chemico
(UK) 
Alexa Fluor 
488 goat a-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
Caspase-3 
1:300 
Serotec(UK)
Monoclonal 
mouse α-rat 
NeuN 
1:2000 
Chemico
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
MMP-3 
1:200 
Santa-Cruz 
(USA) 
Monoclonal 
mouse α-rat 
CD200R 
1:100 
Serotec 
 
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
Polyclonal 
rabbit α-rat 
Caspase-3 
1:300 
Serotec(UK)
Monoclonal 
mouse α-rat 
CD68 
1:750 
Serotec 
(UK) 
Alexa Fluor 
488 goat α-rabbi
1:300 
519 
Cy3 conjugat
goat α-mouse
1:300 
670 Invitrogen(UK) 
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2.2.3 Cell counting and morphological assessment of immunostained cells 
2.2.3.1 Quantitative cell counting for TH+ve, glial cells, MMP-3+ve and MMP-9 +ve in 
SNc and VTA 
 
In order to quantify the number of TH+ve dopaminergic neuronal bodies the 
counting was performed manually using a Nikon Eclipse E800 microscope (Nikon, Tokyo, 
Japan) connected to a JVC analogue camera at x100 magnification. TH+ve neurons were 
counted in both ipsi and contralateral hemispheres of the brain in each of the stereotaxic 
regions of the SN and adjacent VTA area, (-4.80,-5.30,-5.60,-5.80 and -6.30 mm from 
bregma) (Carman et al., 1991) to ensure complete sampling of the entire structures; ventral 
tegmental area (VTA) and SNc. The stereotaxic region in each section was determined by 
examination of the shape and distribution of TH+ve neurons at low magnification (x40) 
with reference to the standard rat brain atlas of Paxinos and Watson (1986). The SNc was 
delineated from the VTA by reference to specific anatomical landmark of the third cranial 
nerve rootlet as previously described by Iravani et al., (2002). To minimise bias the operator 
was assessed for the consistency of counting in each stereotaxic level of the SNc prior to 
cell counting. Cells that were intact with a nucleus, clear cytoplasm and axonal processes 
were included into the counts and cells that appeared deformed with no obvious axonal 
processes were excluded from the counts (Iravani, et al, 2002). For each animal, cell counts 
were carried out through the entire structure of the SN. The counts were pooled together to 
give a total mean cell count for ipsi and contralateral hemispheres in each group. To ensure 
an unbiased cell counts the operator was blinded to the treatment under analysis. The same 
approach was employed for quantitative counting of MMP-3+ve and MMP-9+ve cell. 
Representative photomicrographs were captured at x100, x400 magnifications using Image 
ProPlus v5.0 software (Media Cybernetics, UK). A similar approach was utilized for 
quantitative counting of the inflammatory markers using x200 magnification.  
 
2.2.3.2 Morphological assessment of glial cells 
 
The criteria that was used for the assessment of the activational state of glial cells in 
the SNc and VTA is outlined below. It should be noted that criteria for assessment of any 
other non glial markers which had a glial expression are dealt with in individual sets of 
experiments in relevant sections. 
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Glial cells acquire different morphologies depending on their function. Therefore 
alongside quantitative counting, assessment of their morphology and pattern of expression 
is necessary when their functional properties are being studied. The pattern of expression of 
microglia (OX6 and OX42+ve cells) and macrophages (CD68+ve cells) was divided into 
three categories that are referred to as, no expression, focal expression and widespread. No 
expression: no immunoreactivity for OX6, OX42 and CD68 was observed in the SN and 
VTA. Focal expression:   OX6, OX42 and/or CD68 immunoreactive cells were observed to 
be present in the SN and/or VTA and their expression is confined to these areas only. 
Widespread: the immunoreactivity is observed in other regions of the brain tissue sections 
as well as the SNc and the VTA. Microglia/macrophages (OX6 and OX42 and CD68+ve 
cells) go through a morphologically graded response, from resting to activated. These cells 
are considered activated when they show intense expression of either OX42 or OX6 or 
CD68, their cell soma is hypertrophied and they have thickened and shortened processes 
(Fig 4.2C). These cells are fully active when they have amoeboid morphology with very 
short and thick processes (Fig 4.2B). Microglial cells were considered to be at rest when 
they had moderate expression of either OX42 or OX6 or CD68, a small cell body with very 
thin but numerous processes with ramifications (Fig 4.2A). The pattern and morphology of 
microglial cells was analysed using Nikon Eclipse E800 light microscope (Nikon, Tokyo, 
Japan) under x200 magnification. Figure 2.4 shows representative photomicrographs of 
OX6+ve  and OX42+ve microglia taken at x400 magnification. 
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Figure 2.4 Representative photomicrographs of DAB peroxidase immunostaining for 
OX6+ve and OX42+ve microglia in the SNc following 6-OHDA lesion induction. 
 
A) Activated OX6+ve microglial cell with hypertrophied cell body and very few 
processes. 
B) Fully activated OX6+ve microglia (black arrows) with amoeboid morphology and 
no processes. 
C) Activated microglia with intense expression of  OX42 antibody and  hypertrophied 
cell bodies with  thickened and shortened processes. 
 Images were taken at x400, scale bar represents 10μm. 
OX 6 
OX 6 
A B
OX 6 
A B
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2.2.4 Assessment of the concentrations of striatal monoamine by High Performance 
Liquid Chromatography (HPLC) 
 
 
HPLC with electrochemical detection (ECD) was performed to measure the 
concentration of monoamines in the brain in order to assess the functionality of the 
nigrostriatal tract. Therefore concentrations of striatal monoamines, specifically dopamine 
(DA) and its metabolites, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid 
(HVA) were measured.  
 
2.2.4.1 HPLC methodology  
 
HPLC procedure was performed as previously described by Datla et al., (2002). 
Briefly, individual samples from left and right striatum were weighed and homogenised in 
500 µl of ice-cold homogenising buffer (50 mM trichloroacetic acid, 0.5 mM disodium 
ethylenediaminetetraacetic acid (EDTA) and 0.5 pmol/μl 3,4-dihydroxybenzylamine 
hydrobromide as an internal standard, for 20 sec using an ultrasonicator (Soniprep, Sanyo, 
UK). Samples were placed on ice for 10 min to allow complete extraction of monoamines 
and then centrifuged at 13,000 rpm for 10 min at 4°C (Heraeus, UK). The resultant 
supernatant was then filtered through a 0.45 μM syringe pore filter (Whatman, UK) into 
glass HPLC vials (Chromacol, UK) and loaded onto an autosampler (Gina 50 Dionex, UK) 
maintained at 5°C and  connected to a PC-based control system running Chromeleon 
software (Dionex UK). From each sample 20 μl was injected and chromatographically 
separated on an Altex ultrasphere 5 μM column (4.6 mm x 7.5 cm; Beckman, UK) using a 
mobile phase consisting of 0.1 mM KH2PO4, 0.1 mM EDTA, 1 mM octyl sodium sulfonate, 
18% methanol V/V, adjusted to pH 2.5 with orthophosphoric acid, at a flow rate of 1.2 
ml/min. To reduce background current and improve base line noise samples passed through 
a guard cell (model 5020,ESA Bioscience, UK) containing a porous graphite electrode set at 
+400mV to remove any electroactive impurities before reaching the column and the 
detector. Samples were quantified by an analytical cell (model 5011, ESA Bioscience UK) 
attached to a Coulochem II electrochemical detector (ESA Analytical) with electrode one at 
-0.20 V and electrode two at +0.34 V with respect to the palladium reference electrode. 
Calibration curve were calculated for each monoamine to ensure a linear relationship 
between the solute and the concentration of each monoamine. In addition, to facilitate the 
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quantification of monoamines and to determine the exact retention time for each 
monoamine in the samples, external standards of known concentration were analysed prior 
to each sample run (Fig 2.5). Chromatographic data were collected and analysed using PC-
based Chromeleon software (Dionex, UK). The levels of monoamines in the lesioned and 
unlesioned rats for control and drug treated groups were then compared and analysed 
statistically as described below (see section 2.3).  
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Figure 2.5 Representative chromatogram trace, showing detection of monoamines in 
the external standards by HPLC-ECD. Typical retention times were: Internal std 1.75 
min, dihydroxyphenylacetic acid (DOPAC) 2.6 min, dopamine (DA) 2.8 min, 5-
hydroxyindoleacetic acid (5-HIAA) 3.8 min, homovanillic acid (HVA) 5.3 min and 5-
hydroxytryptamine (5-HT) 6.0 min. 
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2.3 Statistical analysis of the data 
 
All data (except where stated) are presented as the mean ± SEM based on n 
independent observations. Multiple comparisons were made within and between different 
groups of 6-OHDA lesioned and/or drug treated animals. The significance levels for the 
extent of cell loss in SNc and VTA and increase or decrease in the number of inflammatory 
cells were calculated by two-way analysis of variance (ANOVA) and post- tested with  
post-hoc parametric Newman-Keuls Multiple Comparison test using GraphPad Prism v5.00 
(GraphPad software, USA) software. The significance of monoamines loss in the striatum 
within and between different groups of animals was calculated by two-way analysis of 
variance (ANOVA) and post- tested with  post-hoc parametric Newman-Keuls Multiple 
Comparison test using GraphPad Prism v5.00 software (Graphpad software, USA). The 
concentration of monoamines are presented in (ng monoamine/mg striatal tissue) as mean ± 
SEM. Differences were considered statistically significant at p <0.05. 
All the above mentioned methods and data analysis were carried out by the author, 
however due to the large number of animals technical assistance was received from Miss 
Lauren Broom in oral dosing of the experimental animals. 
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Chapter 3   
A time course study into the relationship between microglial 
activation and dopaminergic neuronal cell loss in the 
substantia nigra of 6-hydroxydopamine model of Parkinson’s 
disease. 
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3.1 Introduction  
 
Inflammation is the first line of defence against injury and infection. However, an 
excessive inflammatory response can be a source of additional injury to host cells (Wyss-
Coray and Mucke, 2002). The brain has a relatively low adaptive immune response but is 
vulnerable to innate immune reactions. Neurons, as a result of a lack of ability to divide and 
little ability to recover from injury, are extremely vulnerable to auto destructive immune 
and inflammatory processes (Carson et al., 2006). This might hinder the recovery of 
neurological function at sites of inflammation or even exacerbate neuronal injury. The 
hallmark of brain inflammation is the activation of glia, particularly microglia. Studies into 
the role of microglia in PD pathology are recent and little is known about the cellular events 
between activated microglia and degenerating neurons in the in vivo models of PD. Indeed, 
convincing evidence of a pathogenic role for activated microglia in PD has already begun to 
emerge.  Microglia comprise approximately 12% of cells in the brain that are derived from 
myeloid cells in the periphery with the highest concentrations being found in the substantia 
nigra, basal ganglia and hippocampus (Lawson et al., 1990). Microglia, are the resident 
innate immune cells in the brain that during homeostasis perform a dynamic surveillance of 
the CNS environment. Although phenotypically down regulated, recent imaging studies in 
vivo show that microglial cells, even in their so-called resting state, are highly active, with 
their fine processes continually surveying their local microenvironment (Fetler and 
Amigorena, 2005). 
Conversely under pathological conditions such as neurodegenerative diseases 
activated microglia contribute to neuronal damage in which the over activation and 
dysregulation of microglia results in progressive neurotoxic consequences (Kim et al., 
2007). The exact cause and cellular events that leads to microglial activation is not yet fully 
understood however factors including, brain bacterial and viral exposure, pesticides, drug 
contaminants, and repeated head trauma lead to an active glial response. Once activated, 
microglia display conspicuous functional plasticity and transform into a macrophage-like 
phenotype, which involves morphological changes, proliferation, increased expression of 
cell surface receptors and the production of neurotrophic and neurotoxic factors. Activated 
microglia, are thought to contribute to neuronal damage, particularly via the release of pro-
inflammatory and neurotoxic factors. In PD, nigral microglia are not only highly activated 
but also highly clustered around dystrophic dopaminergic neurons. A glial response has 
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been observed in the vicinity of dying dopamine-containing neurons in human post-mortem 
SN from PD patients (McGeer et al., 1988) and MPTP-intoxicated individuals (Langston et 
al., 1999). In PD patients higher levels of the pro-inflammatory cytokines such as:  IL-1β 
and interferon-γ (IFN- γ) were detected in the cerebrospinal fluid (CSF) and the striatum 
(Liu  et al., 2003) indicating a state of chronic inflammation in the PD brain.  
 
Inflammation has also been implicated in the neurodegenerative process in animal 
models of PD created by using neurotoxic compounds such as MPTP, 6-OHDA or rotenone. 
Many studies indicate that in addition to the impairment of dopamine-containing neurons 
following MPTP intoxication there is also microglial and astroglial reaction in the damaged 
regions that is associated and co-localised with increased iNOS expression and nitrotyrosine 
formation (Wu et al., 2002). Reduction in MPTP-induced toxicity that was observed after 
genetic inactivation or pharmacological inhibition of iNOS (Dehmer et al., 2000) further 
supports important role of glia-derived NO in mediating MPTP toxicity. Additionally, 
inactivation of genes involved in inflammation such as those encoding cyclooxygenase 2 
(COX-2) (Feng et al., 2002), NADPH oxidase (Gao, 2003) and both TNF-α receptors 
(Ferger et al.,  2004) protects dopamine-containing neurons against MPTP-induced 
neurotoxicity, indicating that inflammation is an important component of the MPTP 
mediated neurodegenerative process. 6-OHDA-induced degeneration of the dopamine-
mediated pathway is associated with a microglial response in the nigrostriatal system 
(Cicchetti et al., 2002). Elevated levels of TNF-α have also been observed in both the 
striatum and the SNc of 6-OHDA-injected rats (Mogi et al., 1999). Another line of evidence 
supporting glial involvement in PD is that microglial activation induced by pro-
inflammatory lipopolysaccharide (LPS) is capable of initiating the degeneration of 
dopamine-containing neurons in the SNc of experimental animals and in cell cultures 
(Iravani et al., 2002; Liu, 2003). Furthermore, LPS and the pesticide rotenone 
synergistically induce a selective degeneration of dopamine-containing neurons in primary 
midbrain neuron–glia cultures (Gao et al., 2003), further supporting an important role of 
inflammation in the pathogenesis of PD. Post-mortem and experimental models of PD all 
indicate that chronic inflammation is an on going process in the pathogenesis of PD. 
Particularly, nearly all the proposed aetiologies of PD, including brain bacterial and viral 
exposure, pesticides, and repeated head trauma, are known to cause brain inflammation 
suggesting that microglial activation caused by preceding brain inflammation may trigger 
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the onset of a cascade of events leading to chronic, progressive degeneration of 
dopaminergic neurons (Liu and Hong 2003; Herrera et al., 2005). Indeed evidence shows 
that an inflammatory response in the brain is not always deleterious; in acute 
neuroinflammatory conditions such as stroke or acute brain injury, microglial activation is 
accompanied by secretion of anti-inflammatory and trophic factors to promote tissue repair 
and minimise the damage (Wyss-Coray and Mucke, 2002). Following an acute insult the  
innate immunity primes the microglia to exert phagocytic activity in removal of cell debris 
and dead neurons to reduce secondary damage (Glezer et al., 2006; Neumann et al., 2006; 
Simard and Rivest, 2006; Simard et al., 2006; Sriram et al., 2006). Therefore, a crucial 
factor in determining the fate of activated microglia following an insult is time. To date , 
limited information is available on the time frame of activation of microglia in PD. It is not 
known  whether inflammation precedes dopaminergic cell loss or is a consequence of it?  
The mechanism by which activated microglia might specifically target dopaminergic 
neurons and the cell to cell interaction between activated microglia and degenerating 
dopaminergic neurons in the in vivo models of PD remains a critical missing link .Therefore 
the aim of this study was to address the following questions:  what is the kinetic (time 
course) of immunophenotypic changes of activated microglia and the subsequent fate of 
activated microglial cells during the initiation and progression of dopaminergic neuronal 
loss in the SNc after unilateral injection of 6-hydroxydopamine (6-OHDA) into the medial 
forebrain bundle (MFB).  
To satisfy these aims each group (n=6) of animals was sacrificed on days 
1,3,5,7,9,13 and 15 after 6-OHDA lesion induction. The integrity of dopaminergic neurons 
in the SNc was determined by counting the number TH+ve dopaminergic neurons in the 
SNc in each group compared to control sham operated animals. The functionality of the 
nigrostriatal tract was determined by measuring the amount of striatal dopamine in each 
group utilising HPLC-ECD. In addition, the time course of microglial activation and their 
morphological characteristics were determined by immunostaining for different glial 
markers such as: OX42, OX6 and CD68, detailed experimental design may be found in the 
following section (see section 3.2).  Finally the association of microglial activation with 
dopaminergic neuronal cell death was studied by carrying out different double 
immunofluorescent stainings for co-localisation of different markers, which is described in 
detail in the following section (see section 3.2.1.2). 
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3.2 Experimental design 
 
3.2.1 Dopaminergic neuronal loss in the SNc following 6-OHDA lesion induction in  
relation to the dynamic of microglial activation 
 
3.2.1.1 Assessment of the nigrostriatal lesion progression after 6-OHDA injection 
into the MFB 
 
To investigate the relationship between the kinetics of reactive gliosis and the extent 
of dopaminergic neuronal cell loss in the SNc, male Sprague-Dawley rats were divided into 
experimental groups (n=6) and a unilateral 6-OHDA lesion was induced stereotaxically into 
the MFB (see section 2.1.2.2). Subsequently animals were sacrificed by CO2 over dose at 
day 1 (24 hours after 6-OHDA injection), 3, 5, 7,9,13 and 15  after 6-OHDA or sham (4µl 
0.1% ascorbic acid) lesion induction and the brains were removed (see section 2.1.3). To 
assess the integrity of dopaminergic neurons in the  SNc and the VTA at different time 
points following 6-OHDA lesioning immunohistochemistry was performed for Tyrosine 
hydroxylase (TH) positive dopaminergic neurons (see section 2.2.1.3). The number and 
morphology of TH+ve cells were then determined according to the criteria described in (see 
section 2.2.3). To investigate the effect of 6-OHDA lesioning on the functionality of the 
nigrostriatal system on days 1, 3, 5, 7,9,13 and 15 after lesioning concentration of dopamine 
in the striatum was measured using HPLC-ECD (see section 2.2.4). To further assess the 
kinetic of microglial activation at different time points following 6-OHDA or sham lesion 
induction  immunohistochemistry was performed for OX42, OX6 and CD68 expression that 
is outlined in the following section (see 3.2.1.2). 
 
3.2.1.2. Assessment of the kinetics of microglial activation and changes in morphology 
following 6-OHDA lesion induction  
To assess the number of activated microglial cells and their morphology in the SNc 
on days 1 ,3,5,7,9,13 and 15 after 6-OHDA lesioning, peroxidase immunohistochemistry 
was performed using the following antibodies, details of staining procedure is outlined in 
(see section 2.2.1.4).  
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OX6: was used to detect the population of activated microglial cells that express major 
histocompatibility complex II (MHC II) surface receptor. 
OX42 (CD11b): to monitor the activation of a population of brain resident 
monocytes/microglial cells that express the leukocyte integrin complement receptor type 
3 (CR3). 
CD68: to detect the activation of a population of macrophages with phagocytic function, 
that expresses CD68 glycoprotein predominantly on their lysosomal membrane. 
Microglial cells expressing OX6, OX42 and CD68 were morphologically assessed 
and counted in the SNc according to the criteria described in (see section 2.2.3). To 
investigate the interaction between TH+ve dopaminergic neurons and microglial cells at 
different time points following 6-OHDA or sham double immunofluorescence staining was 
performed which is outlined in the following section. 
3.2.1.3 Assessment of neuron-glia interactions following 6-OHDA/sham lesion 
induction in the SNc 
To be able to explore the effect of neuron-microglia interactions on dopaminergic 
cell loss the following double immunofluorescence stainings were performed; detailed 
description of immunofluorescence protocol is described in (see section 2.2.2) 
TH+ Neuronal-N (NeuN) 
To determine the expression of TH in neurons and to be able to associate any observed loss 
of TH immunoreactivity to neuronal loss rather than the enzyme down-regulation. 
TH + OX6  
To observe the interaction between TH+ve dopaminergic neurons and MHC II antigen 
presenting microglial cells at different time points following 6-OHDA lesioning in the SNc.  
TH + CD68 
To observe the interaction between TH+ve dopaminergic neurons and CD68+ve phagocytic 
macrophages in the SNc at different time points following 6-OHDA lesioning. 
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OX6 + Ki67 
To assess the proliferative activity of MHC II antigen presenting microglial cells following 
6-OHDA/sham lesion induction at different time points. 
OX6+iNOS 
To determine the expression of iNOS by the activated microglial cells in the SNc following 
6-OHDA lesion induction. 
Caspase 3 + NeuN 
To assess the occurrence of neuronal apoptosis following 6-OHDA or sham lesion induction 
in the SNc.  Therefore co-localisation of NeuN antibody, a neuron-specific nuclear protein 
with caspase3, a key protease that is activated during the early stages of apoptosis was 
studied. 
Caspase 3 + CD68 
To assess the interaction between CD68+ve phagocytic microglia and apoptotic cells in the 
SNc following 6-OHDA lesion induction. 
3.3 Statistical analysis  
 
Manual cell counts for dopaminergic neurons and different populations of glial cells 
were carried out on serial sections through the entire nigra for each animal .The data from 
each time point are  expressed as the mean + SEM based on n independent observations 
(n=6). Multiple comparisons were made comparing different time points and the statistical 
significance between and within groups was assessed using repeated measures two-way 
ANOVA followed by post-hoc Newman-Keuls Multiple Comparison test as described in 
(see section 2.3). A value of P < 0.05 was considered statistically significant. 
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3.4 Results 
3.4.1 6-OHDA induces a progressive loss of dopaminergic neurons and striatal  
Dopamine, with local activation of microglia in the SNc 
 
3.4.1.1 Effect of 6-OHDA on TH+ve dopaminergic neurons in the SNc and dopamine  
content in the striatum 
To detect the effects of 12µg 6-OHDA (in 4µl) injection into the MFB on neuronal 
survival in the SNc, the number of TH+ve dopaminergic neurons in the SNc were 
monitored. The results are shown as the mean number of cell counts for TH+ve neurons in 
the SNc at different time points after toxin injection. As shown in (Fig. 3.1) 6-OHDA 
injection caused a progressive loss of nigral TH+ve neurons in the SNc.  Comparison of the 
number of nigral TH+ve neurons between lesioned and unlesioned sides showed no 
significant loss of TH+ve neurons within the first 7 days after 6-OHDA injection. Cell 
counts on day 7 were lesioned: 73 ± 8.08, unlesioned 93 ± 8.80, p>0.5.  However, 
significant loss of TH+ve neurons in the lesioned hemisphere started to manifest from day 9 
compared to the unlesioned hemisphere (lesioned: 40 ±5.25, unlesioned: 86±5.25, p<0.01). 
Unilateral dopaminergic neuronal loss progressed up to day 15 after lesion induction 
comparing lesioned and unlesioned hemispheres. Cell counts on day 15 showed unlesioned: 
75±12, lesioned 32.5±1.5, p<0.01. Whereas, TH+ve cells were not observed in the VTA 
(Fig 3.1). In particular, neurons in the lateral portion and ventral tier of the SNc were most 
vulnerable (Fig 3.2 panel B). At all time points studied the loss TH immunoreactivity was 
accompanied by a comparable loss of NeuN immunoreactivity, indicating that neuronal cell 
bodies are lost, rather than a down regulation of TH expression (Fig 3.3). In sham lesioned 
animals no significant loss of TH+ve dopaminergic neurons were observed compared to the 
unlesioned side (data not shown). Concomitant with the loss TH+ve dopaminergic neurons 
in the SNc injection of 12µg 6-OHDA (in 4µl) into the MFB was followed by significant 
depletion of striatal dopamine ipsilateral to the lesioned hemisphere compared to the 
unlesioned hemisphere (Fig 3.4). Dopamine depletion started to manifest itself  from day 9 
[lesioned: 4±1.68 (ng/mg), unlesioned: 11.1±0.14 (ng/mg), p<0.001] similar to the loss of 
TH+ve neurons in the SNc. Unilateral loss of dopamine was observed  to the day 15 after 
lesion induction on the side of the lesion compared to the unlesioned hemisphere (lesioned : 
4±2.2 , unlesioned: 13.02± 1.1, p<0.001)   In the sham lesioned animals no significant loss 
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of dopamine content was observed in the lesioned hemisphere compared to unlesioned 
hemisphere (data not shown). Hence, progressive and partial lesion in the nigrostriatal 
system started to manifest from day 9 following 12µg 6-OHDA injection into the MFB.  
The lesion is characterised by dopaminergic neuronal loss in the SNc that is concurrent with 
progressive depletion of dopamine in the striatum.  
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Fig 3.1 Time dependent TH+ve dopaminergic neuronal cell death in the SNc but 
not VTA following 6-OHDA lesion induction. 
 
Male SD rats were injected with 12 μg 6-OHDA or with ascorbic acid (as sham) into 
the MFB and maintained under normal conditions. Animals were sacrificed at the 
indicated time points and coronal brain sections (20 μm thick) were cut through the 
nigra. Immunostaining was carried out with TH antibody and TH+ve neurons in SNc 
and in VTA were counted. Results are expressed as   mean number of cells + SEM. 
Panel (A) shows the number of TH +ve neurons in SNc at different time points after 6-
OHDA injection, significant TH+ve dopaminergic neuronal cell death occurs from day 
9 after 6-OHDA lesion induction onwards. Panel (B) shows the number of TH+ve 
neurons in VTA at different time points after 6-OHDA injection, no significant loss 
TH+ve dopaminergic neuronal loss is observed. ** p< 0.01,*** p<0.001  compared to 
the non lesioned side. ns= non-significant. Number of animals was 6/group per time 
point.  
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Fig 3.2 Injection of 6-OHDA into the left MFB resulted in a  unilateral  
degeneration of dopaminergic neurons in the SNc. Sequential coronal brain section 
(20μm) taken at day 9 after lesion induction were immunostained   for TH as 
marker for dopaminergic neurons. 
 
 A)  Shows selective loss of TH immunoreactivity in the SNc ipsilateral to the side of 
injection. No apparent loss TH immunoreactivity in the VTA was observed (100x). 
 
B) Unilateral loss of TH+ve dopaminergic neurons in the SNc after 6-OHDA lesion 
induction ipsilateral to the lesion side on day 9. Neurons in the lateral portion and 
ventral tier (arrows) of SNc were mostly affected and lost TH immunoreacativity (x200).  
 
C) TH+ve dopaminergic neurons in the SNc contralateral to the 6-OHDA lesion side 
(x200). 
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Fig 3.3 Injection of 6-OHDA into the left MFB resulted in a  unilateral  
degeneration of dopaminergic neurons in the SNc ispsilateral to the lesion side on 
day 9 as indicated by the loss of TH+ve and  NeuN+ve cell bodies. 
 
Left panel: Co-localisation of TH+ve (green) and NeuN+ve (red) in dopaminergic 
neurons ispsilateral to the lesion side. White arrows points to loss of both TH and NeuN 
immunoreactivity in the SNc after 6-OHDA lesion induction (x100). 
 
Right panel: Co-localisation of TH+ve (green) and NeuN+ve (red) in intact 
dopaminergic neurons in the SNc contralateral to lesion side. White arrows points to 
representative dopaminergic neurons that express TH and NeuN in the SNc (x100). 
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Fig 3.4 Time dependent unilateral depletion of striatal dopamine content (ng/mg) 
following 6-OHDA lesion induction. 
Male SD rats were injected with 12 μg 6-OHDA or with ascorbic acid (as sham) 
into the MFB and maintained under normal conditions. Animals were sacrificed at the 
indicated time points and the striata were removed and processed for HPLC-ECD to 
measure the striatal dopamine content (ng/mg). Results are expressed as   mean (ng/mg) 
+ SEM. Graph shows time dependent depletion of striatal dopamine content (ng/mg) 
after 6-OHDA lesion induction in lesion side compared to the unlesion side. Dopamine 
deletion manifests from day 9 after 6-OHDA lesion induction and progresses to day 15 
after lesioning. ** p< 0.01, ***<0.001 compared to the non lesioned side. ns= non-
significant. Number of animals was 6/group per time point.  
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3.4.2 The extent of activation of microglia and their localisation in the SNc 
following 6-OHDA lesioning 
 
3.4.2.1 Effect of 6-OHDA on the number OX42+ve microglial cells in the SNc 
Interestingly, staining for microglia using OX42 antibody, indicated that overall the 
SNc contained more activated OX42+ve cells on the lesioned side at all time points studied 
compared to the unlesioned side (Fig 3.5A). The number of OX42+ve microglial cells 
increased as early as day 1 after 6-OHDA lesion induction on the lesioned hemisphere to 
the compared to unlesioned hemisphere: (lesion:  7.8 ± 0.54 ; unlesion: 1.8 ± 0.79 ). 
Significant increase in the number of OX42+ve microglial cells in the lesioned hemisphere 
compared to the unlesioned side started to manifest on day 9 after lesion induction. The 
greatest number of OX42+ve cells was observed on day 15 (lesioned: 68±10.48, unlesioned: 
11.50±2.21). This was concomitant with a significant loss of TH+ve dopaminergic neurons 
in the SNc (see section 3.4.1.1). In the sham lesioned animals no expression of OX42+ve 
cells was observed.  
3.4.2.2 Effect of 6-OHDA lesioning on the number OX42+ve microglial cells in the  
VTA 
OX-42+ve microglial cells also significantly increased in the VTA  as early as 5 
days after 6-OHDA lesion induction ipsilateral to the side of lesion compared to 
contralateral control side: (lesion:  8.70 ± 0.66 ; unlesion: 3.0 ± 0.57, p<0.05) (Fig 3.5B). 
Increase in the number OX-42+ve microglial cells progressed significantly up to day 15 
after lesion induction ipsilateral to the lesion side compared to contralateral control side 
(lesion: 21.0± 1.79 , unlesion: 8.25 ± 1.31, p<0.001), however, this was not associated with 
dopaminergic neuronal cell loss . In the sham operated animals no expression of OX42+ve 
microglial cell was observed in the VTA. The presence of activated microglia in the SNc 
and VTA following 6-OHDA lesion induction at early days post lesioning indicates that 
microglial activation is a rapid response even before any dopaminergic neuronal loss has 
been observed. Preservation of TH+ve neurons in the VTA in presence activated microglia 
suggests that the SNc is more vulnerable to a toxic insult. 
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Fig 3.5 Graphs demonstrate, time dependent increase in the number of OX42+ve 
microglia in the SNc and VTA after 6-OHDA lesion induction. 
 
A) Injection of 6-OHDA into the MFB induced an increase in the number of OX42+ve 
microglial cells in the SNc in a time dependent manner. Immunostaining was performed 
with OX42 antibody which is a general microglial marker and stains for CR3 receptor 
on microglial cells. The number of OX42+ve microglia increased significantly from day 
1 after lesion induction and progressed up to day 15 ispsilateral to the side of lesion 
compared to the contralateral side. Cell counts were performed as described in (see 
Chapter 2, section 2.2.3). B) Injection of 6-OHDA into the MFB induced increase in the 
number of OX42+ve microglial cells in the VTA in time dependent manner. The 
number of OX42+ve microglia increased significantly from day 3 after lesion induction 
and progressed up to day 15 ispsilateral to the side of lesion compared to the 
contralateral side. Results are expressed as mean number of cells + SEM, n=6. * p<0.5, 
** p<0.01, *** p< 0.001, ns= not significant. . Number of animals was 6/group per 
time point. 
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3.4.2.3 Effect of 6-OHDA lesioning on the number of OX6+ve microglial cells in the  
SNc  
OX6 +ve cells are the antigen presenting population of microglia.  OX6+ve  
microglia were  first observed in the medial part  and ventral tier of the SNc at day 1 after 6-
OHDA lesion induction when no apparent changes were observed in the number of TH+ve 
cells in the lesioned hemisphere compared  to the  non lesioned hemisphere. The number of 
OX6+ve cells gradually increased and a focal accumulation of these cells in both the lateral 
and medial portions of the SNc ipsilateral to the lesion was observed at day 7 (cell counts: 
lesion: 19.80± 2.85, unlesion: 1.25 ± 0.35, p<0.01) (Fig 3.6A). The number of OX6+ve 
cells increased significantly at day 9 following 6-OHDA lesion induction (lesioned: 
46±2.25, unlesioned: 0.75± 0.4, p<0.001), with the greatest number of OX6+ve cells at day 
13 (lesioned: 54±0.5, unlesioned: 0 ±0, p<0.001) in the lesioned side compared to the 
unlesioned side. At which time point a significant loss of TH+ve neurons in the SNc was 
also evident (Fig.3.1A). OX-6+ve microglia decreased significantly by day 15 after lesion 
induction compared to the lesion side on day 13 (Day 15 post-lesion: 35.5±11.8, Day 13 
post-lesion: 54±0.5, p<0.5). In sham lesioned animals no expression of OX6+ve microglial 
cells was observed (data not shown). Thus, OX6+ve microglial cell were focally expressed 
in the SNc   following 6-OHDA lesion induction before any dopaminergic neuronal loss 
was observed in the SNc. 
3.4.2.4 Effect of 6-OHDA lesioning on the number of OX-6+ve microglial cells in the 
VTA  
Activation and increases in the mean number of OX-6+ve microglial cells in VTA 
showed a similar dynamic pattern as observed in the SNc (see section 3.4.2.1).  The overall 
mean number of OX6+ve cells in the VTA was less than the SNc. By day 9 OX6+ve 
microglial cells reached their greatest number on the 6-OHDA lesion side compared to 
unlesion side (lesion: 18.2 ± 2.37, unlesion 0.80 ±0.20 p<0.001). The number of OX6+ve 
cells decreased significantly by day 15 (lesion: 11.0 ± 2.2, unlesion: 2.2 ± 0.4) (Fig 3.6B). 
However activation of antigen presenting microglial cells in the VTA was not associated 
with TH+ve dopaminergic neuronal loss in this area.  
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3.4.2.5 iNOS expression by OX6+ve microglia cells in the SNc following 6-OHDA  
lesion induction  
Double immunofluorescence staining demonstrated that a sub-population of 
OX6+ve microglial cells express iNOS in the SNc in the lesioned side of the brain from day 
3 after 6-OHDA lesion induction (Fig 3.7,  top and bottom panels). iNOS expression was 
observed up to day 9 after the lesion; on day 13 and 15 iNOS expression was not detected. 
This observation indicated that OX6+ve activated microglial could have the potential to up-
regulate NO production.  
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Fig 3.6 Unilateral time dependent increase in the number of OX6+ve microglial cells in 
the SNc and VTA following 6-OHDA lesion induction. 
Injection of 6-OHDA induced accumulation of OX6+ve cells in the SNc and VTA in a time 
dependent manner. A) Time-course quantification of OX6+ve microglia in the SNc. 
Immunostaining was carried out with OX6 antibody as markers for MHC II expressing 
activated microglia. The number of OX6+ve cells reached its full manifestation on day 13 
after 6-OHDA lesion induction in the lesioned hemisphere compared to the unlesioned 
hemisphere. OX6+ve microglia significantly decreased in number by day 15 after 6-OHDA 
lesion induction. Positive cells in the SNc were counted as described in (see Chapter 2, 
section 2.2.3). B) Time-course quantification of OX6+ve in the VTA. The number of 
OX6+ve cells reached its full manifestation on day 9 after 6-OHDA lesion induction in the 
lesioned hemisphere compared to the unlesioned hemisphere. OX6+ve significantly 
decreased in number by day 15 after 6-OHDA lesion induction. Results are expressed as 
mean number of cells + SEM. * p<0.5, ** p<0.01, *** p< 0.001, ns= not significant. . 
Number of animals was 6/group per time point. 
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Fig 3.7 Unilateral 6-OHDA lesion induction into the MFB resulted in activation of 
OX6+ve microglial cells (red) in the SNc ispsilateral to the 6-OHDA lesioned 
hemisphere compared to the contralateral side. The photomicrograph shows that a 
sub population of OX6+ve microglia express iNOS (green) on day 3 after lesion 
induction. 
Top panel: Shows double immunofluorescence staining for OX6+ve (red) and iNOS (green). 
The combined image shows co-localisation of a number of OX6+ve microglia with iNOS 
(white arrows) in the SNc on day 3 after 6-OHDA lesion induction in the lesioned 
hemisphere compared to the unlesioned hemisphere where no OX6+ve microglia where 
present (x200). 
Bottom panel: Shows a higher magnification of a morphologically active OX6+ve microglia 
(red) that is fully co-localised with iNOS (green). Microglial cells once activated have the 
potential to express iNOS 3 days after 6-OHDA challenge ispsilateral to the lesioned 
hemisphere (x400). 
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3.4.2.6 Effect of 6-OHDA on the number of CD68+ve microglial cells in the SNc 
 
CD68+ve phagocytic microglia were present ipsilateral to the side of the lesion 3 
days after 6-OHDA induction compared to contralateral control side. Whereas in sham 
operated animals no CD68+ve cells were detectable. Their localisation was very similar if 
not identical to that of OX6+ve cells. CD68+ve cells were mainly confined to the medial 
portion of SNc until day 7. Thereafter, the number of CD68 expressing cells progressively 
increased up to day 15 and a large number of CD68+ve cells in the medial and lateral 
portion of SNc ipsilateral to the lesion was observed, no immunoreactivity was detected on 
the unlesion side (lesioned: 40.17±3.76) (Fig 3.8). Presence of CD68+ve 
microglia/macrophages indicated that phagocytic activity accompanied neuronal 
degeneration. CD68+ve macrophages were not detected in the VTA after 6-OHDA lesion 
induction. 
 
Taken together, glial cell counts revealed that a unilateral reactive gliosis occurred 
in the SNc following 6-OHDA lesion induction. The focal activation of 
microglia/macrophages took place before any dopaminergic neuronal loss was observed. 
The number of activated microglia increased in a time-dependent manner indicating that 
their activation was associated with degeneration of dopaminergic neurons. 
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Fig 3.8 Graph showing a time dependent increase in the number of CD68+ve 
macrophages in the SNc after 6-OHDA lesion induction. 
Injection of 6-OHDA induced accumulation of CD68+ve cells in the SNc in a time 
dependent manner.  Immunostaining was carried out with CD68 antibody as markers for 
phagocytic macrophages. The number of CD68+ve cells reached its full manifestation on 
day 15 after 6-OHDA lesion induction in the lesioned hemisphere compared to the 
unlesioned hemisphere. CD68+ve cells significantly increased in number on day 9 after 6-
OHDA lesion induction that progressed to day 15. Positive cells in the SNc were counted as 
described in (see Chapter 2, section 2.2.3). Results are expressed as mean number of cells + 
SEM.  ** p<0.01, *** p< 0.001, ns= not significant. . Number of animals was 6/group per 
time point. 
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3.4.3 Morphological and phenotypic characteristics of the activated microglia  
following 6-OHDA lesion induction 
 
Morphological changes of the activated microglia following 6-OHDA lesion 
induction were studied in DAB-immunolabelled sections from the SNc.   
 
3.4.3.1 Morphological and phenotypic characteristics of OX6+ve and OX42+ve  
microglia in the SNc 
 
Following unilateral 6-OHDA administration into the MFB, OX6 and OX42+ve 
microglia not only increased in number but also appeared morphologically active. OX6 and 
OX42+ve cells were densely stained with an activated morphology characterised by an 
enlarged somas and thickened processes. OX6+ve microglia were focally accumulated in 
both the lateral and medial portions of the SNc ipsilateral to the lesion side from day 7 (Fig 
3.9 panels A and B). The observed morphology of these cells was characteristic of activated 
microglial cells that are capable of producing pro-inflammatory and cytotoxic factors. 
 
3.4.3.2 Morphological and phenotypic characteristics of CD68+ve cells in the SNc 
 
 CD68+ve microglia had a predominant amoeboid macrophage-like appearance. An 
accumulation of granular staining in the lysosomal membranes was observed in the 
cytoplasm of CD 68+ve cells indicating phagocytic activity. The observed morphology of 
CD68+ve cell was indicative of their role as active phagocytic macrophages. 
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Fig 3.9 Injection of 6-OHDA into the left MFB resulted in a unilateral and focal 
accumulation of OX6+ve activated microglia in the SNc and the VTA. Sequential 
coronal brain section (20μm) taken at day 9 after lesion induction were 
immunostained   for OX6 as marker for MHC II presenting activated microglia. 
 
 A)  Shows focal accumulation of OX6+ve microglia in the SNc and VTA in the 6-
OHDA lesioned hemisphere with no OX6+ve cells in the unlesioned hemisphere. In the 
lesioned hemisphere OX6+ve microglia are localised in both medial and lateral portions 
of the SNc (x10). B) Shows higher magnification of the SNc in the lesioned hemisphere. 
Activated OX6+ve microglia are densely stained with OX6 antibody and predominantly 
accumulated in the medial and lateral portions of the SNc and few microglial cells are 
observed in the ventral tier 9 days after 6-OHDA lesion induction (x100). Inset: 
Inserted box illustrates typical ramified morphology OX6+ve cells (x400). C) Shows 
10x higher magnification of the VTA in the lesioned hemisphere. Activated microglia 
are densely stained with OX6 antibody (x100). 
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3.4.4 The dynamics of MHC class II expressing OX6+ve microglial cell 
proliferation in the SNc 
 
The number of OX6+ve microglial cells increased locally in the SNc up to 13 days 
after 6-OHDA lesion induction (see section 3.4.2). To elucidate mechanism of proliferation 
double immunofluorescence staining was performed for cell nucleus mitotic protein marker, 
Ki67 and OX6 antibody. Microglial cells demonstrated active mitotic and proliferative 
activity on days 3, 5, 7 and 9 after 6-OHDA lesion induction. This was characterised by the 
co-localisation of the nuclear mitotic protein, Ki67 with OX-6+ve microglial cells on 
lesioned hemisphere of the brain (Fig 3.10 bottom panel). This observation further indicated 
that the glial response to 6-OHDA was a rapid response starting on day 3 after the toxin 
injection. A peak in proliferation was observed on day 7 when a large proportion of 
activated microglial cells were positive for OX6 and Ki67. Thus, a sub population of 
activated microglial cells that are OX6+ve do proliferate locally from 3 days after 6-OHDA 
lesion induction. To further assess the contribution of activated microglia to dopaminergic 
neuronal cell loss, neuron-glia interactions were studied as outline below (see section 3.4.5). 
3.4.5 Close interaction between activated microglia and degenerating  dopaminergic  
neurons in the SNc following 6-OHDA lesion induction  
 
3.4.5.1 Interaction between TH+ve dopaminergic and OX6+ve microglia cells in the  
SNc following 6-OHDA lesion induction 
 
The double- immunofluorescence staining of TH with OX6 revealed that in the  
lesioned hemisphere 3 and 5 days after 6-OHDA lesion induction considerable number of 
OX6 expressing cells were in the vicinity of the morphologically intact TH+ve neurones 
that had an intact nucleus and clear cytoplasm with axonal processes in the SNc (Fig 
3.10 ,middle panel). However, on day 9 post 6-OHDA lesion, a large number of OX6 
expressing cells were observed in close contact with the cell debris of TH+ve dopaminergic 
neurons as well as to the morphologically shrunken neurons. As shown in the 
photomicrograph in (Fig 3.10, top panel) TH immunoreactivity is preserved, however the 
morphology of the cells presents a damage neuron lacking dendritic processes. This 
observation suggests that activated microglial cells surround healthy looking neurons before 
they appear apoptotic.  
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Fig 3.10 Locally proliferating activated OX6+ve microglia are attached to 
morphologically intact TH+ve dopaminergic neurons as well as neuronal debris on 
days 7 and  9 after 6-OHDA lesion induction respectively. 
 Top and middle panels show double immunofluorescence images of OX6 (red) and TH 
(green) on days 9 and 7 respectively, post 6-OHDA lesion in the lesioned hemisphere.  
Note that OX6+ve microglia are specifically adhered to dendrites of degenerating 
neurons (top panel) or are  in close proximity to dendritic processes of structurally intact 
TH+ve neurons (middle panel, white arrows) (x400). Bottom panel shows double 
immunofluorescence photomicrograph of OX6 (red) and Ki 67 (green). Merge image 
indicates that some of OX6+ve cells are proliferating in the SNc ipsilateral to the lesion 
side on day 7 post lesion (x400). 
 
TH+ve neuronal debris 
TH+ve intact 
Ki67+ve mitotic 
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3.4.5.2 Interaction between TH+ve dopaminergic and CD68+ve macrophages in the  
SNc following 6-OHDA lesion induction  
 
CD68+ve cells were observed in close contact with morphologically normal 
appearing TH+ve dopaminergic neurons at day 3 following 6-OHDA lesion induction. 
However, CD68+ve cells were also observed to be in close proximity or adhered to the 
degenerating TH+ve cell bodies, axons and cell debris by day 9 to 15 post 6-OHDA lesion 
induction even engulfing the dying TH+ve dopaminergic neurons as shown in the 
representative photomicrograph shown in (Fig 3.11, top panel ) Moreover, staining with 
apoptotic marker caspase3, which is the executioner enzyme of apoptosis, showed that 
CD68+ve cells were in close contact to caspase3 expressing cells from day 3 after 6-OHDA 
lesion induction (Fig 3.11, bottom panel). This evidence suggests that microglial phagocytic 
activity may be initiated prior to the TH+ve neuronal demise suggesting that phagocytosis 
of apoptotic cells may take place at very early stage of neuronal loss in SNc.  
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Fig 3.11 Phagocytosis of apoptotic dopaminergic neurons by CD68+ve 
macrophages in the SNc after 6-OHDA lesion induction. Double 
immunofluorescence image of CD68+ve macrophages (red) and TH (green) or 
Caspase3 (green) on days 9 and 3 respectively post 6-OHDA lesion  
Top panel: Composite image shows engulfment of dopaminergic neurons by CD68+ve 
microglia. Note that the TH+ve dopaminergic neuron appears apoptotic (yellow arrow, 
middle image, top panel) (x400). 
 Lower panel: Composite image shows Caspase 3+ve apoptotic cells are in close contact 
with CD68+ve phagocytic microglia (white arrows) (x400). 
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3.5 Discussion 
 
In the current study the kinetic (time course) of immunophenotypic changes of 
activated microglia and the subsequent fate of activated microglial cells during the initiation 
process of dopaminergic neuronal loss in the SNc after unilateral injection of 6-
hydroxydopamine (6-OHDA) into the medial forebrain bundle (MFB) was determined. To 
be able to explore this aim, four aspects of the role of microglia were investigated. (1) The 
time course of microglial activation following 6-OHDA lesion induction, (2) morphological 
changes and immunophenotypic characteristics of activated microglial cells, (3) their 
interaction with dopaminergic neurons in the SN, and (4) the subsequent impact on neuronal 
loss.  
 
3.5.1 Microglial activation preceded dopaminergic neuronal loss in the SNc and  
dopamine depletion in the striatum 
 
Unilateral injection of 12µg 6- OHDA into the MFB led to a progressive partial 
lesion in the SNc that was evident by loss of >53% of TH+ve dopaminergic neurons. 
Significant neuronal loss started to manifest 9 days after 6-OHDA injection. It is well 
documented (Pickel et al., 1977; Wassef et al, 1981) that loss of TH-immunoreactivity in 
the SNc is indicative of degeneration of nigral dopaminergic neurones. However to rule out 
the possibility  that the observed decrease in the number of TH+ve dopaminergic neurons 
was due to the down-regulation of the enzyme, TH, or a transient atrophy of cells following 
6-OHDA, double staining for TH and NeuN was performed. The staining clearly 
demonstrated that 6-OHDA led to loss of both TH and NeuN immunoreactivity. This 
observation indicates neuronal cell bodies are lost in the lesioned hemisphere compared to 
the unlesioned hemisphere rather than down regulation of the enzyme per se or a transient 
atrophy of neurons. Studies have shown that another approach to ascertain that TH loss is 
indeed an indication of dopaminergic neuronal loss is to pre-label dopaminergic neurons 
with the retrograde neuronal tracer, Flurogold (FG). In this setting equal loss of TH 
immunoreactive neurons as well as FG immunoreactive neurons is indicative of neuronal 
loss rather than TH down regulation (Iravani et al., 2002).   6-OHDA injection into MFB 
led to concomitant partial depletion of dopamine in the striatum that also started to manifest 
on day 9 in the lesioned hemisphere compared to unlesioned hemisphere.  Dopamine was 
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depleted by >62% 9 days post-lesion induction that progressed time dependently. This is in 
accord with the characteristics of the partial lesion model of PD (see section 2.1.1.2) 
Following 6-OHDA injection to the MFB the innervation of the striatum is gradually lost 
which consequently leads to the retrograde loss of dopaminergic cell bodies in the SNc, as 
demonstrated the groups previous studies (Datla et al., 2001; 2003; 2004; Zbarsky et al., 
2005). Prior to any significant dopaminergic neuronal loss however, activated microglia 
(OX42+ve) appeared in the SNc ipsilateral to the lesion side as early as day 1–3 post 6-
OHDA lesioning. Some activated microglia also adhered to the axons or cell bodies of 
morphologically intact dopaminergic neurons, although no significant decrease in the 
number of nigral TH+ve neurons was detected by 7 days after 6-OHDA. In addition 
OX6+ve microglia increased in number significantly in SNc from day 7 following 6-OHDA 
lesion induction and their full manifestation was observed on day 9 when dopaminergic 
neuronal loss was statistically significant. This finding indicates that activated microglia 
participate in the neurodegenerative process from a very early stage when there has been no 
apparent loss of dopaminergic neurons. Moreover significant number of activated microglia 
specifically adhered to axons, dendrites, and cell bodies of degenerating DA neurons 
throughout all time points of the study. This heavy adhesion of activated microglia to the 
various parts of DA neurons was followed by a significant decrease in the number of DA 
neuronal cell bodies indicating that activated microglia are directly associated with the cell 
loss at later time points.  
To monitor the presence of different sub-populations of microglia/macrophages in 
the SNc and to distinguish between these sub-populations we utilise different antibodies, 
each targeted against a specific protein present on the surface of microglial cells. Microglia 
which, constitute the immune defence system of the CNS, share many properties with 
peripheral monocytes and macrophages, but retain unique morphological and molecular 
characteristics (Perry and Gordon, 1991; Sedgwick et al., 1991). For example, microglia can 
bind several lectins, including Griffonia simplicifolia agglutinin I B4, Ricinus communis 
agglutinin, and Mistletoe agglutinin as well as express complement receptor 3 (CR3), even 
in the resting state. Following CNS injury, microglial activation occurs within a few hours 
and activated microglia are characterised by an up regulation or de novo expression of 
several marker proteins, e.g. major histocompatibility complex (MHC) class I and II (Streit 
and Kreutzberg, 1988; Kaur and Ling, 1992; Kreutzberg, 1996). In this study, the 
expression of OX6 on a sub-population of activated microglia indicated, that microglial 
cells underwent immunological changes acquiring the ability to process and present an 
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antigen. In addition, expression of OX42 by activated microglia demonstrated the presence 
of leukocyte integrin complement receptor type 3 (CR3) on these microglia. Furthermore, a 
sub-population of activated rat microglia expressed an antigen in the lysosomal membranes 
that was recognized by the monoclonal antibody CD68 (ED1). The amount of CD68 
expression in a single cell can be correlated to phagocytic activity of the respective cell type 
(Damoiseaux et al., 1994). In fact, it has been demonstrated that ED1+ve microglia are 
phagocytic in several types of neurodegenerative conditions, such as traumatic brain injuries 
(Rinaman et al., 1991; Frank and Wolburg, 1996). We found that OX6+ve microglia, which 
recognize rat MHC II, appeared at the 6-OHDA lesioned hemisphere of the brain in the very 
early stages of neurodegeneration. These cells appeared earlier than those labelled with 
CD68. Moreover, throughout all time points of our study it was found that the number of 
OX6+ve microglia was slightly greater than that of CD68+ve microglia, suggesting that the 
vast proportion of the OX6 +ve cells acquired a phagocytic phenotype. In fact, it has been 
demonstrated that a significant proportion of OX6+ve microglial cells are ED1+ve at the 
site of neurodegeneration after MFB transection (Cho et al., 2003; 2007). This finding 
implies that the transformation of microglia to antigen presenting cells expressing MHC II 
antigens precedes microglial phagocytosis. 
Taken together, we have demonstrated that dopaminergic neuronal loss is preceded 
by microglial activation. Similarly, in MFB axotomised brain, it has also been demonstrated 
that the activation of microglia preceded neuronal loss and that activation of microglia was 
followed by a significant loss of neuronal fibres and nigral dopaminergic neurons (Cho et 
al., 2006). These findings strongly suggest that activated microglia play an important role in 
the progress of neurodegeneration. 
 
3.5.2 Morphological and phenotypic characteristics of activated microglia  
correlates with their function 
 
The highly ramified form of resting microglia observed the SNc of normal brains 
supports their immune surveillance function (Fetler and Amigorena, 2005). Pathological 
conditions lead to their activation and morphological changes. An increase in somal size, as 
well as the presence of thickened and shortened processes are observed in early stages of 
microglial activation, before their final transformation into amoeboid microglia with 
phagocytic activity (Streit and Kreutzberg, 1988; Mor et al., 1999; Stence et al., 2001). 
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These results demonstrated the presence of numerous activated microglia ipsilateral to the 
lesioned side of the SNc with both ramified and amoeboid like morphology.  Both forms of 
activated microglia showed strong OX6 immunoreactivity and attachment to the TH+ve 
neurons, axons and dendrites which was followed by significant loss of dopaminergic 
neurons. This suggests that activated microglia with ramified and/or amoeboid morphology 
participated in neuronal cell death. Active participation and neurotoxic role of activated 
microglia was further supported by our data demonstrating the expression of inducible nitric 
oxide synthase (iNOS) by OX6 +ve microglial cells following 6-OHDA lesion induction. 
There is a strong body of evidence demonstrating that once microglial cells are active they 
produce neurotoxic factors such as reactive oxygen and nitrogen species, and nitric oxide 
(NO) from inducible nitric oxide synthase (iNOS) (Iravani et al., 2002). In addition, other 
pro-inflammatory cytokine are secreted including:  tumour necrosis factor (TNF)-alpha, 
interleukin (IL)-1beta, and IL-6  which have also detected in cerebrospinal fluid (CSF) from 
patients with sporadic PD, and in animal models, such as MPTP and 6-OHDA- induced PD 
( Nagatsu T. et al., 2005). Since activated microglia express iNOS and nitrated protein 
aggregates are present in Lewy bodies (Good et al., 1998; Hunot et al., 1996; Hunot et al., 
2003) it has been suggested that part of the inflammatory response may be mediated by 
nitric oxide (NO) / peroxynitrite (ONOO-). Under conditions of oxidative stress, NO reacts 
with superoxide anions (-O2) and produces peroxynitrite, (ONOO-). Peroxynitrite formation 
leads to production of highly toxic hydroxyl radicals (Beckman et al., 1990), neurotoxicity 
and cell death (Allan S.M and Rothwell N.J, 2001).  
 
As demonstrated in the findings, injection of 6-OHDA produced apparent apoptosis 
of DA neurones. DAPI staining of the nuclei of DA neurons in the SNc at day 7 post 
lesioning showed multiple, rounded chromatin clumps similar to that observed during 
apoptosis (Tatton and Kirsh, 1997). However, distinguishing the apoptosis/necrosis 
dichotomy in the CNS is a difficult task, and many variations of apoptotic processes are 
possible (Roy and Salovsky, 2000). We observed DNA clumps in the nuclei of shrunken, 
apparently dead neurons in the lesioned side of SNc. Since a continuum of neuronal death 
occurs post 6-OHDA lesioning, it is reasonable to assume that a few of the dopaminergic 
neurons degenerate soon after toxin inoculation without having been phagocytosed by 
microglia. However, at days 3-5 post-lesion, the prevalence of phagocytic microglia in the 
SNc attached to DA neurons which were apparently morphologically intact with normal 
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nuclear chromatin distribution and were expressing tyrosine hydroxylase led to the 
conclusion that a majority of degenerating neurons were targeted for phagocytosis at very 
early apoptotic stage. In fact, we observed that the majority of Caspase 3+ve cells were in 
close contact with CD68+ve phagocytic microglia in SNc ipsilateral to the lesion as early as 
5- 7 days post lesion. This observation is in accordance with recent reports demonstrating 
that apoptotic neurons could be phagocytosed by activated microglia in early neuronal 
apoptosis (Savil and Fadok, 2000, Cho et al, 2003, Sugama et al, 2003). Thus, early 
microglial phagocytosis of apoptotic neurons might preclude the possibility of their 
recovery.  We observed that CD68+ve activated microglia appeared at day 3 post lesion 
induction, and the analysis of TH +ve neuron numbers at this time point indicated no 
significant difference between the SNc ipsilateral and contralateral to the lesion suggesting 
that microglial phagocytic activity preceded neuronal death. Moreover, observed 
engulfment of apoptotic neurons clearly demonstrate that the role of microglia in apoptotic 
neurodegeneration in the CNS is similar to that of macrophages in cellular apoptosis outside 
the brain. A major implication of these observations would be that early phagocytosis of 
apoptotic neurons might prevent neuronal survival by phagocytosing potentially recoverable 
neurons in neurodegenerative disorders such as PD. This is consistent with reports by Chao, 
et al (2006) where the ramified form of activated microglia showed strong expression of 
CD68 at the lesioned site where the MFB had been cut. Thus, adhesion of activated 
microglia to damaged DA neurons represents a process linked with the phagocytic clearance 
of those neurons. 
 
3.5.3 Dynamics of activated microglia in the SNc 
 
Activated microglia can also be characterized by their proliferative and migratory 
properties. Accumulation of activated microglia around regions of the brain undergoing 
degeneration may be attributed to migration of microglia to the affected sites (Akiyama et 
al., 1994; Heppner et al., 1998; Schiefer et al., 1999; Marella and Chabry, 2004; Rodriguez 
et al., 2007), as well as their local proliferation (Graeber et al., 1988; Amat et al., 1996; 
Schwab et al., 2001). We have observed a time-dependant unilateral relocation of activated 
microglia from the ventral tier to the medial and lateral portions of the SNc following 6-
OHDA lesion induction suggesting that at least some of the activated microglia 
accumulated in the SNc might be derived as a result of migration. Similar to this 
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observation, movement of amoeboid microglia along dendrites of neurons has been 
identified in brainstem slices using infrared-gradient contrast microscopy and time-lapse 
video recording (Schiefer et al., 1999). In parallel , using nuclear mitotic protein marker 
Ki67, our data revealed numerous locally proliferating OX6+ve microglial cells in the SNc 
at day 3 to 7 post 6-OHDA lesioning. Thus, accumulation of activated microglia in the SNc 
ipsilateral to the lesion with 6-OHDA can be explained by both local proliferation and 
migration.  
The data presented in this chapter provides evidence of the potentially damaging 
effects of microglial activation on the adjacent dopaminergic neurons. However, it is worth 
noting that in contrast to the harmful effects of microglial activation these cells have the 
capacity to secrete factors that can promote neuronal survival or regeneration. Transforming 
growth factor-beta  (TGF-β),brain derive neurotrophic factor ( BDNF,)  and nerve growth 
factor (NGF), to name just a few examples, promote neuronal survival and are secreted by 
microglial cells .Microglial cells monitor the physiological integrity of their 
microenvironment to promote tissue repair and maintain the homeostasis of the brain 
parenchyma (Kreutzberg et al., 1996).  Therefore, as presented in the results, the increase in 
microglia/macrophages cell numbers prior to neuronal loss could be an attempt to rescue 
neurons from the toxic effects of 6-OHDA by secreting anti-inflammatory cytokines and 
other protective factors. Future studies are necessary to examine the time course of 
production of pro v anti inflammatory factors by the microglial cells in the SNc following 6-
OHDA challenge.  
Conclusions 
 
The present study clearly demonstrates that microglial activation preceded 
dopaminergic neuronal cell death in the SNc after 6-OHDA lesion induction. Moreover 
glial response was associated with dopaminergic cell loss in the SNc.  CD68+ve and 
OX6+ve microglia specifically adhered to degenerating neurons throughout the whole 
neurodegenerative process, from an early stage to phagocytosing dying neurons. This 
process is probably in response to expression of apoptotic signals, such as 
phosphatidylserine (PS) and the expression of their receptors, including PS receptor (PSR), 
on the phagocyte membrane which initiate  phagocytosis  (Huynh, 2002; Ravichandran, 
2003), or in response to contents released from dying neurons. Our results indicate that 
neurons undergoing neuronal cell death may be phagocytosed by activated microglia 
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concomitantly at various stages.  The presence of microglia in neurodegeneration may not 
be limited to phagocytosis of dead neurons, but in fact microglia may actively contribute to 
neurodegenerative processes. 
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Chapter 4   
 
The role of Matrix metalloproteinases and CD200 
receptor in the neurodegenerative process in the 
substantia nigra of 6-hydroxydopamine model of 
Parkinson’s disease. 
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4.1 Introduction 
 
 
As concluded in chapter 3, microglial activation and phagocytosis of early stage 
apoptotic neurons preceded dopaminergic neuronal cell death in the SNc following 6-
OHDA MFB lesions. Moreover, a sub-population of the activated microglia showed 
activation of iNOS, suggesting active microglia are involved in dopaminergic neuronal 
death in the SNc. However, very little is known about the mechanisms responsible for 
the activation of microglial cells following an insult to the CNS, particularly in PD 
pathology.  Although research has focused on identifying triggers that lead to glial 
activation, it is becoming increasingly clear that interaction with other cells plays a 
significant role in modulating activation. In addition the changes that occur in the 
homeostasis of the brain leading to microglial activation and the cell to cell interactions 
regulating this process are not yet fully understood.  The following sections will provide 
an outline of some mechanisms responsible for keeping microglia quiescent during 
homeostasis and events that leads to their activation following an insult to the CNS. 
 
4.1.1 Maintaining microglia quiescence 
 
 The pro-inflammatory and damaging nature of microglial activation only applies 
to pathologic conditions. In homeostasis, the immune responsiveness of the microglia is 
tightly regulated in the CNS keeping them quiescent. The regulatory processes that are 
involved in keeping microglia in a resting state can be classified into those that rely on 
secreted factors and those that depend on the intimate communication of proteins on 
opposing cells such as neurons and astrocytes. Microglia receive cues from other cell 
types namely, neurons that enable them to remain quiescent in the absence of an 
immune stimulus. For example, neuronal electrical activity inhibits microglial activation, 
as demonstrated in neuron-glia co-cultures where blockade of neuronal electrical 
activity by tetrodotoxin induces microglial activity that was characterised by MHC II 
expression (Neumann et al., 2001). Other factors including, neuropeptides such as 
alpha-melanocyte stimulating hormone (α-MSH) and vasoactive intestinal peptide (VIP) 
inhibit proinflammatory cytokine and NO production by lipopolysaccharide-activated 
cultured microglia, while the neurotransmitter Gamma-aminobutyric acid (GABA) has 
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immunosuppressive effects on T and B-cell function (Reinke et al., 2006). Evidence 
suggests that neurons are not the only cell type that are capable of keeping microglia 
quiescent, interestingly astrocytes are able to suppress microglial activation by releasing 
soluble and insoluble factors such as TGFβ or anti-inflammatory IL-10 (Vincent, et al, 
1997; Aloisi et al., 2001; Min et al., 2006). 
In addition to various secreted factors from neurons and other cell types that 
regulate microglial activity a recently recognized local modulator of the inflammatory 
response, hence microglial activation, is the interaction between CD200 glycoprotein 
and its receptor, CD200R. CD200 is a type 1 membrane glycoprotein (Jenmalm et al., 
2006) that is expressed on several cell types, including neurons, and exerts its effect by 
binding to the CD200R receptor triggering intracellular signalling cascades (Wright et 
al., 2003). CD200R is highly expressed on macrophages, neutrophils, monocytes, mast 
cells, and lymphocytes, and expression has also been localized on microglia (Barclay et 
al., 2002). The suppressive effect that neurons exert on microglia can explain how 
microglial activation is controlled during homeostasis through an interaction of the 
glycoprotein CD200 ligand on their surface with CD200R on microglia (Hoek et al., 
2000). Under pathological conditions when the neuron-glia interactions are disturbed, 
the suppressive effect of neurons on microglia is inevitably compromised leading to 
activation and proliferation of microglia.  Data from CD200 knockout mice, best 
demonstrate the CD200 interactions (Hoek et al., 2000). In these mice there are 
increased numbers of macrophages in the spleen (especially in young animals) and a 
defect occurs in the organization of the mesenteric lymph nodes. In addition, in such 
knockout mice, microglia were spontaneously activated. The activated microglia 
showed an activated phenotype with less ramified morphology. In addition, microglia in 
CD200 knockout mice showed the presence of clusters of differentiation on their 
surface including: CD11b and CD45 that are indicative of their activation. Moreover the 
expression of inducible nitric oxide synthase (iNOS) by microglia and macrophages in 
CD200 knockouts was significantly increased. These data indicates that CD200 
expressed by resident CNS cells, including neurons, might silence or down regulate 
innate immune function of microglia. During an inflammatory reaction pro-
inflammatory signals also play a major role in modulating microglial activation. Several 
factors, including LPS, IFN- γ, CD40L, chemokines, neurotransmitters and gangliosides, 
and several proteases such as thrombin, tissue plasminogen activator (tPA), matrix 
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metalloproteinase- 3 (MMP-3) and MMP-9  are found to be involved in microglial 
activation. Some of them are produced by neurons and others are from pathogens, 
immune cells or microglia (abd- el-Basset and Fedoroff, 1995; Tsirka, 1997; Suzumura 
et al., 1998; Tan et al., 1999; Aloisi et al., 1999). Other factors that are suggested to 
activate microglia include neuromelanin that is released from degenerating 
dopaminergic neurons (Wilms et al., 2003). Among these various molecules that lead to 
microglial activation, matrix metalloproteinases (MMPs) are currently being 
investigated as one of the signals responsible for activating microglial cells in 
neurodegenerative disorders like PD. Therefore the following sections will provide an 
overview of the importance and significance of MMPs in PD pathology.  
 
4.2 Matrix metalloproteinases (MMPs) and Parkinson’s disease 
 
4.2.1 Overview 
 
 
There are 23 MMPs, belonging to the matrixin subfamily of zinc 
metalloproteinases and are able to cleave extracellular matrix (ECM) as well as non-
matrix proteins (Nagase et al., 2006). ECM is a complex macromolecular structure that 
occupies the extracellular space. This matrix is composed of a variety of 
polysaccharides and proteins and it is strongly associated with the cell surface. In the 
brain, the matrix is mainly developed as the basal lamina surrounding blood vessels. 
Local cells normally produce the extracellular matrix components and therefore the 
composition of the matrix is dependent on the cellular environment. MMPs are released 
from variety of cell types in the brain including astrocytes, neurons and microglia as 
well as leukocytes and macrophages and are involved in tissue remodelling such as 
wound healing and angiogenesis (Puistola et al., 1989; Turpeenniemi-Hujanen et al., 
1992, Salo et al., 1994; Chambers & Matrisian, 1997) during development and 
homeostasis. All MMPs are secreted as pro-enzymes and require extracellular activation. 
In homeostasis, to avoid unwanted proteolysis MMP activation is tightly regulated at 
various levels, including regulation at the level of transcription by endogenous tissue 
inhibitors of metalloproteinases (TIMPs) (Rosenberg et al., 2002). The MMPs can be 
classified into five sub-groups, depending on their substrate specificity. These groups 
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include: the collagenases (MMP-1, MMP-8, MMP13, and MMP-14), which degrade the 
interstitial collagens, types I, II and III; the gelatatinases (MMP-2 and MMP-9), which 
degrade type IV collagen in basement membrane; the stromelysins (MMP-3, MMP-10, 
and MMP-11), which degrade non-collagen matrix proteins, such as fibronectin, 
laminin, aggregan, etc.; and a miscellaneous group, which include matrilysin (MMP-7) 
and MMP-12 (elastase). 
 Accumulating evidence indicates that MMPs are involved in the pathogenesis 
of various central nervous system disorders including  bacterial meningitis (Paul et al., 
1998), stroke (Clark et al., 1997), multiple sclerosis (Maeda and Sobel, 1996 ), and 
neurodegenerative diseases such as Alzheimer’s disease (AD) (Asahina et al., 2001) and 
PD (Lorenzl et al., 2002).  
 
4.2.2 Evidence of involvement of MMPs in PD pathology 
 
The role MMPs in PD pathology is supported by their involvement in 
inflammation and neuronal death, two key components of the disease. MMP-3 
(stromlysine1) is the main member of MMPs family that has been studied in the context 
of PD. Stromelysin-1, known also as MMP-3, degrades various collagens, elastin, 
fibronectin, laminin but also activates latent forms of other matrix metalloproteinases 
such as MMP-9 (Ramos-De Simone et al., 1999). First studies that supported a 
pathogenic role for MMPs came from post-mortem studies from PD patients. A study 
by Lorenzl et al, (2002) investigated the levels of MMP-2, MMP-9, MMP-1, tissue 
inhibitor of metalloproteinase 1 (TIMP-1) and TIMP-2 in post-mortem brain tissue from 
PD patients. This study revealed reduced levels of MMP-2, increased levels of TIMP-1 
in the SN suggesting that alterations in MMPs/TIMPs may contribute to disease 
pathogenesis. The pathogenic role of MMPs in PD pathology is also supported by in 
vivo and in vitro studies. In the 6-OHDA model of PD a study by Sung and colleagues 
(2005) demonstrated that increased levels of MMP-3 are found in the SNc three weeks 
post lesion induction. Using immunohistochemistry, significant MMP-3 expression was 
seen arising from the SNc area into the nigrostriatal dopaminergic pathways after 
stereotactically injecting the toxin at three points in the right striatum. Cell culture 
studies by (Kim et al., 2005) have also shown that MMP-3 may be a microglia-
activating signalling molecule released from neurons in early apoptosis. MMP-3 was 
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released from apoptotic cells incubated in serum deprived media (SDM) as early as 2 
hours after serum deprivation and before cellular morphological change could be 
detected. Furthermore, cell culture studies have shown that MMP-3 appears to be 
induced in neurotoxin-stressed DA neurons and activated inside the cell before release. 
Whether this induction and activation of MMP-3 is specific to degenerating DA neurons 
or dying cells in general, still needs to be investigated (Kim et al., 2005).  More recently 
Kim et al., (2007) have demonstrated a dose dependent release of MMP-3 in primary 
mesencephalic cultures treated with 1-methyl-4-phenylpyridinium (MPP+), a toxic 
metabolite of MPTP. Expression of MMP-3 occurred specifically in DA neurons.  The 
release of MMP-3 resulted in microglial activation and superoxide generation as well as 
enhanced dopamine cell death.  
Animal studies have demonstrated that activated microglia are highly visible in 
the striatum and the SN at 2 and 5 days after MPTP injection in wild type mice but were 
minimal in MMP-3 knockout mice, as was dopaminergic neuron degeneration (Kim et 
al., 2007). In mesencephalic culture, MMP-3 activated microglia, have been shown to 
produce NADPH oxidase (NADPHO) derived superoxide, which causes dopaminergic 
neuronal death. It was found that MMP-3 caused dopamine cell death in wild type mice; 
however in cells from NADPHO knockout mice death was attenuated. This suggests, 
NADPHO may mediate MMP-3 induced superoxide production and dopamine cell 
death (Wu et al., 2003; Gao et al., 2003). Furthermore, recent studies have suggested 
that MMPs play a role in cell death via apoptotic mechanisms, including caspase-
dependent cascades (Mannello et al., 2005). Cell culture studies have also shown that 
MMP-3 activity stimulates the production of inflammatory cytokines by microglia, such 
as TNF-α. Administration of a specific MMP-3 inhibitor NNGH (N-isobutyl-N-(4-
methoxyphenylsulfonyl) –glycylhydroxamic acid), resulted in inhibition of TNF-α 
release from activated microglia (Kim et al., 2005).  Studies into the role of MMPs, in 
particular MMP-3, in PD pathology provide convincing evidence that MMP-3 may play 
a role in PD pathogenesis that is at least partially mediated by activation of 
inflammatory pathways. 
 In addition to the role of MMP-3 in PD pathology, MMP-9 is also being 
investigated. Elevated levels of MMP-9 were observed in the striatum and the SNc of 
MPTP treated mice (Lorenzl et al., 2004). Using immunohistochemistry and Western 
blot analysis, Lorenzl, et al (2004) demonstrated that the activity of MMP-9 was up 
regulated 3 hours after MPTP injection in the striatum and after 24 h in the substantia 
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nigra, activity remained elevated for up to 7 days. Furthermore, the significance of 
MMP-9 in PD pathology was determined when pharmacological inhibition of the 
enzyme led to significant dopaminergic neuroprotection following MPTP 
administration in mice (Lorenzl et al., 2004).  
Thus, in vivo and in vitro studies suggest that MMPs, in particular MMP-3, play 
a crucial role in microglial activation in different models of PD leading to dopaminergic 
neuronal loss.  Therefore we hypothesise that MMP-3 is a microglial activating signal 
released from dopaminergic neurons early in the disease process, and contributes to 
dopaminergic neuron degeneration. However, in the in vivo models of PD limited 
information is available on the time course of MMP-3 or MMP-9 expressions in relation 
to microglial activation and /or quiescence.  To test our hypothesis we addressed the 
following aims:  
1) Are MMPs released from neurons as signalling molecules and how are these 
signal(s) modulate microglial activation in the 6-OHDA model of PD.  
2) What are the kinetics of MMP-3 and MMP-9 activation during the 
progression of dopaminergic cell loss in the SNc after 6-OHDA lesioning?  
3) Does the expression of MMP-3 and MMP-9 correlate with the degree of 
microglial activation? 
4) What are the neuron-microglia interactions with focus on the role of CD200R 
in dopaminergic cell death in the SNc after 6-OHDA lesion induction.  
To satisfy these aims the classical 6-OHDA model of PD will be produced by 
unilateral injection of 6-OHDA into the MFB. The animals will be sacrificed on days 
1(24 hours after lesion induction) ,3,5,7,9,13 and 15 after lesioning.  MMP-3 and MMP-9 
expression following 6-OHDA lesion induction in relation to dopaminergic neuronal 
cell death and microglial activation will be studied. Immunohistochemistry will be 
performed for active forms of MMP-3 and MMP-9 in addition to CD200R+ve cells. To 
assess the integrity of dopaminergic neurons in the SNc after 6-OHDA lesion induction, 
TH immunohistochemistry will be performed for dopaminergic neurons and cell counts 
performed for TH+ve neurons in the SNc.  In addition, to assess the time course of 
microglia/macrophage activation in relation to MMP-3 and MMP-9 expression 
immunohistochemistry will be performed for OX6 and CD68 expressing 
microglia/macrophages in the SNc following 6-OHDA lesion induction. The complete 
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description of the experimental design may be found in the following section (see 
section 4.2). New batches of animals were used in this chapter’s experiments compared 
to Chapter 3 experiments therefore certain key parameters were assessed again such as 
the expression of TH, OX6 and CD68. 
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4.2 Experimental design 
4.2.1 Relationship between MMP-3 and MMP-9 expression and dopaminergic  
neuronal cell death in the SNc following 6-OHDA lesioning 
 
4.2.1.1 Assessment of the kinetics of MMP-3 and MMP-9 expressions in the SNc after  
6-OHDA lesion induction 
To investigate the relationship between the expression of MMP3 and MMP-9 
and the progression of dopaminergic neuronal cell loss in the SNc,   male Sprague-
Dawley rats were divided into experimental groups (n=6). Unilateral 6-OHDA lesion 
was induced stereotaxically into the MFB (see section 2.1.2.2). Subsequently animals 
were sacrificed by CO2 over dose at day 1, 3, 5, 7,9,13 and 15 following 6-OHDA or 
sham (4µl 0.1% ascorbic acid) lesion induction and the brains were removed (see 
section 2.1.3).  
To assess the expression and morphology of MMP3+ve and MMP-9+ve cells at 
different time points following 6-OHDA or sham lesion induction peroxidase 
immunohistochemistry with Nickel enhancer was performed for the active form of 
MMP-3 and MMP-9 using the following antibodies, details of staining procedure is 
outlined in (see Chapter 2,  section 2.2.1.4): 
 
MMP-3: A polyclonal antibody was used against the active form of MMP-3 enzyme 
mapping at C-terminus of the enzyme of human origin. This antibody recognises the 45 and 
28 kDa active forms of the enzyme. 
 
MMP-9: A polyclonal antibody was used against the active form of MMP-9, also known as 
92-kDa gelatinase/type IV collagenase, in mammals mapping near the C-terminus of MMP-
9 of human origin.  
To determine the cell types that express MMP-3 and MMP-9 in the SNc after 6-
OHDA lesion induction the following double immunofluorescence stainings were 
performed. Details of antibody combinations are listed below. The full description of 
staining procedure is outlined in (see Chapter section 2.2.2). 
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MMP-3+NeuN 
To investigate the expression of MMP-3 by neurons in the SNc following 6-OHDA or sham 
lesion induction. 
MMP-3+ Glial fibrillary acidic protein (GFAP) 
To investigate the expression of MMP-3 by astrocytes that express GFAP in the SNc 
following 6-OHDA or sham lesion induction. GFAP is a type III intermediate filaments 
protein that is expressed by astrocytes. 
MMP-9 + NeuN 
 
To investigate the expression of MMP-9 by neurons in the SNc following 6-OHDA or 
shame lesion induction. 
 
MMP-9 and GFAP 
To investigate the expression of MMP-9 by astrocytes in the SNc following 6-OHDA or 
sham lesion induction.  
 
4.2.1.2 Assessment of the dopaminergic neuronal cell death progression induced by 6-
OHDA injected into the MFB 
 
 Integrity of dopaminergic neurons in the  SNc at different time points following 6-
OHDA lesioning was assessed by using immunohistochemistry for Tyrosine 
hydroxylase (TH) positive dopaminergic neurons (see section 2.2.1.3). The number and 
morphology of TH+ve cells were then determined according to the criteria described in 
(see section 2.2.3). 
 4.2.2 Relationship between microglial activation and MMP-3 and MMP-9  
expression in the SNc following 6-OHDA lesion induction 
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4.2.2.1 Assessment of the kinetics of microglial activation in the SNc after 6-OHDA  
lesion induction  
As described in chapter 3, to asses the kinetics and morphology of microglial 
activation at different time points following 6-OHDA or sham lesion induction 
peroxidase immunohistochemistry was performed for OX6 and CD68 expression.  
Description of the antibodies used is listed below, details of staining procedure is 
outlined in (see section 2.2.1.4): 
OX6: was used to detect the population of activated microglial cells that express major 
histocompatibility complex II (MHC II) antigens. 
CD68: was used to detect the activation of a population of macrophages with phagocytic 
function that expresses CD68 glycoprotein on their lysosomal membrane. 
 
4.2.2.2 Assessment of MMP-microglial interaction in the SNc after 6-OHDA lesion  
induction 
To explore the potential interaction between the MMP-3 expressing cells and 
microglial cells in the SNc following 6-OHDA lesioning, the following double 
immunofluorescence stainings were performed; detailed description of immunofluorescence 
protocol is described in (see section 2.2.2)  
MMP-3 +OX6 
To observe the interaction and spatial association between MMP-3 expressing cells with 
MHC II antigen presenting microglial cells following 6-OHDA lesion induction at different 
time points. 
MMP-3+ CD68 
To study the interaction and spatial association between MMP-3 expressing cells and 
CD68+ve phagocytic macrophages at different time points following 6-OHDA lesioning in 
the SNc. 
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4.2.3 Role of CD200R expression during the progression of 6-OHDA lesion in the 
SNc 
4.2.3.1. Assessment of the kinetics of CD200R expressing cells in the SNc after 6- 
OHDA lesion induction 
The kinetics and morphology of CD200R+ve cells at different time points 
following 6-OHDA or sham lesion induction was assessed utilising peroxidase 
immunohistochemistry for CD200R expression.  (See chapter 2, section 2.2.1.4). 
CD200R: A mouse monoclonal antibody was used to detect cells that express CD200 
receptor (R), a membrane glycoprotein, mainly found on the surface of myeloid cells, 
including microglia. Studies suggest that CD200-CD200R interaction may be involved 
in the control of myeloid cellular function. 
 
4.2.3.2 Assessment of the interaction between neurons and CD200R expressing cells in  
the SNc following 6-OHDA lesion induction 
To study the interactions between TH+ve and/or MMP-3+ve neurons with 
CD200R+ve cells in the SNc after 6-OHDA lesioning the following double 
immunofluorescence stainings were performed. Description of the antibodies used are 
listed below, details of staining procedures are outlined in (see section 2.2.1.4). 
TH + CD200R 
To investigate the spatial association and interaction of CD200R, a cell surface 
glycoprotein that is involved in regulation of microglial activation, in relation to TH+ve 
dopaminergic neurons in the SNc following 6-OHDA or sham lesioning.  
 
MMP-3+ CD200R  
 
To investigate the expression and spatial association of CD200R, a cell surface 
glycoprotein that is involved in regulation of microglial activation, with MMP-3 
expressing cells in the SNc following 6-OHDA or sham lesioning. 
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4.3 Results 
4.3.1 Involvement of neuronal MMP-3 and MMP-9 activities in the progression of  
dopaminergic neuronal cell death in the SNc following 6-OHDA lesioning 
 
4.3.1.1. Extent and localisation of MMP-3 expressing cells following 6-OHDA or sham  
lesioning in the SNc 
 
  MMP-3+ve cells were observed in the SNc on both the lesioned and the 
unlesioned hemispheres from day 1 after 6-OHDA lesion induction. However, the 
number of cells expressing MMP-3 increased significantly in the lesioned hemisphere 
compared to the unlesioned hemisphere on day 7 after 6-OHDA lesion induction 
(lesioned: 25.0 ± 5; unlesioned: 10± 0.5 , p <0.5) (Fig 4.1,Graph). This was 
concomitant with presence of significantly high numbers of OX6+ve microglia in the 6-
OHDA lesioned hemisphere of the SNc.  The number of MMP-3 +ve cells gradually 
increased up to day 13 after lesioning (lesioned: 30.5 ± 0.5; unlesioned: 6.0 ± 0.1, p< 
0.01). However number of MMP-3+ve cells  decreased significantly on day 15 after 
lesion induction compared to the lesioned side on day 13 (Day 15 post-lesion: 18.0±8.0, 
Day 13 post-lesion: 30.5 ± 0.5,  p<0.5) (Fig 4.1, Graph). In sham operated animals the 
number of MPP-3+ve cells increased on the lesioned side compared to the unlesioned 
side, however, it did not reach significance level (data not shown), suggesting that the 
physical experimental procedures had no significant impact on MMP-3 expression only 
the presence of 6-OHDA. It is noteworthy that constitutive expression of MMP-3 was 
detected in control sections: levels of MMP-3 did not differ on either side of the SNc 
(data not shown). 
  MMP-3 expressing cells were not specifically confined to any particular area in 
the SNc, however the distribution was particularly dense in the dorsal tier of the SNc 
and clusters of cells were observed in lateral aspect of the ventral tier of the SNpc and 
pars reticulate (Fig 4.1, Photomicrograph).  
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Fig 4.1 Graph-Time dependent increase in the number of MMP-3+ve cells in the 
SNc after 6-OHDA lesion induction. 
 
Injection of 6-OHDA in to the MFB induced a significant increase in the number of 
MMP-3+ve cells in a time dependent manner. Graph demonstrates time-course 
quantification of MMP-3+ve cells in the SNc. Immunostaining was carried out with 
MMP-3 antibody as marker for active form of this enzyme. The number of MMP-
3+ve cells significantly increased on day 7 after 6-OHDA lesion induction in the 
lesioned hemisphere compared to the unlesioned hemisphere. On day 13 after lesion 
induction the number of MMP-3+ve cells reached its maximum in the lesioned 
hemisphere compared to the unlesioned hemisphere. MMP-3+ve cells significantly 
decreased in number by day 15 after 6-OHDA lesion induction. Positive cells in the 
SNc were counted as described in (see Chapter 2, section 2.2.3). Results are 
expressed as mean number of cells + SEM, n=6.*p< 0.5, ** p<0.01, *** p< 0.001, 
ns= not significant. 
 
 
 
 
  
 113
 
 
 
Fig 4.1 Photomicrograph- Representative photomicrographs of immunoperoxidase 
staining for MMP-3 with Nickel enhancer showing the localisation of up-
regulated MMP-3+ve cells in the SNc on day 7 after 6-OHDA lesion induction in 
the lesioned hemisphere compared to the unlesioned hemisphere. 
 
A) Shows MMP-3+ve cells in the unlesioned hemisphere (x40). Few MMP-3+ve cells 
are present in the lateral and ventral portions of the SNc after 6-OHDA lesion 
induction (x40). 
B) Higher magnification photomicrograph of (A) shows peroxidase immunostained 
MMP-3+ve cells that are present as cluster of very few cells in the lateral portion of 
the SNc with MMP-3+ve cells scattered in ventral and dorsal aspects of the SNc in 
the unlesioned hemisphere following 6-OHDA lesion induction (x100). 
C)  Shows increased number MMP-3+ve cells in the lesioned hemisphere after 6-
OHDA lesion induction. At this low magnification dense staining is observed in the 
ventral lateral and dorsal portions of the SNc (x40). 
D) Higher magnification photomicrograph of (C) shows peroxidase immunostained 
MMP-3+ve cells that are present as cluster of numerous cells accumulated in the 
lateral, ventral and dorsal portions of the SNc in the lesioned hemisphere following 6-
OHDA lesion induction (x100).  
Inserted box: Inset shows immunoperoxidase stained MMP-3+ve cell in the SNc of 6-
OHDA lesioned hemisphere,  MMP-3+ve cell represents a neuronal morphology with 
dendritic processes, staining of MMP-3 is present in the cytoplasm (x400). 
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4.3.1.2 Morphological characteristics of MMP-3 expressing cells in the SNc following  
6-OHDA or sham lesioning 
 
Morphological characteristics of MMP-3+ve cells following 6-OHDA lesion 
induction was studied in DAB immunolabelled sections with Nickel staining enhancer. 
Assessment of the sections revealed that most MMP-3+ve cells had neuronal 
morphology with a defined cell bodies and dendritic processes (Fig 4.2 A). To 
determine which cell types express   MMP-3 following 6-OHDA lesion induction 
double immunofluorescence staining was performed for MMP-3 and NeuN or GFAP. 
The staining revealed that the majority of MMP-3 expressing cells were neurons (Fig 
4.2B, Top panel). This observation was consistent at all time points studied. However 
no astrocytic expression of MMP-3 was detected since, MMP-3+ve cells were negative 
for GFAP expression (4.2B, Bottom panel). 
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Fig 4.2A: Morphological characteristics of MMP-3+ve cells following 6-OHDA 
lesion induction DAB immunolabelled sections with Nickel staining enhancer. 
 Assessment of the sections revealed that most MMP-3+ve cells had neuronal 
morphology with a defined cell bodies and dendritic MMP-3 is mainly expressed in the 
cytoplasm of these neurons (x400).  
 
Fig4.2B: To determine  which cell types express   MMP-3 (green) following 6-
OHDA lesion induction double immunofluorescence staining was performed for 
MMP-3 and NeuN (Red-Top panel) or GFAP (Red-Bottom panel) Blue represent 
DAPI staining. 
 Top panel: The staining revealed that the majority of MMP-3 expressing cell were co-
localised with neuronal cell marker NeuN (combined image) hence, MMP-3 was 
expressed by neurons in the SNc following 6-OHDA lesion induction. This observation 
was consistent at all time points studied (x400). Bottom panel: Staining revealed no co-
localisation of GFAP expressing astrocytes and MMP-3+ve cells in the SNc following 
6-OHDA lesion induction (x200). This was consistent at all time points studied. 
MMP3 NeuN combined 
MMP3 GFAP combined 
lesion 
A 
B 
MMP-3 
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4.3.1.3 Extent and localisation of MMP-9 expressing cells following 6-OHDA or sham  
lesioning in the SNc 
 
MMP-9 expressing cells were present in the SNc as early as day 1 after 6-
OHDA lesion induction in the lesioned side compared to the unlesioned side. Cell 
counts revealed that  MMP-9 expressing cells were significantly increased in number 
from day 1 after 6-OHDA lesion induction in the lesioned hemisphere compared to the 
unlesioned hemisphere in the SNc: (lesioned: 40.35± 3.63; unlesioned: 22.0 ± 5.43, 
p<0.5). The number of MMP-9 +ve cells remained significantly increased in the 
lesioned hemisphere compared to the unlesioned hemisphere through out the rest of the 
study and cell counts on day 15 further confirmed this observation: (lesioned : 36.67 ± 
4.25 ; unlesioned: 9.33± 0.6, p <0.001) (Fig 4.3A). MMP-9 expressing cells were 
localised in the SNc in a very similar manner to MMP-3+ve cells. MMP-9+ve cells 
were not confined to particular portion of the SNc. Being detected in the dorsal tier of 
the SNc and lateral aspect of the ventral tier in the SNc. A common observation was 
that MMP-9 expressing cells were denser in the SNc compared to the SN pars reticulata 
through out all time points studied (Fig 4.3B). In sham operated animals MMP-9 
expressing cells increased in number on the side of the lesion however the increase did 
not reach significance (data not shown). These observations indicated that MMP-9 
expressing cells were up regulated very early in the process and remained up regulated 
until the end of the study on day 15 on the side of lesion. This phenomenon suggested 
that MMP-9 activation might be a down-stream mechanism of MMP-3 activation. 
Therefore once MMP-3 was activated it primed MMP-9 expressing cells to express this 
enzyme. This is further supported by the lack of constitutive expression of MMP-9 in 
control brains.  
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Fig 4.3 Unilateral MFB injection of 6-OHDA resulted in a significant increase in 
the number of MMP-9+ve cell in the SNc from day 1 after lesion induction that 
progressed up to day 15 on the lesioned hemisphere compared to the unlesioned 
hemisphere. 
 
A) The graph shows the number of MMP-9+ve cells immunostained with MMP-9 
antibody. The number of MMP-9+ve cells in the SNc significantly increased on 
day 1 after lesion induction in the lesioned hemisphere compared to the 
unlesioned hemisphere. MMP-9+ve cells reached their greatest number on day 9 
post 6-OHDA lesioning that progressed up to day 15 after lesioning. Results are 
expressed as mean number of cells + SEM, n=6.*p< 0.5, ** p<0.01, *** p< 
0.001. Number of animals was 6/group per time point. 
B) DAB immuperoxidase staining utilising Nickel staining enhancer was carried out 
for MMP-9 as a marker for the active form of this enzyme in the SNc following 
6-OHDA lesion induction. The photomicrograph represents the SN in the 
lesioned hemisphere on day 9 after 6-OHDA lesion induction. MMP-9+ve cell 
are detected in the dorsal tier of the SNc and lateral aspect of the ventral tier in 
the SNc. A common observation was that MMP-9 expressing cells were denser in 
the SNc compared to the SN pars reticulate (SNr) through out all time points 
studied (x100). 
 
A 
B 
lesion 
MMP-9 
SNc 
SNr 
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4.3.1.4. Morphological characteristics of MMP-9 expressing cells in the SNc following  
6-OHDA lesioning 
 
Morphological characteristics of MMP-9+ve cells in the SNc following 6-
OHDA lesion induction were studied in DAB immunolabelled sections with Nickel 
staining enhancer.   Most MMP-9+ve cells had neuronal morphology with a defined cell 
bodies and dendritic processes very similar if not identical to MMP-3+ve cells. 
Neuronal expression of MMP-9 was observed in both the lesioned and unlesioned 
hemispheres following 6-OHDA or sham lesioning. Double immunofluorescence 
staining was performed to assess the expression of MMP-9 by neurons and/or astrocytes 
in the SNc. Double fluorescence staining for MMP-9 and NeuN revealed that the 
majority of MMP-9 expressing cell were neurons. However no astrocytic expression of 
MMP-9 was detected by GFAP and MMP-9 double immunofluorescence staining 
throughout all time points studied following 6-OHDA lesion induction.  
 
Thus, a significant increase in the number of cells expressing both active form of 
MMP-3 and the downstream molecule, MMP-9 occurred very early after 6-OHDA 
lesion induction. This observation suggested that activation of these enzymes following 
6-OHDA lesioning could be involved in dopaminergic neuronal loss in the SNc.  
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Fig  4.4: To determine  which cell types express   MMP-9 (green) following 6-
OHDA lesion induction double immunofluorescence staining was performed for 
MMP-9 and NeuN (Red-Top panel) or GFAP (Red-Bottom panel) Blue represent 
DAPI staining. 
 
 Top panel: The staining revealed that the majority of MMP-9 expressing cell were co-
localised with neuronal cell marker NeuN (combined image-white arrows) hence, 
MMP-3 was expressed by neurons in the SNc following 6-OHDA lesion induction. This 
observation was consistent at all time points studied (x400).  
Bottom panel: Staining revealed no co-localisation of GFAP expressing astrocytes and 
MMP-9+ve cells (green-white arrows) in the SNc following 6-OHDA lesion induction 
(x200). This was consistent at all time points studied. 
 
 
 
 
 
 
 
 
 
 
 
MMP-9 GFAP combined 
MMP-9 NeuN combined 
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4.3.1.5 Kinetics of MMP-3 and MMP-9 expressions in relation to loss of TH+ve  
dopaminergic in the SNc following 6-OHDA lesion 
 
To detect the effect of 12µg 6-OHDA (in 4µl) injection into the MFB on 
neuronal cell loss in the SNc, the number of TH+ve dopaminergic neurons in the SNc 
were monitored. The results are shown as the mean number of cell counts for TH+ve 
neurons in the SNc at different time points after toxin injection. As shown in (Fig 4.5) 
6-OHDA injection caused a progressive loss of nigral TH+ve neurons in the SNc.  
Comparison of the number of nigral TH+ve neurons between lesioned and unlesioned 
sides showed no significant loss of TH +ve neurons within the first 7 days after 6-
OHDA injection (lesioned: 73 ± 8.08, unlesioned 97.33 ± 8.80 p>0.5.).  However, both 
MMP-3+ve and MMP-9+ve cell number significantly increased on day 7 after lesioning 
in the lesioned hemisphere compared to unlesioned hemisphere (Figures 4.1 and 4.3A, 
respectively). Significant loss of TH+ve neurons in the lesioned hemisphere started to 
manifest from day 9 compared to the unlesioned hemisphere (lesioned: 40 ±5.25, 
unlesioned: 86±5.25, p<0.01) when MMP-3 and MMP-9 expression were also 
significantly increased. Unilateral dopaminergic neuronal loss progressed up to day 15 
after lesion induction comparing lesioned and unlesioned hemispheres. Cell counts on 
day 15 showed (unlesioned: 75±12, lesioned 32.5±1.5, p<0.01). In particular, neurons in 
the lateral portion and ventral tier of the SNc were most vulnerable to 6-OHDA toxicity. 
However, MMP-3 expression decreased significantly on day 15, whereas MMP-9 
expression remained increased. At all time points studied the loss TH immunoreactivity 
was accompanied by a comparable loss of NeuN immunoreactivity, indicating that 
neuronal cell bodies are lost, rather than demonstrating a down regulation of TH 
expression (data not shown in this chapter, see chapter 3, figure 3.3). In sham lesioned 
animals no significant loss of TH+ve dopaminergic neurons were observed compared to 
the unlesioned side of the brain. 
Taken together these observations indicated that following 6-OHDA lesion 
induction both MMP-3 and MMP-9+ve cells significantly increased in number in the 
SNc on the lesioned hemisphere before any dopaminergic neuronal loss was evident. In 
addition, neuronal expression of both MMP-3 and MMP-9 indicated that MMP-3 and 
MMP-9 released from neurons after lesioning might act as signalling molecules to 
activate microglia and/or directly affect the neighbouring dopaminergic neurons in the 
SNc leading to cell death.  
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Fig 4.5 Time dependent TH+ve dopaminergic neuronal cell death in the SNc 
following 6-OHDA lesion induction. 
 
Male SD rats were injected with 12 μg 6-OHDA or with ascorbic acid (as sham) into 
the MFB and maintained under normal conditions. Animals were sacrificed at the 
indicated time points and coronal brain sections (20 μm thick) were cut through the SNc. 
Immunostaining was carried out with TH antibody and TH+ve neurons in SNc were 
counted. Graph shows the number of TH +ve neurons in SNc at different time points 
after 6-OHDA injection. Significant TH+ve dopaminergic neuronal cell death occurs 
from day 9 after 6-OHDA lesion induction in the lesioned hemisphere compared to the 
unlesioned side that progresses to day 15 post lesioning. Results are expressed as   mean 
number of cells + SEM.  ** p< 0.01, ***p<0.001, ns= non-significant. Number of 
animals was 6/group per time point.  
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Fig 4.6 Graphical demonstration of the increase in the mean number of nigral 
MMP-3 and MMP-9 expressing cells in the 6-OHDA lesioned hemisphere prior to 
TH+ve nigral dopaminergic neuronal cell death in the 6-OHDA lesioned 
hemisphere.  
Blue line demonstrates the time dependent increase in the mean number of MMP-3+ve 
cells in the SNc following 6-OHDA lesion induction in the lesioned hemisphere. On 
day 7 (yellow circle) the mean number MMP-3+ve cells increased significantly as 
shown in (Fig 4.1) compared to day 5 post lesion. Green line demonstrates the time 
dependent increase in the mean number of MMP-9+ve cells in the SNc following 6-
OHDA lesion induction in the lesioned hemisphere. MMP-9+ve cells  significantly up-
regulate from day 1 after 6-OHDA lesioning ( yellow circle) and remained up-regulated 
up to day 15 after 6-OHDA lesion induction (Fig 4.3A). Red line represent time 
dependent decrease in the number of TH+ve dopaminergic neurons in the SNc after 6-
OHDA lesion induction in the lesioned hemisphere. Significant loss of dopaminergic 
neurons is observed on day 9 after lesioning (black circle) that progressed to day 15 post 
6-OHDA lesioning (Fig 4.5). Hence it is graphically demonstrated that significant 
increase in the number MMP-3 and MMP-9 expressing cells precedes TH+ve 
dopaminergic neuronal cell death in the SNc after 6-OHDA challenge. Results are 
presented as mean number of cell± SEM. Number of animals was 6/group per time 
point.  
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4.3.2 Kinetics of MMP-3 expression in relation to OX6+ve and CD68+ve activated  
microglia/macrophages in the SNc following 6-OHDA lesion induction 
 
4.3.2.1. Comparison between the kinetics of MMP-3 expression and OX6+ve activated  
microglia in the SNc after 6-OHDA lesion induction 
 
Similar to the data reported in chapter 3, OX6+ve cells are the antigen 
presenting population of microglia.  OX6+ve  microglia were  first observed in the 
medial part  and ventral tier of the SNc at day 1 after 6-OHDA lesion induction when no 
apparent changes were observed in the number of TH+ve cells in the lesioned 
hemisphere compared  to the  non lesioned hemisphere. At which time point increased 
number of MMP-3 +ve cells were also observed in the SNc (see section 4.3.1.1). The 
number of OX6+ve cells gradually increased and a focal accumulation of these cells in 
both the lateral and medial portions of the SNc in the lesioned hemisphere was observed 
on day 7 (cell counts: lesion: 19.83± 6.16, unlesion: 0.83 ± 0.47, p<0.01) (Fig 4.7). At 
this time point MMP-3+ve cells were significantly increased in number in the lesioned 
hemisphere compared to the unlesioned side of the brain (see section 4.3.1.1). The 
number of OX6+ve cells increased significantly on day 9 following 6-OHDA lesion 
induction (lesioned: 55.57±4.71, unlesioned: 1.57± 0.75, p<0.001), when significant 
loss of TH+ve neurons in the SNc was also evident (Fig 4.5). The number of OX-6+ve 
microglia decreased significantly by day 15 after 6-OHDA lesion induction compared to 
the lesion side on day 9 (Day 15 post-lesion: 29.25±5.96, Day 9 post-lesion: 55.57±4.71, 
p<0.001). In sham lesioned animals no expression of OX6+ve microglial cells was 
observed. 
 Thus, focal expression of OX6+ve microglia in the SNc on the lesioned 
hemisphere from day 7 -13 after lesioning was concurrent with significant increase in 
the number of MMP-3+ve cells in the SNc following 6-OHDA lesion induction that 
preceded any dopaminergic neuronal loss in the SNc (Fig 4.8). 
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Fig 4.7 Unilateral time dependent increase in the number of OX6+ve microglial cells in 
the SNc following 6-OHDA lesion induction. 
Injection of 6-OHDA induced accumulation of OX6+ve cells in the SNc in a time 
dependent manner. Graph shows at time-course quantification of OX6+ve microglia in 
the SNc. Immunostaining was carried out with OX6 antibody as markers for MHC II 
expressing activated microglia. The number of OX6+ve cells reached its full 
manifestation on day 9 after 6-OHDA lesion induction in the lesioned hemisphere 
compared to the unlesioned hemisphere. OX6+ve microglia significantly decreased in 
number by day 15 after 6-OHDA lesion induction. Positive cells in the SNc were 
counted as described in (see Chapter 2, section 2.2.3). Results are expressed as   mean 
number of cells + SEM.  ** p< 0.01, ***p<0.001, ns= non-significant. Number of 
animals was 6/group per time point.  
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Fig 4.8 Graphical demonstration of the time dependent  increase in the mean 
number of nigral  MMP-3 expressing cells   in the 6-OHDA lesioned hemisphere 
concomitant with significant increase in the number of OX6+ve microglia in the 6-
OHDA lesioned hemisphere.  
 
Blue line demonstrates the time dependent increase in the mean number of MMP-3+ve 
cells in the SNc following 6-OHDA lesion induction in the lesioned hemisphere. On 
day 7 (red circle) the mean number MMP-3+ve cells increased significantly as also 
shown in (Fig 4.1) compared to day 5 post lesion.  
Grey line demonstrates the time dependent increase in the mean number of OX6+ve 
cells in the SNc following 6-OHDA lesion induction in the lesioned hemisphere. 
OX6+ve cells significantly up-regulate on day 7 after 6-OHDA lesioning (black circle) 
as also demonstrated in (Fig 4.7). The mean number of both MMP-3+ve cells and 
OX6+ve microglia decreased significantly on day 15 after 6-OHDA lesion induction in 
the SNc ipsilateral to the lesion side (red and black arrows respectively). Results are 
presented as mean number of cell± SEM. Number of animals was 6/group per time 
point.  
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4.3.2.2 Comparison between the kinetics of MMP-3 expression and CD68+ve activated  
microglia in the SNc after 6-OHDA lesion induction 
 
CD68+ve phagocytic microglia were present ipsilateral to the side of the lesion 
3 days after 6-OHDA induction compared to contralateral control side. Whereas, in 
sham operated animals no CD68+ve cells were detectable. Their localisation was very 
similar if not identical to that of OX6+ve cells. CD68+ve cells were mainly confined to 
the medial portion of SNc until day 7. Thereafter, the number of CD68 expressing cells 
progressively increased up to day 15 and a large number of CD68+ve cells in the medial 
and lateral portion of SNc ipsilateral to the lesion was observed, no immunoreactivity 
was detected in the unlesion side. Cell counts revealed that significant increase in the 
number of CD68+ve macrophages was observed on day 9 after lesion induction in the 
lesioned hemisphere compared to the unlesioned hemisphere (lesioned: 18.20± 1.43; 
unlesioned: no cells were detected, p<0.001) (Fig 4.9). At this time point  MMP-3+ve 
cells  also significantly increased in number in the lesioned hemisphere compared to the 
unlesioned side (see section 4.3.1.1). CD68+ve cells increased in number up to day 15 
after 6-OHDA lesion induction in the lesioned hemisphere (lesioned:  40.57±3.2; 
unlesioned : no cells detected, p<0.001). Interestingly, the number of MMP-3+ve cells 
decreased on day 15 after 6-OHDA lesioning in the lesioned hemisphere compared to 
the unlesioned hemisphere (see section 4.3.1.1). The presence of CD68+ve 
microglia/macrophages indicated that phagocytic activity accompanied neuronal 
degeneration with simultaneous MMP-3 expression in the SNc following 6-OHDA 
lesioning.  
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Fig 4.9 Graph showing a time dependent increase in the number of CD68+ve 
macrophages in the SNc after 6-OHDA lesion induction. 
Injection of 6-OHDA induced accumulation of CD68+ve cells in the SNc in a time 
dependent manner.  Immunostaining was carried out with CD68 antibody as markers for 
phagocytic macrophages. The number of CD68+ve cells reached its full manifestation on 
day 15 after 6-OHDA lesion induction in the lesioned hemisphere compared to the 
unlesioned hemisphere. CD68+ve cells significantly increased in number on day 9 after 6-
OHDA lesion induction that progressed to day 15. Positive cells in the SNc were counted as 
described in (see Chapter 2, section 2.2.3). Results are expressed as mean number of cells + 
SEM.  ** p<0.01, *** p< 0.001, ns= not significant. . Number of animals was 6/group per 
time point. 
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Fig 4.10 Graphical demonstration of the time dependent   increase in the mean 
number of nigral  MMP-3 expressing cells in the 6-OHDA lesioned hemisphere 
concomitant with significant increase in the number of nigral  CD68+ve 
macrophages in the 6-OHDA lesioned hemisphere.  
 
Blue line demonstrates the time dependent increase in the mean number of MMP-3+ve 
cells in the SNc following 6-OHDA lesion induction in the lesioned hemisphere. On 
day 7 (purple circle) the mean number MMP-3+ve cells increased significantly as also 
shown in (Fig 4.1) compared to day 5 post lesion.  
Red line demonstrates the time dependent increase in the mean number of CD68+ve 
cells in the SNc following 6-OHDA lesion induction in the lesioned hemisphere. 
CD68+ve cells significantly up-regulate on day 9 after 6-OHDA lesioning (black circle) 
as also demonstrated in (Fig 4.8). The mean number of MMP-3+ve cells decreased 
significantly by day 15 after 6-OHDA lesion induction however, the mean number  
CD68+ve macrophages increased significantly compared to day 9 on day 15 after 6-
OHDA lesion induction in the SNc ipsilateral to the lesion side (purple and black 
arrows respectively). Results are presented as mean number of cell± SEM. Number of 
animals was 6/group per time point.  
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4.3.2.3 Interaction between MMP-3 expressing cells and OX6+ve microglia in the SNc 
 after 6-OHDA lesion induction 
 
 Double immunofluorescence staining revealed that OX6+ve activated microglia 
were in the  vicinity of MMP-3 expressing cells on days 7-15 after lesion induction in 
the SNc on the lesioned side compared to the unlesioned side (Fig 4.11). The presence 
of activated OX6+ve microglia very close to the MMP-3+ve neurons was observed up 
to day 15 after 6-OHDA lesion induction but not in the sham lesioned animals. This 
observation indicated that MMP-3 expression was closely related to microglial 
activation. 
 
4.3.2.4 Interaction between MMP-3 expressing cells and CD68 +ve macrophages in the  
SNc after 6-OHDA lesion induction 
  
Double immunofluorescence staining revealed that MMP-3 expressing cells 
were in very close contact with CD68+ve macrophages on days 3, 7, 9 and 13 after 6-
OHDA lesion induction on the side of the lesion (Fig 4.12). This indicated that MMP-
3+ve cells are in nature mostly neuronal and interact with CD68+ve macrophages. 
Secretion of MMP-3 by neurons could act as a signal to activate CD68 expressing 
macrophages in the SNc following 6-OHDA lesion induction. As shown in chapter 3 
(see section 3.4.5.1) microglial phagocytic activity may be initiated prior to the TH+ve 
neuronal demise, suggesting that phagocytosis of apoptotic cells may take place at very 
early stage of neuronal loss in SNc.  
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Fig 4.11 Spatial association between OX6+ve and MMP-3+ve on day 9 after 6-
OHDA lesion induction.  
Unilateral injection of 6-OHDA resulted in a time dependent increase in the number of 
MMP-3+ve and OX6+ve cells in the SNc ispsilateral to the side of the lesion. Double 
immunofluorescence staining for MMP-3 (green) and OX6 (red) shows spatial 
association between MMP-3+ve  and OX-6+ve microglia in the SNc following 6-
OHDA lesion induction in the lesioned hemisphere (combined image, white arrows) . 
OX6+ve microglia are in a close vicinity to MMP-3+ve cells indicating a possible 
interaction between them. Blue: Represents DAPI staining as marker of the cell nucleus 
(x400). 
 
 
 
 
  Fig 4.12 Spatial association between CD68+ve and MMP-3+ve on day 9 after 6-
OHDA lesion induction.  
Unilateral injection of 6-OHDA resulted in a time dependent increase in the number of 
MMP-3+ve and CD68+ve cells in the SNc ispsilateral to the side of the lesion. Double 
immunofluorescence staining for MMP-3 (green) and CD68 (red) shows a close contact 
between MMP-3+ve  and CD68+ve macrophages  on day 3 after 6-OHDA lesion 
induction in the SNc following 6-OHDA lesion induction in the lesioned hemisphere 
(white arrow). Indicative of possible phagocytosis of MMP-3+ve cells before 
dopaminergic neuronall cell death occurs. The combined image is presented due to 
corruption in the files containing the individual picture of MMP-3 and CD68 stained 
cells. Blue: Represents DAPI staining as marker of the cell nucleus (x400). 
MMP OX6 combined 
MMP3 and CD68 
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4.3.3 Expression of CD200R during lesion progression in the SNc after 6-OHDA  
injection 
 
4.3.3.1 Effect of 6-OHDA lesion induction on the number of CD200R expressing cells  
in the SNc 
 
CD200R +ve cells significantly  increased in number in the SNc on day 3 after 
6-OHDA lesioning in  the lesioned hemisphere compared to the unlesioned hemisphere: 
(lesioned : 13.67±1.85 ; unlesioned: 5 ± 0.57, p<0.5 ) (Fig 4.13). CD200R expressing 
cells reached their highest number on day 13 after 6-OHDA lesion induction compared 
to the unlesion side: (lesioned: 33.67 ± 2.33 ; unlesioned: 14.0 ± 1.3, p<0.001 ) (Fig 
4.13). The number CD200R+ve cells decreased significantly on day 15 compared to day 
13 after 6-OHDA lesioning in the lesioned side (Day 15 post lesion: 11.67  ± 1.66 ; Day 
13 post lesion : 33.67 ± 2.33, p<0.01) (Fig 4.13). Control animals did not demonstrate 
any CD200R immunoreactivity. Under homeostasis CD200R is bound to its ligand, 
CD200 which is expressed on neurons. Following a 6-OHDA challenge and the 
resultant disturbance of the ECM, CD200R will unbind from the CD200 glycoprotein 
and is detectible by CD200R antibody. This observation further suggested that CD200-
CD200R interactions that exert an inhibitory effect on the microglial activation were 
disturbed following 6-OHDA lesion induction leading expression of uncoupled 
CD200R. 
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Fig 4.13 Time dependent unilateral increase in the number of CD200R expressing 
cells in the SNc following unilateral injection of 6-OHDA into the MFB. 
Immunoperoxidase staining was performed on 20μm coronal sections of the SNc with 
CD200R antibody. Cell counts revealed that the number of CD200R+ve cells increased 
significantly in the lesioned hemisphere on day 3 after 6-OHDA lesion induction 
compared to the unlesioned hemisphere. The number of CD200R+ve cells in the 
lesioned hemisphere increased time dependently and reached its greatest on day 13 after 
6-OHDA lesioning. By day 15 the number CD200R+ve cells decreased significantly. 
Results are expressed as mean number of cells + SEM. * p<0.5,   ** p<0.01, *** p< 
0.001, ns= not significant. . Number of animals was 6/group per time point. 
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4.3.3.2 Localisation of CD200R+ve cells in the SNc following 6-OHDA lesion  
induction 
 
CD200R expressing cells were mainly observed in the medial portion of the SNc 
up to day 7 after 6-OHDA lesion induction on the side of lesion. On day 9 after 6-
OHDA lesioning CD200R+ve cells were observed in both the medial and the lateral 
portions of the SNc before they relocated to the ventrolateral portion of the SNc on days 
13 and 15 after lesioning on the side of the lesion. In control animals no CD200R+ve 
cells were detected. 
Thus, the kinetics and localisation of CD200R+ve cells were similar if not 
identical to CD68 and OX6 expressing microglia/macrophages. Both OX6+ve microglia 
and CD200R+ve cells relocated from the medial portion of the SNc to the lateral and 
ventral aspects of the SNc in a time dependent manner in addition to increase in their 
numbers following 6-OHDA lesion induction. 
4.3.3.3 Interaction between TH+ve dopaminergic neurons and CD200R+ve cells in the  
SN after 6-OHDA lesion induction 
 
 Double immunofluorescence staining showed that on days 7,9,13 and 15 after 6-
OHDA lesion induction, CD200R expressing cells were observed in a close vicinity to 
the morphologically intact TH+ve dopaminergic neurons in the SNc as well as attached 
to the cell bodies of morphologically damaged TH+ve neurons with round cell bodies 
and absence of dendritic processes in the lesioned hemisphere compared to the 
unlesioned hemisphere (Fig 4.14, bottom panel and top panel, respectively).  The 
interaction between TH+ve dopaminergic neurons and CD200R+ve cells was very 
similar to the interaction observed between TH+ve dopaminergic neurons and OX6+ve 
microglial cells (see chapter 3, section 3.4.5.1). CD200R+ve cells surrounded 
morphologically intact dopaminergic neurons, in addition to damaged ones, suggesting 
that signals from traumatised or damaged neurons could trigger the activation of 
CD200R+ve cells which demonstrated a phenotype characteristic of activated microglia.  
To further explore the interaction between ECM disturbance and CD200R expression, 
the relationship between MMP-3+ve cells and CD200R expressing cells was 
investigated (see section 4.3.2.7). 
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Fig 4.14 Close interaction between intact and morphologically damaged TH+ve 
dopaminergic neurons with CD200+ cell in the SNc  on day 9 after 6-OHDA lesion 
induction in the lesioned hemisphere. 
Top panel: The combined image shows double immunofluorescence staining for TH 
(green ) and CD200R (red) on 20μm thick nigral sections. CD200R+ve cells are in very 
close vicinity almost attached to the dendrites of a morphologically intact TH+ve 
dopaminergic neuron (white arrow) in the SNc ipsilateral to the lesioned hemisphere 
(x400). Blue: Represents DAPI staining as marker of the cell nucleus. 
 
Bottom panel: The combined image shows double immunofluorescence staining for 
TH (green) and CD200R (red) on 20μm thick nigral sections. CD200R+ve cells are 
attached to morphologically damaged TH+ve dopaminergic neurons in the SNc, TH+ve 
cell have lost their dendritic processes and have a round morphology (white arrow). 
This indicates that TH+ve dopaminergic neurons are damaged following 6-OHDA 
lesion induction(x400). Blue: Represents DAPI staining as marker of the cell nucleus. 
 
 
 
Combined TH  CD200R  combined
combined  CD200R TH 
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4.3.3.4 Interaction between MMP-3 expressing cells and CD200R+ve cells in the SNc  
after 6-OHDA lesion induction 
 
Double immunofluorescence staining revealed that on days 3 and 5 after 6-
OHDA lesion induction CD200R expressing cells were attached to MMP-3+ve cells 
with neuronal morphology in the SNc (Fig 4.15, Top panel). On days 7-15 after 6-
OHDA lesion induction CD200R +ve cells were observed to be in close proximity to 
MMP-3+ve cells that showed neuronal morphology in the SNc (Fig 4.15 Bottom panel). 
This observation indicated that during the early days post 6-OHDA lesioning the release 
of MMP-3 by neurons could lead to the dissociation of the CD200R expressing cells 
from the CD200 glycoprotein on neurons, hence CD200R expressing cells were 
detectable whilst still attached to MMP-3+ve neurons. However, at later time points 
after 6-OHDA lesion induction, CD200R +ve cells were dissociated from MMP-3+ve 
neurons. This observation suggested that disturbance in the ECM could have led to a 
disassociation of the CD200R from its ligand CD200, hence dysregulation in neuron-
glia interaction contributing to microglial activation. 
 
 
 
 
 
 
 
 
 
 
 
  
 136
 
 
Fig 4.15 Spatial association between MMP-3+ cells and CD200R+ve microglia in 
the SNc following 6-OHDA lesion induction. 
Top panel: The combined image shows double immunofluorescence staining for 
MMP3 (green) and CD200R (red) on 20μm thick nigral sections. CD200R+ve cells are 
attached to MMP-3+ve neurons (white arrows) in the SNc ipsilateral to the lesioned 
hemisphere on day 3 after 6-OHDA lesioning (x400). Blue: Represents DAPI staining 
as marker of the cell nucleus 
Bottom panel: The combined image shows double immunofluorescence staining for 
MMP3 (green) and CD200R (red) on 20μm thick nigral sections. CD200R+ve cells are 
in close proximity to MMP-3+ve neurons (white arrows) but not attached to them in the 
SNc ipsilateral to the lesioned hemisphere on day 7 after 6-OHDA lesioning (x100). 
Blue: Represents DAPI staining as marker of the cell nucleus. 
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4.4 Discussion 
The main aim of this study was to elucidate the mechanisms that are involved in 
initiation of microglial activation, with particular emphasis on signals released from 
neurons in the SNc after unilateral injection of 6-hydroxydopamine (6-OHDA) into the 
medial forebrain bundle (MFB). Hence, we studied the kinetics of MMP-3 and MMP-9 
activation in relation to the extent of dopaminergic neuronal loss during the lesion 
progression in the SNc. In addition, we assessed how the expression of MMP-3 and 9 
correlate with the extent of microglial activation in the SNc following 6-OHDA lesion 
induction. Finally, we have studied the association and spatial interactions between 
CD200R expressing cells and neurons in the SNc during the progression of 
dopaminergic neuronal loss in our PD model. 
 4.4.1 MMP-3 and MMP-9 expressions preceded dopaminergic neuronal loss in the  
SNc following 6-OHDA lesion induction 
 
Limited constitutive MMP-3 expression was observed in the SNc, in both 
control and sham operated animals, however the numbers of cells were not significantly 
different between control and sham lesioned animals. Therefore, any significant 
increase in the number of MMP-3 +ve cells was considered to be due to the effects of 6-
OHDA lesion induction. As our results demonstrate ( see section 4.3.1.1) that MMP-
3+ve cells are present in the SNc from day 3 after lesioning on the lesioned side and 
significantly increased in number in the SNc on day 7 after 6-OHDA lesion induction. 
Increases in the number of MMP-3+ve cells progressed up to day 13 followed by a 
significant decrease on day 15 after lesion induction. Concomitant with the increase in 
MMP-3+ve cell number, unilateral injection of 12µg 6- OHDA into the MFB led to a 
progressive partial lesion in the SNc that was evident by loss of >55% of TH+ve 
dopaminergic neurons as discussed in chapter 3 (see section 3.5.1). Significant neuronal 
loss started to manifest itself 9 days after 6-OHDA injection. It is well documented 
(Pickel et al., 1977; Wassef et al., 1981) that loss of TH-immunoreactivity in the SNc is 
indicative of degeneration of nigral dopaminergic neurones. However as mentioned in 
chapter 3, to rule out the possibility that the observed decrease in the number of TH+ve 
dopaminergic neurons was due to the down-regulation of TH following 6-OHDA, 
double staining for TH and NeuN was performed (see Chapter 3, section 3.4.1.1) that 
clearly demonstrated that 6-OHDA led to loss of neuronal cell bodies (data not shown 
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in this chapter). Our data clearly demonstrated that the up-regulation of MMP-3 
expressing cells preceded dopaminergic neuronal cell death in the SNc. MMP-3 
expression reached a maximum on day 9 after lesion induction when significant 
dopaminergic neuronal loss was also apparent; supporting our hypothesis that MMP-3 is 
associated with dopaminergic neuronal loss in PD pathology. Moreover, the loss of 
TH+ve dopaminergic neurons was observed to be mostly in the ventral tier of the SNc 
where MMP-3+ve cells were present in clusters, further emphasising MMP-3 
involvement in dopaminergic neuronal cell death. To assess whether the observed 
MMP-3 expression is in fact the active enzyme, we monitored the expression of its 
downstream MMP, MMP-9. As our results demonstrate, a significant increase in the 
number of MMP-9 expressing cells was observed from days 1-15 after 6-OHDA lesion 
induction in the SNc ipsilateral to the lesioned hemisphere compared to the unlesioned 
hemisphere. Interestingly, in the control animals no constitutive expression of MMP-9 
in the SNc was detected. Not only was MMP-9 expression very rapid following 6-
OHDA lesioning but since no constitutive MMP-9 expression was observed, it is likely 
that MMP-9 expression is down-stream to MMP-3, further suggesting that MMP-3 is in 
its active form. This is in line with reports from Ogata et al., (1992) which demonstrated 
that MMP-3 was an activator for pro-MMP-9 in vitro.  In addition, cell culture studies 
have shown that microglia-derived MMP-3 was critical for the activation of MMP-9 
during LPS-induced inflammatory response (Rosenberg et al., 2001).  
The observation that MMP-3+ve cells decreased in number by day 15 after 6-
OHDA lesion induction when MMP-9+ve  cells remained up-regulated through out the 
study indicated that MMP-3 activity might be  involved in early cellular events and 
activates MMP-9 which subsequently may  lead to cell death following 6-OHDA 
lesioning . However, it is worth noting that the significant increase in the number of 
MMP-9+ve cells in the SNc 24 hours after 6-OHDA lesioning could be through an 
MMP-3 independent pathway. To this end, other factors such as presence of pro-
inflammatory cytokines such as, TNF-α and IFN−γ, are implicated in direct activation 
of MMP-9 (Lorenzl et al., 2004). 
Morphological assessment and double immunofluorescence stainings revealed 
that MMP-3 and MMP-9+ve cells were expressed by neurons and not astrocytes. Indeed, 
in vitro studies demonstrated that astrocytes only express MMP-2 under basal 
conditions but not MMP-3 and MMP-9 (Colton et al., 1993; Wells et al., 1996). Our 
finding of the neuronal expression of MMP-3 and 9 in the SNc is in accord with 
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findings of Kim, et al, (2005, and 2007) who demonstrated that the active form of 
MMP-3 was in fact released from dopaminergic neurons and was most likely 
responsible for microglial activation and generation of NADPHO-derived superoxide, 
eventually enhancing nigrostriatal dopaminergic neuronal degeneration. We observed 
that the majority of neurons expressing MMP-3 or MMP-9 were morphologically  intact, 
which may support the studies suggesting that MMP-3 release occurs early before any 
morphological changes indicative of apoptosis occur (Kim et al., 2007). 
Specific expression of MMP-3 and 9 by neurons in the SNc following 6-OHDA 
administration could be an indication that the activation of MMP-3 and 9 in the SNc, 
following an insult, is not a heterogeneous response but rather it has a precise functional 
characteristic leading to the subsequent microglial activation and progression of 
dopaminergic neuronal cell death in the SNc. The exact role of MMPs in neuronal 
degeneration is however not clear. Previous reports by Yong et al., (1998) revealed that 
MMPs can exert direct neurotoxic effects to neurons in vitro by the destruction of 
component of the ECM, such as laminin.  However, recent evidence suggests that 
although characterized for their ability to degrade matrix proteins, MMPs are becoming 
increasingly recognized as effectors of cell signalling (Conant et al., 2004). MMPs are 
able to cleave non-matrix proteins and thereby generate potential cell surface receptor 
signalling ligands. For example, MMP-1 can degrade insulin-like growth factor-binding 
proteins and thereby stimulate insulin-like growth factor signalling (Fowlkes et al., 
1994).  Another mechanism by which MMPs could affect cell survival might include 
direct effects on cell surface receptors raising the possibility that they may directly affect 
cell signalling. For example, MMP-9 and MMP-3 can both bind to CD44, a cell 
adhesion molecule involved in cell-cell and cell matrix interactions which regulate 
many pathological conditions such as brain tumour invasion (Stricker et al., 2001). In 
addition, MMP-1 can exert direct neurotoxic effects in neuronal cell cultures by 
dephosphorylation of Akt and through other non-proteolytic mechanism (Conant et al., 
2004). MMPs not only exert direct neurotoxicity to neurons, but they can also lead to 
neurodegeneration indirectly. One indirect mechanism by which MMP-3 and MMP-9 
activity leads to neurodegeneration in different brain diseases is by the activation of 
microglial cells. MMP-3 could potentially serve as a signalling molecule that mediates 
the interaction between apoptotic neurons, which are caspase-3+ve (see Chapter 3), and 
microglia in early apoptosis.  
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As demonstrated in our results microglial activation, characterised by up-
regulation of MHC II and CD68 expressing microglia/macrophages, not only preceded 
dopaminergic cell death in the SNc following 6-OHDA lesioning but also occurred 
concomitant with an increase in MMP-3 and MMP-9 expression. Detailed discussion on 
the role MMPs in microglial activation in context of our findings may be found in the 
following section (see section 4.4.2) 
 
4.4.2 Interaction between activated microglia and MMP-3 expressing neurons in  
the SNc following 6-OHDA lesion induction 
 
6-OHDA MFB lesion induction led to the focal activation of microglia that was 
detected by their expression of OX6, a marker of major histocompatibility complex 
class II antigen presentation (Sugama et al., 2003) and CD68. CD68 is an antigen in the 
lysosomal membranes which stains phagocytic microglia (Croisier et al., 2005). The 
amount of CD68 expression in a single cell can be correlated to phagocytic activity of 
the respective cell type (Damoiseaux et al., 1994). Under normal conditions, microglia 
have a resting, ramified appearance with small somas and long fine processes (Vilhardt, 
2004; Raivich et al., 1999). OX6 expressing activated microglia, were densely stained 
with enlarged cell bodies and thick contracted lamellipodia, while CD68 phagocytic 
microglia had an amoeboid macrophage-like appearance. OX6 expression was 
particularly dense in the medial aspect of the SNc, spreading laterally. CD68 expressing 
cells showed identical localisation and time dependent relocation to lateral portion of 
the SNc similar to OX6+ve microglia. A further indication of microglial activation is 
the increase in cell numbers (Raivich et al., 1999). 
The increase in the number of OX6+ve activated microglia in the SNc was 
significant from day 7 after 6-OHDA lesion induction on the lesioned hemisphere 
compared to the unlesioned hemisphere. This coincided with a significant increase in 
the number of MMP-3+ve cells on the side of the lesion compared to the unlesioned 
side. Increases in the number of OX6+ve activated microglia and MMP-3+ve cells 
progressed in a time dependent manner and on day 9 after 6-OHDA lesioning concurred 
with significantly decrease in the number of dopaminergic TH positive neurons. This 
supports previous studies demonstrating that MMP-3 activated microglia may 
contribute to dopaminergic neuronal degeneration (Kim et al., 2007). In addition, the 
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early presence of phagocytic CD68 expressing microglia on day 3 after lesioning, when 
TH loss is not measurable, is an indication that early phagocytic activity may be taking 
place. MMP-3 expression not only occurred in parallel to OX6 expression but a 
significant increase in the number of  CD68 expressing phagocytic microglia was also 
observed  on day  9 after 6-OHDA lesioning . These findings indicated MMP-3 
expression might be associated with microglial activation in the neurodegenerative 
process from a very early stage when there has been no apparent loss of dopaminergic 
neurons.  
The kinetics of microglial activation and MMP-3 expression indicated that these 
two phenomena coincide in the SNc after 6-OHDA lesion induction, suggesting an 
involvement of MMP-3 activity and its downstream MMP, MMP-9, in microglial 
activation. This is further supported by our results showing the spatial interaction 
between activated microglia and MMP-3 expressing neurons.  This was characterised 
by presence of OX6 and/or CD68+ve microglia/macrophages in close vicinity and even 
in contact with MMP-3+ve neurons. This interaction between OX6+ve microglia and 
MMP-3 expressing neurons was observed from 7-15 days after 6-OHDA lesioning. The 
continuous presence of MMP-3 +ve neurons and OX6+ve microglia at close proximity 
indicates that once MMP-3 was expressed in the SNc, it progressively contributed to the 
activation of microglia, which preceded the initiation of dopaminergic neuronal cell 
death. 
Interaction between MMP-3+ve neurons and CD68+ve macrophages was 
observed from days 3-13 after 6-OHDA lesioning, suggesting that phagocytosis of 
damaged and/or apoptotic neurons is initiated very early in the process following 6-
OHDA lesion induction. Up regulation of MMP-3 and MMP-9, that coincided with 
CD68 expression, plays a possible role in activation of phagocytic activity in the SNc. It 
has been demonstrated that in MMP-3-/- knockout mice, microglial activation and 
subsequent dopaminergic neuronal loss in the SNc and the striatum were attenuated 
following MPTP administration (Kim et al., 2007). The mechanism by which MMP-3 
expression leads to microglial activation is not yet fully understood. Indeed, ECM 
molecules, such as laminin and fibronectin, are substrates of MMPs and can be modified 
or cleaved by MMPs to release soluble forms. Soluble ECM molecules have been 
demonstrated to regulate microglia/macrophages function (Chamak and Mallat, 1991; 
Tate et al., 2007). Studies on BV2 cell lines, demonstrated that in addition to 
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degradation of the ECM macromolecules by MMP-3, MMP-3 is involved in microglial 
activation through its enzymatic activity (Kim et al., 2005). It has been demonstrated 
that MMP-3 expression by chondorocytes was required for the generation of a 
macrophage chemoattractant and the subsequent infiltration of proteolytically active 
macrophages (Haro et al., 2000).  
An additional finding of our study was a decrease in the levels of MMP-3 at day 
15 to levels similar to the unlesion side. This could be due to the reduced levels of 
dopaminergic neurons present at this point, thus implicating MMP-3 as an early 
microglial activator. It also supports that dopaminergic neurons are releasing MMP-3 
since their declining content leads to decreased MMP-3 expression. To further 
investigate the interaction between MMP-3 expressing neurons and microglia that lead 
to microglial activation in the SNc following 6-OHDA lesion induction we studied the 
dynamics of CD200R and its relation to both dopaminergic cell loss and MMP-3 
expression.  
 
4.4.2 The dynamics of CD200R expression in relation MMP-3 expression and  
dopaminergic neuronal cell death in the SNc 
 
Interaction between neurons and microglia is a local modulator of microglial 
activation (Wang et al., 2007). In this study, we assessed both the kinetics of CD200R 
expression and the interaction between the CD200R expressing cells and dopaminergic 
neurons in the SNc following 6-OHDA lesion induction. CD200R belongs to the 
immunoglobulin super-family that received immunoregulatory signals from CD200 
glycoprotein to regulate the activation of microglia. We demonstrated that the number 
of CD200R expressing cells increased in the SNc, on the lesioned hemisphere compared 
to the unlesioned hemisphere, in a time dependent manner following 6-OHDA lesioning. 
The number of these cells reached their maximum on day 13 but decreased there after. 
In sham and control animals CD200R was not expressed to a significant level. The 
kinetics of CD200R was very similar to that of MMP-3+ve neurons and OX6+ve 
microglia. The presence of CD200R+ve cells attached to the cell bodies and dendrites 
of dopaminergic neurons from 7-15 days after 6-OHDA lesion induction indicated that 
CD200-CD200R dysregulation occurs following 6-OHDA lesioning which leads to 
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expression of CD200R by microglia. Furthermore activated CD200R+ve cells 
demonstrated very similar properties to OX6+ve cells. These data support the 
immunomodulatory role of neuron-microglia interaction that keeps the microglia 
quiescence during homeostasis. 
The time dependant relocation of C200R+ve cell from the medial portion of the 
nigra from day 7 up to day 15 to the more ventrolateral parts of the SNc is also similar 
to the dynamics of OX6+ve and CD68+ve microglia. However, the total number of 
CD200R+ve on average was lower than the OX6+ve microglia in our study. This might 
be an indication that CD200-CD200R interaction is a local modulator of microglial 
activation where it regulates the resident sub-population of microglia in the SNc.  
Our study for the first time reports on a spatial relationship between MMP-3+ve 
neurons and CD200R+ve cell in the SNc (Fig 4.12). Attachment of CD200R+ve cells to 
MMP-3+ve neurons on days 3-7 after lesioning suggested that distribution in the ECM 
and expression of MMP-3 could play a role in the dissociation of CD200R from its 
ligand and subsequent activation of microglia. In addition, the observed  dissociation of 
CD200R+ve cells from the MMP-3+ve neurons on day 9-15 further indicated that 
MMP-3 might be an early signalling molecule for activation of microglia in the 
initiation process of PD pathology that mediates the interactions with the ECM or cell 
surface receptors (Schlondorff and Blobel, 1999). Increased MMP activity leads to 
enhancement of proteolytic activity with simultaneous degradation of ECM component 
such as laminin. This might result in the alteration of adhesive contact with the 
extracellular matrix, and consequently the expression of cell- cell interaction proteins 
such as CD200/CD200R glycoprotein or other members of the IgG super family such as 
ICAMS (Hubbard and Rothlein, 2000).  
 
Conclusions  
 
Our results, clearly demonstrated that there is a temporal relationship between 
MMP-3/MMP-9 expressions and microglial activation followed by degeneration of 
dopaminergic neurons in the SNc in the 6-OHDA model. MMP-3 and MMP-9 may be 
released from injured dopaminergic neurons leading to the disturbance of the neuron-
microglia interactions. Which was evident by CD200R up-regulation and activation of 
microglial cells that contributed to progressive dopaminergic neuronal cell death in SNc. 
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Fig 4.16 Cartoon showing the involvement of MMP-3 expression in microglial 
activation upon neuronal damage.  
 
Upon 6-OHDA induced neuronal damage microglia are rapidly activated as a result of 
both a weakening neuronal inhibitory signals and activating stimulatory signals. Loss of 
neuronal integrity results in breakdown of microglial inhibitory molecules such as 
CD200-CD200R interaction. Instead, microglial stimulatory signals including MMP-3 
are rapidly turned on and activate microglia. Activated microglia phagocytose at sites of 
neuronal damage, and increase in numbers, either from proliferation or recruitment, in 
order to remove damaged tissue and promote repair. However, their inappropriate 
activation as in neurodegenerative disorders causes direct damage to the CNS either by 
releasing potentially toxic substances such as proinflammatory cytokines, chemokines, 
NO, superoxide and prostanoids or by early phagocytosis against normal neurons 
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Chapter 5  
Neuroprotective effects of modulation of glial activity by 
peroxisome proliferator activated receptor gamma (PPAR-
γ ) agonists in the 6-hdroxydopamine model of Parkinson’s 
disease. 
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5.1 Introduction 
 
Data from preceding chapters demonstrated that activation of 
microglia/macrophages prior to dopaminergic neuronal demise is strongly associated with 
the initiation and progression of dopaminergic neuronal cell death in the SNc following 6-
OHDA lesioning.  To elucidate the significance of microglial activation  in dopaminergic 
neuronal loss in the SNc, the potential neuroprotective effects of modulation of glial 
activation was studied by targeting one of the  players in the inflammatory process,  the 
peroxisome proliferator activated receptor gamma sub-type (PPAR-γ).  
 
5.1.1 PPAR-γ and inflammation 
 
PPARs are members of a super-family comprising of the nuclear hormone receptors 
for steroids, thyroid hormones and retinoids, that were cloned more than 15 years ago  
(Issemann and Green, 1990) .  Three different but structurally homologous PPAR isotypes 
(PPAR-α, PPAR-β, also known as δ, and PPAR-γ) have been identified in various species. 
PPARs (α,β/δ and γ) bind to specific DNA regions, the peroxisome proliferator response 
elements (PPREs) and enhance the expression of regulated genes that are mainly involved 
in reproduction, metabolism, development and the immune response. In addition, PPARs 
control gene expression, such as inhibition of pro-inflammatory genes independent of PPAR 
binding, through a poorly understood mechanism termed transrepression. This results in the 
inhibition of several transcription factors, including nuclear factor kB (NF-kB), activator 
protein-1 (AP-1) and activator of transcription-1 (STAT-1) (Kielian and Drew, 2003).  
The distribution of PPARs in different organs has been studied in many species 
including humans and rodents. In both species, PPAR-α is mainly expressed in organs with 
high catabolic rates of fatty acids such as hepatocytes and cardiomiocytes (Palmer et al., 
1998). PPAR-γ is mainly found in brown and white adipocytes and the nervous system. 
PPAR-β/δ is ubiquitously expressed, with a higher expression in the digestive tract and the 
placenta ( Desvergne and Wahli, 1999; Escher et al., 2001).  
Reflecting their distribution, PPARs act principally as lipid sensors and regulate 
whole-body metabolism in response to dietary intake of lipids (Michalik et al., 2006). 
PPAR-γ in particular stimulates lipid metabolism and adipocyte differentiation.  In addition, 
activation of PPAR-γ is linked to reduction of serum glucose levels. This property has led to 
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the development of specific PPAR-γ agonists for the treatment of type 2 diabetes (Willson 
et al., 2001). The best-characterized synthetic PPAR-γ agonists belong to the insulin 
sensitizers, thiazolidinedione class of drugs, which includes pioglitazone (Actos®, Takeda 
Pharmaceutical Company Ltd, Osaka, Japan) and rosiglitazone (Avandia®, 
GlaxoSmithKline, Philadelphia, PA), both are used for treatment of type 2 diabetes. Other 
synthetic PPAR-γ agonists include, non-steroidal anti-inflammatory drugs (i.e. 
indomethacin, fenoprofen and flufenamic acid), (Lehmann et al., 1995). Endogenous 
ligands for PPARs include naturally occurring molecules, such as fatty acids and the 
prostaglandin D2 metabolite, 15-deoxy- 12,14prostaglandin J2 (15d-PGJ2) that bind to PPAR-
γ and stimulate transcription of target genes (Kliewer et al., 1994 ; Forman et al., 1995). 
PPAR-γ despite having a major role in metabolic tissues, it is also expressed in 
several other cell types, including cells of the immune system such as macrophages, 
dendritic cells, eosinophils, T cells and B cells. Interestingly, it was documented that this 
receptor is expressed at high levels in mouse spleen (Kliewer et al., 1994) indicating its role 
in the immune system. In recent years, parallel to investigations on the functions of PPAR-γ 
in lipid metabolism, a new aspect of PPAR-γ function has been revealed and developed that 
is its potential anti-inflammatory activity (Bernardo et al., 2006). Studies by Ricote et al., 
(1998) demonstrated that murine activated peritoneal macrophages express high levels of 
PPAR-γ. Therefore, macrophages were the first cell type that linked PPAR-γ and 
inflammatory diseases. One of the first pieces of evidence suggesting a role for PPAR-γ in 
inflammation, came from the observation of an antagonistic effect of   PPAR-γ on 
metabolic/pro-inflammatory effects of TNFα in adipocytes (Zhang et al., 1996). 
Furthermore Ricote et al., (1998) showed that natural and synthetic PPAR-γ agonists inhibit 
the expression of the inducible nitric oxide synthase (iNOS), matrix metalloproteinase 9 
(MMP-9) and scavenger receptor A (SR-A) mRNAs in vitro. These and other similar in 
vitro observations led to a series of studies on anti-inflammatory effects of PPAR-γ ligands. 
Park et al., (2003) demonstrated that the PPAR-γ agonists including the naturally occurring, 
15d-PGJ2 and synthetic agonists such as rosiglitazone inhibit the phosphorylation of Janus 
kinase-signal transducers and activators of transcription (STAT1, STAT3, JAK1, and JAK2) 
in microglia and astrocytes. The authors further demonstrated that these agonists induce the 
expression of suppressor cytokine signalling (SOCS) 1 and 3, which alters JAK/STAT 
phosphorylation and JAK/STAT mediated signalling. Suggesting that activation of PPAR-γ 
is associated with an inhibitory effect on microglial response. 
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The dominant site of PPAR-γ action is the peripheral tissue, however in recent years 
considerable evidence has emerged on their role in the CNS. The role of PPARs in the CNS 
is mainly been related to lipid metabolism, however these receptors have been implicated in 
neural cell differentiation and death as well as in inflammation and neurodegeneration. The 
expression of PPAR-γ in the brain has been extensively studied in relation to inflammation 
and neurodegeneration (Heneka et al., 2000). The following section is an overview of the 
role of PPAR-γ in the brain with particular emphasis on its role in PD pathology.  
 
5.1.2 Anti-inflammatory role of PPAR-γ in PD 
There is increasing evidence to indicate that PPAR-γ has important roles in 
modulating neuroinflammation and neurodegeneration, therefore PPAR-γ represents a 
valuable therapeutic target in diseases such as PD, Alzheimer’s disease (AD) and Multiple 
sclerosis (MS) where inflammation plays an integral role in their pathogenesis. A number of 
in vitro and in vivo studies have shown that PPAR-γ agonists are potent inhibitors of 
microglia-mediated production of cytotoxic factors.  In LPS treated cortical neuron–glial 
co-cultures, PPAR-γ agonists reduced LPS induced expression of iNOS and COX-2 and 
protected neurons (Kim et al., 2002). In addition, studies on stimulated mouse microglia and 
astrocytes revealed that synthetic PPAR-γ agonists such as: rosiglitazone, pioglitazone, and 
ciglitazone alongside the naturally occurring  15d-PGJ(2) ligand,  inhibited the production 
of nitric oxide, the pro-inflammatory cytokines TNFα, IL-1β, and IL-6, and the chemokine 
monocytes chemotactic protein 1  MCP-1 from microglia and astrocytes (Storer et al., 2005). 
Administration of PPAR-γ agonists to animals who have had LPS administered to the 
cerebellum, resulted in a significant inhibition of iNOS and other inflammatory genes that 
yielded neuroprotection (Heneka et al., 2000). These results suggest that PPAR-γ agonists 
play an anti-inflammatory role following an insult to the brain that leads to neuroprotection. 
In experimental models of AD, the expression of iNOS in neurons was associated 
with a time-dependent neuronal cell death, which was prevented by activation of PPAR-γ in 
vitro and in vivo (Heneke et al., 1999; Heneka et al., 2000). In a model of MS, known as 
experimental allergic encephalomyelitis (EAE) induced in mice, Niino et al, (2001) 
demonstrated that PPAR-γ activation limited the development of clinical symptoms and the 
infiltration of the brain by peripheral leukocytes in EAE induced by myelin oligodendrocyte 
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glycoprotein peptide 35–55 (MOG35–55). These newly appreciated anti-inflammatory actions 
of PPAR-γ agonists, may not only allow novel therapies for AD and MS but any other 
central nervous system diseases with an inflammatory component, including PD.  PPAR-γ 
agonists inhibit several functions associated with microglial activation (Bernardo et al., 
2000 and 2003), suggesting that these natural and synthetic compounds can have important 
roles in controlling brain inflammation. This could be of particular relevance in the case of 
endogenous molecules such as 15d-PGJ2 that can be produced within the brain and act in 
paracrine and/or autocrine manners (Bernardo et al., 2003) to modulate inflammation.  
Given the  in vivo and in vitro anti-inflammatory/neuroprotective  effects of PPAR-γ 
agonists, the first studies to elucidate possible neuroprotective role of PPAR-γ agonists in 
models of PD utilised the MPTP  mouse model of  PD. MPTP treated mice were orally 
treated with synthetic PPAR-γ ligands to test the hypothesis that PPAR-γ mediated anti-
inflammatory effects would exert neuroprotection. Breidert and colleagues (2002) found 
that pioglitazone (PPAR-γ agonist) treatment protected from MPTP-induced dopaminergic 
cell death in the SNc. This finding was confirmed by Dehmer, et al (2004) demonstrating 
that oral pioglitazone treatment also protected tyrosine hydroxylase-positive SNc neurons 
from MPTP-induced cell death. In both studies, pioglitazone decreased microglial and 
astrocyte activation and reduced the number of iNOS-positive cells in both the striatum and 
SNc. In vitro studies showed that PPAR-γ agonists act by blocking the differentiation of 
monocytes into reactive macrophages (Ricote et al., 1998) and the activation of microglia 
(Combs et al., 2000). The molecular mechanisms by which PPAR-γ activation inhibits 
inflammatory response are not yet fully understood. However, Dehmer, et al (2004) 
demonstrated that in MPTP treated mice this may have been achieved by reduced NFκB 
dependent signal transduction, since pioglitazone treatment induced a striatal increase of 
IκB-α, a direct inhibitor of NFκB nuclear translocation. Similar data have been generated 
using an intrastriatal LPS induced inflammation driven rat model of dopaminergic 
neurodegeneration, where pioglitazone effectively reduced microglial activation and 
protected dopaminergic neurons on the SNc (Hunter et al., 2007).  
Recent epidemiological evidence, suggests that medication with non-steroidal anti-
inflammatory drugs (NSAIDs), and in particular ibuprofen, may delay or prevent the 
development of PD (Chen et al., 2005). Since Ibuprofen crosses the blood–brain barrier and 
potentially acts as a PPAR-γ agonist (Lehmann et al., 1997), it is possible that PPAR-γ 
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activation contributes to the observed beneficial effect of Ibuprofen. Taken together, these 
data suggest that treatment with PPAR-γ agonists may offer a new therapeutic approach to 
the treatment of PD.  
Given the neuroprotective properties of PPAR-γ agonists, this study for the first time 
investigated the potential anti-inflammatory effects of PPAR-γ agonists and their 
modulatory effect on the inflammatory cascade leading to dopaminergic cell death in 6-
OHDA rat model of PD. To test whether activation of the gamma sub-type of PPARs is the 
only sub-type that exerts neuroprotective properties we also tested a PPAR-δ agonist. 
 
Our hypothesis was that downgrading inflammation may have a neuroprotective impact 
on PD pathology.  To address this hypothesis we set up our study with the following aims:  
 
-To investigate the effect of different treatment regimes of PPAR-γ agonists 
(GW855266X) and pioglitazone on the extent of dopaminergic cell and striatal dopamine 
loss and glial response in the SNc following 6-OHDA lesion induction into the MFB (see 
chapter 2 section 2.1.2). 
 
To satisfy these aims we studied two PPAR-γ agonists and one PPAR-δ agonist for 
their anti-inflammatory and neuroprotective properties in 6-OHDA rat model of PD. The 
first PPAR-γ agonist (GW855266X) tested was a compound developed and granted to us 
under the licence of GlaxoSmithKline (GSK). The dose used for this compound was 
determined and recommended by GSK according to their in vitro studies carried out 
internally. The second compound, which was also provided by GSK, was the clinically used 
PPAR-γ agonist, pioglitazone that was mainly used as our reference compound. The third 
GSK licensed compound was a PPAR-δ agonist (GW610742X) that was tested to determine 
whether the PPAR-γ sub-type was the only sub-type responsible for the beneficial effects 
observed. As described in the next section (see section 5.2 Experimental design), the two 
PPAR-γ agonists and PPAR-δ agonist were tested in different treatment regimes in order to 
determine the most beneficial treatment strategy. Firstly, we have replicated the treatment   
regime used by Breidert at al, (2002), administering PPAR agonists prior to and after lesion 
induction with 6-OHDA. Secondly, in a highly novel and more clinically relevant regime 
has been exploited by administering the compounds post lesion induction. Finally, to assess 
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whether the potential neuroprotective effect of the PPAR-γ agonists is long lasting we have 
conducted drug withdrawal studies. The neuroprotective effects of different treatment 
regimes were assessed by investigating the integrity and functionality of the nigrostriatal 
tract as described in section 5.2 below. In addition as descried in section 5.2 the effects of 
different treatment regimes were assessed on the inflammatory response by investigating 
the activation and up-regulation of glial cells, as well as members of the matrix 
metalloproteinases in the SNc.  
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5.2 Experimental design 
5.2.1 Treatments with GW855266X, pioglitazone and PPAR-δ agonist 
 
To assess the potential anti-inflammatory/neuroprotective effects of GW855266X, 
pioglitazone and PPAR-δ agonist in the 6-OHDA model the effects of different treatment 
regimes on the integrity of the nigrostriatal system and the inflammatory response were 
compared. All treatments were administered orally via a gavage twice daily (p.o.b.i.d). The 
weight of the animals was monitored through out the study. The treatment regimes were 
chosen as follows:  
A. Treating pre and post 6-OHDA lesion induction 
 
These compounds were to be used for the first time in our study and thus we did not 
know which treatment regime would be most effective. To answer this question,  in this 
initial study we chose to administer the compounds before  6-OHDA lesion induction (see 
chapter 2 section 2.1.2) and continue post lesion to test whether presence of either of these 
PPAR-γ and δ agonists would be neuroprotective in the  6-OHDA lesioned animals. 
Animals were divided into 4 groups (n=6). One group of animals was treated with 
pioglitazone (20mg/kg), another group was treated with GW855266X (5 mg/kg). The next 
group was treated with PPAR-δ agonist (10mg/kg) and the last group of animals served as 
controls and were treated with 0.5% methylcellulose as drug vehicle. Treatments were given 
p.o.b.i.d. for 14 consecutive days starting 7 days before 6-OHDA lesion induction and were 
continued for a further 7 days post lesioning. Animals were sacrificed on day 15 after 6-
OHDA lesion induction. Upon achieving encouraging results with the PPAR-γ compounds 
we then administered them post 6-OHDA lesion induction a more clinically relevant 
treatment regime.  
  
B. Post 6-OHDA lesion treatment regime 
 
  Our  findings from the initial studies with PPAR-γ agonists,  pioglitazone (20mg/kg) 
and GW855266X (5mg/kg) but not PPAR-δ agonist, administered pre and post 6-OHDA 
lesion induction were encouraging therefore, in this study the PPAR-γ agonists  were 
administered after 6-OHDA lesion induction  . To determine the neuroprotective and anti-
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inflammatory effects of GW855266X and pioglitazone after 6-OHDA lesion induction, rats 
were divided into 3 groups (n=6). One group of animals was treated with pioglitazone 
(20mg/kg), another group was treated with GW855266X (5 mg/kg) and the last group of 
animals served as controls and were treated with 0.5% methylcellulose as drug vehicle.  
Treatments were given p.o.b.i.d. for 7 consecutive days starting from day 2 after 6-OHDA 
lesion induction (see chapter 2 section 2.1.2). Animals were sacrificed on day 9 after 
lesioning and specimens were collected for HPLC-ECD and immunohistochemical analysis.  
 
B1. Drug withdrawal following post lesion treatment 
 
To investigate whether the neuroprotective effects  of GW855266X and pioglitazone 
were long lasting or whether the continuous presence of the drugs was necessary to 
maintain their beneficial effect, rats were divided into 3 groups (n=6). One group of animals 
was treated with pioglitazone (20mg/kg), another group was treated with GW855266X 
(5mg/kg) and the last group of animals served as controls and were treated with 0.5% 
methylcellulose as vehicle.  Treatments were given p.o.b.i.d. for 7 consecutive days starting 
from day 2 after 6-OHDA lesion induction, thereafter treatments were ceased for 7 
consecutive days, animals were eventually sacrificed on day 16 after 6-OHDA lesion 
induction and specimens were collected for HPLC-ECD and immunohistochemical analysis. 
 
5.2.2 Assessment of effects of   GW855266X, pioglitazone and PPAR-δ in the 6- 
OHDA model 
5.2.2.1 Assessment of the effects of GW855266X, pioglitazone and PPAR-δ on the  
nigrostriatal tract functionality after 6-OHDA lesion induction. 
 
The effects of treatment with both PPAR-γ and PPAR-δ agonists and on the 
functionality of the nigrostriatal system was assessed by measuring the concentration of 
dopamine and its metabolites (ng/mg) in the striatum using HPLC-ECD and compared to 
the vehicle treated group. Detailed description of the HPLC procedure is found (see section 
2.2.4).   
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5.2.2.2 Assessment of the effects of GW855266X, pioglitazone and PPAR-δ on the  
integrity of dopaminergic neurons in the SNc after 6-OHDA lesioning 
 
For this purpose immunohistochemistry was performed for Tyrosine hydroxylase 
(TH) positive dopaminergic neurons (see section 2.2.1.3). The number and morphology of 
TH+ve cells were then determined according to the criteria described in (see section 2.2.3).  
 
5.2.2.3 Assessment of the effect of GW855266X, pioglitazone and PPAR-δ on the  
extent of microglia/macrophages activation in the SNc after 6-OHDA lesion induction 
 
To investigate the effects of treatment with GW855266X and pioglitazone on the 
extent of microglial/macrophages activation in the SNc and to compare it to the vehicle 
treated group, peroxidase immunohistochemistry was performed for both OX6 and CD68 
expressions. Description of the antibodies used is listed below and details of the staining 
procedure are outlined in (see section 2.2.1.4): 
OX6: was used to detect the population of activated microglial cells that express major 
histocompatibility complex II (MHC II) antigens. 
CD68: was used to detect the activation of a population of macrophages with phagocytic 
function that expresses CD68 glycoprotein on their lysosomal membrane. 
  
5.2.2.4 Assessment of the effects of GW855266X or pioglitazone on the extent of  
MMP-3 and 9 activation in the SNc after 6-OHDA lesion induction 
 
To assess the effects GW855266X and pioglitazone on the  expression of MMP3+ve 
and MMP-9+ve cells following 6-OHDA induction, peroxidase immunohistochemistry with 
Nickel enhancer  was performed to detect  the expression of the active form of MMP-3 and 
MMP-9 using the following antibodies, details of staining procedure is outlined in (see 
chapter 2,  section 2.2.1.4): 
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 MMP-3: A polyclonal antibody was used against the active form of MMP-3 enzyme 
mapping at C-terminus of the enzyme of human origin. This antibody recognises the 45 and 
28 kDa active forms of the enzyme. MMPs are mainly responsible for the degradation of 
extracellular matrix components 
 
MMP-9: A polyclonal antibody was used against the active form of MMP-9, also known as 
92-kDa gelatinase/type IV collagenase, in mammals mapping near the C-terminus of MMP-
9 of human origin. MMP-9 degrades the collagen of the extracellular matrix. 
 
5.2.3 Statistical analysis of data 
 
All data are presented as the mean ± SEM based on n independent observations. 
Multiple comparisons were made between and within groups using two-way ANOVA with 
post-hoc Newman-Keuls test. Striatal dopamine turnover, expressed as the mean values ± 
SEM calculated using the equation [DOPAC (pmol/ml +HVA (pmol/ml)/DA (pmol/ml)]. 
Differences were considered statistically significant at p<0.05 and all statistical analysis 
were performed using GraphPad Prism v5.00 software (GraphPad software, San Diego, CA, 
USA). 
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5.3 Results 
5.3.1 Neuroprotective effects of treatment with GW855266X and pioglitazone but 
not PPAR−δ agonist administered 7 days before and continued for 7 days after 6-
OHDA lesion induction 
5.3.1.1 Effect of treatment with GW855266X (5mg/kg) and Pioglitazone (20mg/kg) and 
PPAR-δ agonist (10mg/kg) administered before and after 6-OHDA lesion induction on 
striatal dopamine concentration (ng/mg). 
 
To assess whether presence of GW855266X (5mg/kg), pioglitazone (20mg/kg) and 
PPAR-δ agonist (10mg/kg) in the brain before and after 6-OHDA lesion induction was 
neuroprotective, the PPAR agonists were  administered p.o.b.i.d. for 14 consecutive days 
starting 7 days before 6-OHDA lesion induction that was continued for further 7 days post 
lesioning. It is noteworthy to mention that the weight of animals did not show any 
unexpected changes throughout all the treatment regimes in this study. 
As Fig 5.1 shows, in vehicle treated animals the striatal dopamine content was 
significantly decreased by ~62% in the lesioned hemisphere compared to the unlesioned 
hemisphere following 6-OHDA lesion induction [lesioned: 4.88 ± 2.31 (ng/mg), unlesioned: 
12.99 ± 0.93 (ng/mg), p<0.001]. In addition, striatal levels of dopamine metabolites, 
DOPAC and HVA were also significantly decreased by ~45% and ~ 52% respectively in 
the lesioned hemisphere compared to the unlesioned hemisphere following 6-OHDA 
lesioning (Table 5.1). In the vehicle treated animals, dopamine turn over increased 
significantly by ~70%  in the lesioned hemisphere compared to the unlesioned hemisphere, 
indicative of compensatory dopamine production by the surviving neurons. However, 
treatment with GW855266X (5mg/kg) before and after lesion induction led to a significant 
preservation of the dopamine content in the striatum in the lesioned hemisphere compared 
to the lesioned hemisphere in vehicle treated 6-OHDA lesioned animals [Drug treated-
lesioned: 9.39 ± 0.52 (ng/mg), vehicle treated-lesioned: 4.88 ± 2.31 (ng/mg),p<0.05]. In 
addition, treatment with GW855266X (5mg/kg) led to preservation of both DOPAC and 
HVA in the lesioned hemisphere compared to the lesioned hemisphere in the vehicle treated 
animals. This was concurrent with a significant decrease in dopamine turnover in the 
striatum compared to the lesioned hemisphere in vehicle treated animals (Table 5.1). 
Similarly, treatment with pioglitazone (20mg/kg) before and after lesion induction led to a 
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significant preservation of the striatal dopamine content in the lesioned hemisphere 
compared to the lesioned hemisphere in vehicle treated animals [Drug treated-lesioned: 9.37 
± 0.96 (ng/mg), vehicle treated-lesioned: 4.88 ± 2.31 (ng/mg),p<0.01] (Fig 5.1). This was 
concomitant with significant preservation of striatal dopamine metabolites, DOPAC and 
HVA (Table 5.1). In addition, dopamine turn over was also decreased significantly and 
normalised in the lesioned hemisphere following pioglitazone treatment compared to the 
lesioned hemisphere in vehicle treated animals (Table 5.1). Unlike PPAR-γ agonists 
treatment with PPAR-δ agonist did not show any protective properties which was evident in 
a significant depletion of striatal dopamine content in the lesioned hemisphere compared to 
the lesioned hemisphere in the vehicle treated animals following 6-OHDA lesion induction 
[(Drug treated-lesioned: 3.87 ± 1.39 (ng/mg), vehicle treated-lesioned: 4.88 ± 2.31 (ng/mg), 
p<0.05]. In addition striatal dopamine metabolites, DOPAC and HVA were significantly 
depleted (Table 5.1)  
 Hence, PPAR-δ agonist (10mg/kg) did not have any neuroprotective properties; 
therefore we did not pursue the studies on this compound further. However, treatment with 
GW855266X (5mg/kg) and pioglitazone (20mg/kg), before and after the 6-OHDA lesion 
induction, led to the preservation of striatal dopamine and its metabolites.  
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Fig 5.1 Protective effect of treatment with pioglitazone and GW855266X administered 
7 days pre and 7 days post 6-OHDA lesion induction on nigrostriatal functionality in 
the lesioned hemisphere compared to the lesioned hemisphere in the vehicle treated 
animas. Graph demonstrates the concentration of striatal dopamine ng/mg in different 
groups of treatment. 
In vehicle treated animals the striatal dopamine content was significantly decreased in the 
lesioned hemisphere compared to the unlesioned hemisphere following 6-OHDA lesion 
induction. However, treatment with pioglitazone (20mg/kg) and GW855266X (5mg/kg) 
before and after lesion induction led to a significant preservation of the dopamine content in 
the striatum in the lesioned hemisphere compared to the lesioned hemisphere in the vehicle 
treated 6-OHDA lesioned animals. Unlike PPAR-γ agonists treatment with PPAR-δ agonist 
did not show any protective properties which was evident in a significant depletion of 
striatal dopamine content in the lesioned hemisphere compared to the lesioned hemisphere 
in the vehicle treated animals following 6-OHDA lesion induction. Results are presented as 
mean striatal dopamine ng/mg of wet tissue weight ±SEM. * p<0.5 ** p<0.01, *** p< 
0.001, ns= not significant. Number of animals was 6/group per treatment group. Treatment 
regime: 
 
 
Day 15 culling 
 
Animals 
 arrive and 
acclimatize for 7 
days  
7 days PPAR agonists 
treatment p.o.b.i.d 
 Day8 
6-OHDA lesion 
induction
 
7days PPARs agonists 
 treatment p.o.b.i.d 
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 DOPAC (ng/mg) HVA (ng/mg) Dopamine turnover 
(pmol/mg) 
   Vehicle 
Lesion:      0.924 ± 0.2
Unlesion:   1.67 ± 0.27
p<0.5 
Lesion:     0.49 ± 0.06
Unlesion: 1.02 ± 0.34
P<0.5 
Lesion:    40.29 ± 21.66 
Unlesion: 12.46 ± 1.41 
p<0.1 
GW855266X 
   (5mg/kg) 
Lesion:      1.19 ± 0.67
Unlesion:   1.55 ± 0.62
p>0.5 
Lesion:    0.36 ± 0.13
Unlesion: 0.44 ± 0.17
p>0.5 
Lesion:      24.17 ± 2.52 
Unlesion:  22.07 ± 3.15 
P>0.5 
Pioglitazone  
   (20mg/kg) 
Lesion:     1.20 ± 0.19
Unlesion: 1.43 ± 0.17 
p>0.5 
Lesion:    0.48 ± 0.30
Unlesion: 0.60 ± 0.49
p>0.5 
Lesion:     22.68 ± 5.75 
Unlesion: 23.51 ± 4.70 
p>0.5 
PPAR-δagonis
    (10mg/kg) 
 
Lesion:    0.60 ±0.20 
Unlesion: 1.19 ±0.05 
p<0.5 
Lesion:    0.17 ± 0.05
Unlesion: 0.40 ± 0.03
p<0.5 
Lesion:    28.28 ±2.99 
Unlesion: 16.46 ±2.26 
P<0.5 
Table 5.1 Treatment  with  pioglitazone and GW855266X administered 7 days pre and 
7 days post 6-OHDA lesion induction led to preservation of the  mean concentration of 
striatal dopamine metabolites: DOPAC and HVA in addition to dopamine turnover in 
the lesioned hemisphere compared to the unlesioned hemisphere in  drug and vehicle 
treated animals. 
Table shows that in the vehicle treated animals, striatal levels of dopamine metabolites, 
DOPAC and HVA were significantly decreased in the 6-OHDA lesioned hemisphere 
compared to the unlesioned hemisphere. In addition, in these animals following 6-OHDA 
lesion induction striatal dopamine turn over increased significantly in the lesioned 
hemisphere compared to the unlesioned hemisphere. Treatment with GW855266X (5mg/kg) 
and pioglitazone (20mg/kg) before and after lesion induction led to a significant 
preservation of both DOPAC and HVA in the lesioned hemisphere compared to the 
lesioned hemisphere in the vehicle treated animals. That was concurrent with a 
normalisation of striatal dopamine turn over in the 6-OHDA lesioned hemisphere compared 
to lesioned hemisphere. Treatment with PPAR-δ agonist pre and post 6-OHDA lesion 
induction did not show any protective properties which was evident in a significant 
depletion of striatal DOPAC and HVA and an increase in dopamine turn over in the 
lesioned hemisphere compared to the unlesioned hemisphere. Concentration of striatal 
dopamine metabolites are shown as ng/mg of wet tissue weight ±SEM. Mean striatal 
monoamine turnover ratio was calculated using the expression ((DOPAC+HVA)/DA). 
Number of animals was 6/group per treatment group. p<0.5 was considered significant. 
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5.3.1.2 Effect of treatment with GW855266X (5mg/kg) and pioglitazone (20mg/kg) 
administered before and after 6-OHDA lesion induction on the number of TH+ve 
dopaminergic neurons in the SNc 
  TH+ve dopaminergic cell counts in vehicle treated animals showed a significant 
decrease in the number of TH+ve dopaminergic neurons in the lesioned hemisphere 
compared to the unlesioned hemisphere (lesioned: 40.69 ± 3.73, unlesioned: 66.38 ± 2.9, 
p<0.001 ) (Fig. 5.2). However, treatment with   GW855266X (5mg/kg) p.o.b.i.d before and 
after 6-OHDA lesion induction led to amelioration of the loss of TH+ve dopaminergic cells 
in the SNc in the lesioned hemisphere compared to the lesioned hemisphere in vehicle 
treated animals (Drug treated-lesioned: 51.14 ± 3.24 , vehicle treated-lesioned: 40.69 ±  
3.73, p<0.05 ). Thus, the presence of GW855266X (5mg/kg) in the brain prior to 6-OHDA 
lesioning was neuroprotective in the SNc and prevented dopamine depletion in the striatum. 
In addition, similar neuroprotective properties were observed with pioglitazone (20mg/kg) 
administered p.o.b.i.d before and after 6-OHDA lesion induction. Nigral TH+ve 
dopaminergic cell counts revealed a significant amelioration of dopaminergic cell death in 
the lesioned hemisphere compared to the lesioned hemisphere in vehicle treated animals 
(Drug treated-lesioned: 49.70 ± 2.62 , vehicle treated-lesioned: 40.69 ±  3.73, p<0.05 ).  
Thus, presence of GW855266X and pioglitazone in the brain before and after 6-
OHDA lesioning exerted beneficial effects that were characterised by significant protection 
of dopaminergic neurons in the SNc and inhibition of dopamine depletion in the striatum. 
We further assessed the effects of GW855266X and pioglitazone on the 
microglia/macrophage activation in the SNc, the data obtained are presented in the 
following sections. 
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Fig 5.2 Treatment with pioglitazone and GW855266X administered 7 days pre and 7 
days post 6-OHDA lesion induction protected nigral TH+ve dopaminergic neurons in 
the lesioned hemisphere compared to the lesioned hemisphere in the vehicle treated 
animals. Graph demonstrates the number mean number of TH+ve dopaminergic 
neurons in the SNc of different treatment groups 
In vehicle treated animals the number of TH+ve dopaminergic neurons significantly 
decreased in the lesioned hemisphere compared to the unlesioned hemisphere following 6-
OHDA lesion induction. However, treatment with both pioglitazone (20mg/kg) and 
GW855266X (5mg/kg) before and after lesion induction led to a significant decrease in 
TH+ve dopaminergic neuronal cell demise in the lesioned hemisphere compared to the 
lesioned hemisphere in vehicle treated 6-OHDA lesioned animals.. Results are presented as 
mean number of cells ±SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant. 
Number of animals was 6/group per treatment group. 
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5.3.2 Treatment with GW855266X and pioglitazone administered 7 days before 
and continued for 7 days after 6-OHDA lesion induction exerted anti-
inflammatory properties 
 
5.3.2.1 GW855266X (5mg/kg) and pioglitazone (20mg/kg) treatment for 7 days before 
and 7 days after 6-OHDA lesion induction inhibited the activation of OX6+ve and 
CD68+ve microglia/macrophages in the SNc 
 
To assess whether the presence of GW855266X (5mg/kg) and pioglitazone 
(20mg/kg) in the brain before and after 6-OHDA lesion induction would inhibit or reduce 
the number of activated microglia/macrophages in the SNc treatments were given p.o.b.i.d. 
for 14 consecutive days starting 7 days before 6-OHDA lesion induction that was continued 
for further 7 days post lesioning.  
Cell counts in the SNc demonstrated that in the vehicle treated animals, OX6+ve 
microglial cells significantly increased in number in the 6-OHDA lesioned hemisphere 
compared to the unlesioned hemisphere (lesioned: 23.14± 3.57, unlesioned: 0.45± 0.31, 
p<0.001). OX6+ve microglia were morphologically active with enlarged somas and 
thickened processes. These cells were focally accumulated in the medial and lateral portions 
of the SNc in the lesioned hemisphere. Interestingly, treatment with  GW855266X (5mg/kg) 
before and after 6-OHDA lesion induction led to a significant decrease in the number of 
activated OX6+ve microglia in both lateral and medial potions of the SNc in the lesioned 
hemisphere compared to lesioned  hemisphere in the vehicle treated animals (Drug treated-
lesioned 7.53± 3.13, vehicle treated-lesioned 23.14± 3.57, p<0.001) (Fig 5.3A). In parallel, 
in vehicle treated animals cell count for CD68+ve macrophages in the SNc demonstrated a 
significant increase in CD68+ve cell numbers in the lesioned hemisphere compared to the 
unlesioned  hemisphere  following 6-OHDA lesion induction (lesioned: 14.80 ± 4.57, 
unlesioned: 0.0, p<0.001) (Fig 5.3B) . As mentioned in previous sections these cells had an 
activated amoeboid morphology and were located similarly to OX6+ve microglia in lateral 
and medial portions of the SNc. Treatment with GW855266X (5mg/kg) before and after 6-
OHDA lesion induction led to a significant inhibition of  the number of CD68+ve 
macrophages in the lesioned hemisphere in the SNc compared to the lesioned hemisphere in 
the vehicle treated animals (Drug treated-lesioned: 1.83 ± 1.09, vehicle treated-lesioned: 
14.80 ± 4.57, p<0.001) (Fig 5.3B). CD68+ve macrophages were inhibited in both medial 
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and lateral portions of the SNc. Thus, treatment with GW855266X (5mg/kg) for 7 days 
before 6-OHDA lesion induction and 7 days after led to a significant inhibition of active 
gliosis characterised by inhibition of both OX6 and CD68+ve microglia/macrophages 
activity in the SNc. Similarly, treatment with  pioglitazone (20mg/kg) before and after 6-
OHDA lesion induction led to a significant decrease in the number of activated OX6+ve 
microglia in both lateral and medial portions of the SNc in the lesioned hemisphere 
compared to lesioned  hemisphere in the vehicle treated animals (Drug treated-lesioned 
9.33± 2.34, vehicle treated-lesioned 23.14± 3.57, p<0.001) (Fig 5.3A). In addition  cell 
counts for CD68+ve macrophages in the SNc showed that treatment with pioglitazone 
(20mg/kg)  before and after 6-OHDA lesion induction led to a significant inhibition of 
CD68+ve macrophages in the lesioned hemisphere compared to the lesioned hemisphere in 
the vehicle treated animals (Drug treated-lesioned: 1.83 ± 0.77, vehicle treated-lesioned: 
14.80 ± 4.57, p<0.001) (fig 5.3B). CD68+ve macrophages were inhibited in both medial 
and lateral portions of the SNc.  
Thus, treatment with pioglitazone (20mg/kg)   for 7 days before 6-OHDA lesioning 
and 7 days after led to a significant inhibition of active gliosis characterised by inhibition of 
both OX6 and CD68+ve microglia/macrophages activity in the SNc. 
Taken together, the presence of GW855266X and pioglitazone in the brain before 6-
OHDA lesion induction and continued drug administration for 7 days after lesioning exerts 
neuroprotective properties and a modulation of the inflammatory response. Having obtained 
positive results with GW855266X and pioglitazone using the above mentioned treatment 
regime, which also replicated the findings of Dehmer at al (2004) in the MPTP model, we 
then decided to administer these compound in a more clinically relevant regime and assess 
their neuroprotective and anti-inflammatory effects. Therefore, the following section 
presents our findings on therapeutic treatment regime with these compounds where they are 
administered post 6-OHDA lesion induction. 
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Fig 5.3 Graphs shows anti-inflammatory effect of treatment with PPAR-γ agonists for 
14 consecutive days starting 7 days before 6-OHDA lesion induction and continuing 
for further 7 days. This is demonstrated as significant decrease in the number of 
OX6+ve and CD68+ve microglia/macrophages in the SNc ipsilateral to the 6-OHDA 
lesioned hemisphere compared to the lesioned hemisphere in the vehicle treated 
animals. 
Graph A: Shows the number of OX6+ve microglia in the SNc in the vehicle and PPAR-γ 
agonists [pioglitazone (20mg/kg) and GW855266X (5mg/kg)] treated animals. 
Immunohistochemistry was performed with OX6 antibody that detects the population of 
microglial cells expressing MHC II antigens. In the vehicle treated animals the number of 
OX6+ve microglial cells increased significantly following 6-OHDA lesion induction. 
Treatment with both pioglitazone (20mg/kg) and GW855266X (5mg/kg) resulted in a 
significant decrease in the number OX6+ve microglial cells in the SNc ipsilateral to 6-
OHDA lesion side compared to the lesioned hemisphere in vehicle treated animals. Results 
are presented as mean number of cell± SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not 
significant.  Number of animals was 6/group per time point.  
Graph B: Shows the number of CD68+ve macrophages in the SNc in the vehicle and 
PPAR-γ agonists [pioglitazone (20mg/kg) and GW855266X (5mg/kg)] treated animals. 
Immunohistochemistry was performed with CD68 antibody that detects phagocytic 
macrophages. In the vehicle treated animals the number of OX6+ve microglial cells 
increased significantly following 6-OHDA lesion induction. Treatment with both 
pioglitazone (20mg/kg) and GW855266X (5mg/kg) resulted in a significant decrease in the 
number CD68+ve microglial cells in the SNc ipsilateral to 6-OHDA lesion side compared 
to the lesioned hemisphere in vehicle treated animals. Results are presented as mean number 
of cell± SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant.  Number of animals 
was 6/group per time point.  
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5.3.3 Neuroprotective effects 7 day continuous treatment with PPAR-γ agonists 
post 6-OHDA lesion induction  
5.3.3.1 Effects of GW855266X (5mg/kg) and pioglitazone (20mg/kg) on the 
concentration (ng/mg) of dopamine in the striatum administered for 7 days after 6-
OHDA lesion induction  
In the vehicle treated animals, striatal dopamine content was significantly decreased 
by ~67% in the lesioned hemisphere compared to the unlesioned hemisphere following 6-
OHDA lesion induction [lesioned: 4.92 ± 2.5 (ng/mg), unlesioned: 14.99 ± 2.37 (ng/mg), 
p<0.001] (Fig 5.4). In addition, 6-OHDA lesion induction in vehicle treated animals led to 
depletion of dopamine metabolites, DOPAC and HVA by ~65% and ~51% respectively in 
the lesioned hemisphere compared to the unlesioned hemisphere. This was concomitant 
with a significant increase in dopamine turn over in the lesioned hemisphere compared to 
the unlesioned hemisphere by ~60% (Table 5.2).  However, 7 days treatment with 
GW855266X (5mg/kg) p.o.b.i.d starting 2 days after 6-OHDA lesioning led to a significant 
preservation of the dopamine content in the striatum in the lesioned hemisphere compared 
to the lesioned hemisphere in the vehicle treated animals [Drug treated-lesioned: 11.79 ± 
1.44 (ng/mg), vehicle treated-lesioned: 4.92 ± 2.5 (ng/mg), p>0.05 ] (Fig 5.4). This was 
concomitant with the preservation of striatal dopamine metabolites, DOPAC and HVA 
compared to vehicle treated animals (Table 5.2). Thus, post-lesion continuous treatment for 
7 days with GW855266X (5mg/kg) protected the functional integrity of the nigrostriatal 
system. Very similar effects were also observed when animals were treated for 7 days with 
pioglitazone (20mg/kg) p.o.b.i.d starting 2 days after 6-OHDA lesioning. Treatment led to a 
significant preservation of striatal dopamine concentration in the lesioned hemisphere 
compared to the lesioned hemisphere in vehicle treated animals [Drug treated-lesioned: 
10.24 ±0.97 (ng/mg), vehicle treated-lesioned: 4.92 ± 2.5 (ng/mg), p<0.001] (Fig 5.4). 
Dopamine metabolites, DOPAC and HVA were also significantly preserved in the lesion 
hemisphere compared to vehicle treated animals (Table 5.2). Evidently, dopamine turn over 
was also reduced significantly and normalised in the lesioned hemisphere compared to the 
vehicle treated animals (Table 5.2). Thus, treatment with GW855266X (5mg/kg) and 
pioglitazone (20mg/kg) starting 2 days post 6-OHDA lesion induction was shown to have 
significant neuroprotective properties and inhibit dopamine depletion in the striatum.  
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Fig 5.4 Protective effect of treatment with pioglitazone and GW855266X administered 
7 days post 6-OHDA lesion induction on nigrostriatal functionality in the lesioned 
hemisphere compared to the lesioned hemisphere in the vehicle treated animals. 
Graph demonstrates the concentration of striatal dopamine ng/mg in different groups 
of treatment. 
In vehicle treated animals the striatal dopamine content was significantly decreased in the 
lesioned hemisphere compared to the unlesioned hemisphere following 6-OHDA lesion 
induction. However, post 6-OHDA lesion treatment with pioglitazone (20mg/kg) and 
GW855266X (5mg/kg) led to a significant preservation of the dopamine content in the 
striatum in the lesioned hemisphere compared to the lesioned hemisphere in the vehicle 
treated 6-OHDA lesioned animals. Results are presented as mean striatal dopamine ng/mg 
of wet tissue weight ±SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant. Number 
of animals was 6/group per treatment group. Treatment regime: 
 
 
 
 
Day 9 culling 
 
Animals 
 arrive and 
acclimatize for 7 
days  
7 days PPAR-γ agonists 
treatment p.o.b.i.d 
 
Day2 
 
 6-OHDA lesion 
 induction 
 PPAR agonists 
treatment p.o.b.i.d 
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 DOPAC (ng/mg) HVA (ng/mg) Dopamine turnover  
(pmol/mg) 
     
   Vehicle 
Lesion:      0.924 ± 0.40
Unlesion:   2.61 ± 0.33 
               p<0.5 
Lesion:     0.48 ± 0.19 
Unlesion: 0.99 ± 0.08 
               P<0.5 
Lesion:    30.03 ± 8.5 
Unlesion: 11.96 ± 0.95 
              p<0.1 
GW855266X 
    (5mg/kg) 
Lesion:      1.19 ± 0.67 
Unlesion:   1.55 ± 0.62 
             p<0.5 
Lesion:    0.46 ± 0.11 
Unlesion: 0.45 ± 0.17 
               p>0.5 
Lesion:     10.70 ± 1.71 
Unlesion:  8.68 ± 1.07 
            P>0.5 
Pioglitazone 
  (20mg/kg) 
Lesion:     1.03 ± 0.10 
Unlesion: 1.59 ± 0.32 
            p>0.5 
Lesion:    0.90 ± 0.12 
Unlesion: 1.12± 0.58 
              p>0.5 
Lesion:    10.09 ± 2.42 
Unlesion: 11.97 ± 1.71 
              p>0.5 
Table 5.2 Treatment with pioglitazone and GW855266X administered for 7 days post 
6-OHDA lesion induction led to preservation of the mean concentration of striatal 
dopamine metabolites: DOPAC and HVA in addition to dopamine turnover in the 
lesioned hemisphere compared to the unlesioned hemisphere in drug and vehicle 
treated animals. 
Table shows that in the vehicle treated animals striatal levels of dopamine metabolites, 
DOPAC and HVA were significantly decreased in the 6-OHDA lesioned hemisphere 
compared to the unlesioned hemisphere. In addition in these animals following 6-OHDA 
lesion induction striatal dopamine turn over increased significantly in the lesioned 
hemisphere compared to the unlesioned hemisphere. Treatment with  GW855266X (5mg/kg) 
and pioglitazone (20mg/kg) for 7 days administered post 6-OHDA   lesion induction led to 
a significant preservation of  both DOPAC and HVA in the lesioned hemisphere compared 
to the lesioned hemisphere in the vehicle treated animals. That was concurrent with a 
normalisation of striatal dopamine turn over in the 6-OHDA lesioned hemisphere compared 
to lesioned hemisphere. Concentration of striatal dopamine metabolites are shown as ng/mg 
of wet tissue weight ±SEM. Mean striatal monoamine turnover ratio was calculated using 
the expression ((DOPAC+HVA)/DA). Number of animals was 6/group per treatment group. 
p<0.5 was considered significant. 
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5.3.3.2 Effects of GW855266X (5mg/kg) and pioglitazone (20mg/kg) on the number of 
TH+ve dopaminergic neurons in the SNc administered for 7 days following 6-OHDA 
lesion induction 
TH+ve cell counts revealed that in the vehicle treated animals, a significant number 
of TH+ve dopaminergic neurons were lost in the lesioned hemisphere compared to the 
control unlesioned hemisphere following 6-OHDA lesioning (lesioned: 35.5  ± 2.97, 
unlesioned: 66.0 ± 4.46, p<0.001) (Fig 5.5). However, 7 days treatment with GW855266X 
(5mg/kg) p.o.b.i.d starting 2 days after 6-OHDA lesioning led to amelioration of nigral 
TH+ve dopaminergic cell death in the lesioned side compared to the lesioned side of the 
vehicle treated animals (Drug treated-lesioned: 61.67± 3.25 , vehicle treated-lesioned: 35.5  
± 2.97 , p<0.001) (Fig 5.5). Thus, post-lesion 7 day continuous treatment with GW855266X 
(5mg/kg) protected the integrity of the nigrostriatal tract. In parallel, pioglitazone treatment 
led to a significant amelioration of nigral TH+ve dopaminergic neuronal demise following 
6-OHDA lesioning. 7 days treatment with pioglitazone (20mg/kg)  p.o.b.i.d starting 2 days 
after 6-OHDA lesioning led to a significant protection of TH+ve dopaminergic neurons in 
the SNc in the lesioned hemisphere compared to the lesioned hemisphere in vehicle treated 
animals (Drug treated-lesioned: 61.67± 3.25 , vehicle treated-lesioned: 35.5  ± 2.97, p>0.05 ) 
(Fig 5.5).  
Thus, treatment with GW855266X (5mg/kg) and pioglitazone (20mg/kg) starting 2 
days post 6-OHDA lesion induction was shown to have significant neuroprotective 
properties in the SNc and inhibit dopamine depletion in the striatum. To further assess the 
effects of treatments on the state of inflammation in the SNc, activation of 
microglia/macrophages were studied, the data are presented in the following section. 
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Fig 5.5 Treatment with pioglitazone and GW855266X administered for 7 days post 6-
OHDA lesion induction protected nigral TH+ve dopaminergic neurons in the lesioned 
hemisphere compared to the lesioned hemisphere in the vehicle treated animals. 
Graph demonstrates the number mean number of TH+ve dopaminergic neurons in 
the SNc of different treatment groups 
In vehicle treated animals the number of TH+ve dopaminergic neurons significantly 
decreased in the lesioned hemisphere compared to the unlesioned hemisphere following 6-
OHDA lesion induction. However, treatment with both pioglitazone (20mg/kg) and 
GW855266X (5mg/kg) for 7 days after lesion induction led to a significant decrease in 
TH+ve dopaminergic neuronal cell demise in the lesioned hemisphere compared to the 
lesioned hemisphere in vehicle treated 6-OHDA lesioned animals. Results are presented as 
mean number of cells ±SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant. 
Number of animals was 6/group per treatment group. 
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5.3.4 Continuous 7 day treatment with GW855266X and pioglitazone after 6-
OHDA lesion induction exerted anti-inflammatory properties 
 
5.3.4.1 Continuous 7 day treatment with GW855266X (5mg/kg) and pioglitazone 
(20mg/kg) decreased the number of activated OX6+ve and CD68+ve 
microglia/macrophages in the SNc following 6-OHDA lesion induction 
 
 To assess the effect of treatment with GW855266X (5mg/kg) and pioglitazone 
(20mg/kg) on the number of activated microglia/macrophages in the SNc following 6-
OHDA lesion induction, cell counts for OX6 and CD68+ve cells was carried out. In vehicle 
treated animals, the number of OX6+ve microglial cells significantly increased in the SNc 
in the lesioned side compared to the unlesioned side after 6-OHDA lesioning (lesioned: 
32.25 ± 6.45, unlesioned:  3.0 ± 0.95, p<0.001) (Fig 5.6A). Activated OX6+ve microglia 
not only increased in number but had an activated morphology characterised by an enlarged 
somas and thickened processes. OX6+ve microglia focally accumulated in both the lateral 
and medial portions of the SNc ipsilateral to the lesioned hemisphere. In parallel, the 
number of CD68+ve cells was significantly increased in the SNc in the lesioned side 
compared to the unlesioned side following 6-OHDA lesion induction (lesioned: 16.0 ± 4.41, 
unlesioned: 0.0, p<0.001) (Fig 5.6B). CD68+ve macrophages had a predominant amoeboid 
macrophage-like appearance with presence of granular staining in the lysosomal membranes 
indicating phagocytic activity. Localisation of CD68+ve macrophages was very similar to 
OX6+ve microglia in the lateral and medial portions of the SNc. Interestingly, 7 days 
treatment with GW855266X (5mg/kg) p.o.b.i.d starting 2 days after 6-OHDA lesioning led 
to a significant decrease in the number of OX6+ve activated microglia in the SNc in the 
lesioned hemisphere compared to the lesioned hemisphere in vehicle treated group (Drug 
treated-lesioned: 10.83 ±1.53, vehicle treated-lesioned: 32.25 ± 6.45, p<0.001 ) (Fig 5.6A). 
The decrease in the number of activated microglia was observed in both lateral and medial 
portions of the SNc. The remaining OX6+ve microglial cells showed a morphologically 
active phenotype with enlarged cell bodies and shortened processes. In addition, activation 
of CD68+ve macrophages was fully blocked by GW855266X and no CD68+ve cells were 
present in medial and lateral portions of the SNc. Thus, post-lesion treatment with 
GW855266X (5mg/kg), exerted anti-inflammatory properties by blocking the activation of 
OX6+ve and CD68+ve microglia/macrophages in the SNc. In parallel, 7 day pioglitazone 
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treatment p.o.b.i.d starting 2 days after 6-OHDA lesion induction also led to a significant 
reduction in the number of activated microglia/macrophages similar to the effect observed 
following treatment with GW855266X. Cell counts in the SNc revealed that the number of 
OX6+ve microglia decreased significantly in the medial and lateral portions of the SNc in 
the lesioned hemisphere compared to the lesioned hemisphere of vehicle treated group after 
pioglitazone  (20mg/kg) treatment ( Drug treated-lesioned: 10.69 ± 2.04, vehicle treated-
lesioned: 32.25 ± 6.45, p<0.001) (5.6 A). Concomitantly, the number of CD68+ve 
macrophages decreased significantly in the medial and lateral portions of the SNc in the 
lesioned  hemisphere  following pioglitazone (20mg/kg) treatment compared to the lesioned 
hemisphere in the vehicle treated group ( Drug treated-lesioned: 5.71 ±1.92, vehicle treated-
lesioned: 9.6 ± 4.49, p<0.1) (Fig 5.6B). Thus, continuous treatment with both GW855266X 
(5mg/kg) and pioglitazone (20mg/kg) post 6-OHDA lesion induction exerted 
neuroprotective and anti-inflammatory properties that were accompanied by preservation of 
the functionality of the nigrostriatal system.  
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Fig 5.6 Anti-inflammatory effect of treatment with PPAR-γ agonists for 7 days starting 
2 days after 6-OHDA lesion induction. This is demonstrated as significant decrease in 
the number of OX6+ve and CD68+ve microglia/macrophages in the SNc ipsilateral to 
the 6-OHDA lesioned hemisphere compared to the lesioned hemisphere in the vehicle 
treated animals. 
Graph A: Shows the number of OX6+ve microglia in the SNc in the vehicle and PPAR-γ 
agonists [pioglitazone (20mg/kg) and GW855266X (5mg/kg)]. Immunohistochemistry was 
performed with OX6 antibody that detects the population of microglial cells expressing 
MHC II antigens. In the vehicle treated animals the number of OX6+ve microglial cells 
increased significantly following 6-OHDA lesion induction. Treatment with both 
pioglitazone (20mg/kg) and GW855266X (5mg/kg) resulted in a significant decrease in the 
number OX6+ve microglial cells in the SNc ipsilateral to 6-OHDA lesion side compared to 
the lesioned hemisphere in vehicle treated animals. Results are presented as mean number 
of cell± SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant.  Number of animals 
was 6/group per time point. Graph B: Shows the number of CD68+ve macrophages in the 
SNc in the vehicle and PPAR-γ agonists [pioglitazone (20mg/kg) and GW855266X 
(5mg/kg)]. Immunohistochemistry was performed with CD68 antibody that detects 
phagocytic macrophages. In the vehicle treated animals the number of OX6+ve microglial 
cells increased significantly following 6-OHDA lesion induction. Treatment with both 
pioglitazone (20mg/kg) and GW855266X (5mg/kg) resulted in a significant decrease in the 
number CD68+ve microglial cells in the SNc ipsilateral to 6-OHDA lesion side compared 
to the lesioned hemisphere in vehicle treated animals. Results are presented as mean number 
of cell± SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant.  Number of animals 
was 6/group per time point.  
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5.3.5 Treatment with GW855266X and pioglitazone for 7 days post 6-OHDA lesion 
induction suppresses the expression of MMP-3 and MMP-9 in the SNc after 6-
OHDA lesioning 
 
5.3.5.1 GW855266X (5mg/kg) and pioglitazone (20mg/kg) suppress the activation of 
MMP-3 and MMP-9 expressing cells in the SNc after 6-OHDA lesion induction 
 
To investigate the effects of GW855266X (5mg/kg) and pioglitazone (20mg/kg) on 
the expression of two members of matrix metalloproteinases, MMP-3 and MMP- 9,  cell 
counts were carried out for both MMP-3+ve and MMP-9+ve cells in the SNc following 6-
OHDA lesion induction. Cell counts in the SNc demonstrated that in the vehicle treated 
animals the number of MMP-3+ve cells increased significantly in the lesioned hemisphere 
compared to the unlesioned hemisphere following 6-OHDA lesion induction (lesioned: 
25.27 ±2.05, unlesioned:  8.01 ±1.02, p<0.001) (Fig 5.7A). MMP-3+ve cells were present 
in clusters in the ventrolateral and medial portions of the SNc.  
Similarly, cell counts for MMP-9+ve cells in the SNc, revealed that in the vehicle 
treated group the number of MMP-9+ve cells significantly increased in the 6-OHDA 
lesioned side compared to the unlesioned side (lesioned: 19.0± 1.35, unlesioned: 8.09± 0.87, 
p<0.001) (Fig 5.7B). Identical to MMP-3 localisation, MMP-9+ve cells were also present in 
the ventrolateral and medial parts of the SNc. However, 7 days treatment p.o.b.i.d with 
GW855266X (5mg/kg) starting 2 days after 6-OHDA lesion induction led to a significant 
decrease in the number of MMP-3+ve cells in the SNc in  the 6-OHDA  lesioned side 
compared to the lesioned side in vehicle treated group  (Drug treated- lesioned: 14.08 ± 1.31, 
vehicle treated-lesioned:  25.27 ±2.05, p<0.001) (Fig 5.7A). In parallel cell counts for 
MMP-9 +ve cells revealed a significant decrease in the number of MMP-9+ve cells in the 
SNc in  the 6-OHDA  lesioned side compared to the lesioned side in vehicle treated group  
(Drug treated- lesioned: 12.77 ± 0.80, vehicle treated-lesioned:  19.0± 1.35, p<0.001) (Fig 
5.7B). Reduction in the number of MMP-3 and MMP-9+ve cells occurred in ventrolateral 
and medial portions of the SNc. These observations indicated that continuous 7 day 
treatment with GW855266X (5mg/kg) after 6-OHDA lesion induction partially, yet 
significantly, inhibited both MMP-3 and MMP-9 activation in the SNc, suggesting a 
significant decrease in the signals for microglial activation in the SNc following 6-OHDA 
challenge. Very similar effects were also observed when animals were treated for 7 days 
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with pioglitazone (20mg/kg) p.o.b.i.d starting 2 days after 6-OHDA lesioning. Following 
pioglitazone treatment (20mg/kg) cell counts in the SNc demonstrated that the number of 
MMP-3+ve cells significantly decreased in the lesioned hemisphere compared to the 
lesioned hemisphere in vehicle treated animals (Drug treated- lesioned: 13.92  ± 1.38, 
vehicle treated-lesioned:  25.27 ±2.05, p<0.001) (Fig 5.7A). Not surprisingly, MMP-9+ve 
cells were also reduced in number in the lesioned hemisphere following pioglitazone 
(20mgkg) treatment compared to the vehicle treated group (Drug treated- lesioned: 13.89 ± 
0.90, vehicle treated-lesioned:  19.0 ±1.35, p<0.001) (Fig 5.7B).  
 
Taken together, our data demonstrated that continuous 7 day treatment with both 
GW855266X (5mg/kg) and pioglitazone (20mg/kg) post 6-OHDA lesion induction was 
neuroprotective and exerted anti-inflammatory properties that was characterised by 
reduction in the number of activated microglia/macrophages in the SNc and reflected in the 
suppression of both MMP-3+ve and MMP-9+ve cells.  
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Fig 5.7 Treatment with PPAR-γ agonists for 7 days starting 2 days after 6-OHDA 
lesion induction leads to significant reduction in the number of both MMP-3+ve and 
MMP-9+ve cells in the SNc in the lesioned hemisphere compared to the lesioned 
hemisphere in vehicle treated animals.  
Graph A: Shows the number of MMP-3+ve cells in the SNc in the vehicle and PPAR-γ agonists 
[pioglitazone (20mg/kg) and GW855266X (5mg/kg)] treated animals. Immunohistochemistry was 
performed with MMP-3 antibody that detects the expression of the active form of MMP-3 in cells. 
In the vehicle treated animals, the number of MMP-3+ve cells increased significantly following 6-
OHDA lesion induction. Treatment with both pioglitazone (20mg/kg) and GW855266X (5mg/kg) 
resulted in a significant decrease in the number MMP-3+ve cells in the SNc ipsilateral to 6-OHDA 
lesion side compared to the lesioned hemisphere in vehicle treated animals. Results are presented as 
mean number of cell± SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant.  Number of 
animals was 6/group per time point. Graph B: Shows the number of MMP-9+ve cells in the SNc in 
the vehicle and PPAR-γ agonists [pioglitazone (20mg/kg) and GW855266X (5mg/kg)] treated 
animals. Immunohistochemistry was performed with MMP-9 antibody that detects the expression of 
the active form of MMP-9 in cells. In the vehicle treated animals, the number of MMP-9+ve cells 
increased significantly following 6-OHDA lesion induction. Treatment with both pioglitazone 
(20mg/kg) and GW855266X (5mg/kg) resulted in a significant decrease in the number MMP-9+ve 
cells in the SNc ipsilateral to 6-OHDA lesion side compared to the lesioned hemisphere in vehicle 
treated animals. Results are presented as mean number of cell± SEM. * p<0.5 ** p<0.01, *** p< 
0.001, ns= not significant.  Number of animals was 6/group per time point. 
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5.3.6 Continuous presence of GW855266X and pioglitazone was vital for the 
treatments to be neuroprotective 
 
  5.3.6.1 The effects of withdrawal of GW855266X (5mg/kg) and pioglitazone 
(20mg/kg) after 7 days of treatment on the dopamine content in the striatum following 
6-OHDA lesion induction 
 
To evaluate whether the effects of treatment with GW855266X and pioglitazone 
were long lasting, treatments were administered starting 2 days after 6-OHDA lesion 
induction p.o.b.i.d. for 7 consecutive days. Thereafter, drugs were withdrawn for 7 days and 
brains were collected on day 16 after 6-OHDA lesioning. In vehicle treated animals, striatal 
dopamine levels significantly decreased by ~63% in the lesioned hemisphere compared to 
the unlesioned hemisphere following 6-OHDA lesion induction [lesioned: 5.0 ± 1.25 
(ng/mg), unlesioned: 13.56 ± 0.63 (ng/mg), p<0.001] (Fig 5.8). This was concomitant with 
depletion of dopamine metabolite, DOPAC and HVA in the lesioned hemisphere compared 
to the unlesioned hemisphere by ~ 55% and ~59% respectively [(Table 5.3)]. In animals 
treated with GW855266X (5mg/kg) for 7 days, drug withdrawal for 7 days led to the loss of 
neuroprotective effects of the treatment. This was reflected in significant depletion of 
striatal dopamine levels in the lesioned hemisphere that reached similar levels to the 
lesioned hemisphere of the vehicle treated animals [Drug treated- lesioned: 4.75± 2.29 
(ng/mg), vehicle treated -lesioned: 7.23 ± 1.55 (ng/mg), p>0.05] (Fig 5.8). Striatal 
dopamine metabolites, DOPAC and HVA were also significantly depleted by ~60% and 
~56% respectively in the lesioned hemisphere (Table 5.3). Thus, these observations 
indicated that the continuous presence of GW855266X (5mg/kg) following 6-OHDA lesion 
induction was necessary for neuroprotective properties of this compound to be maintained. 
In parallel, withdrawal of pioglitazone (20mg/kg) for 7 days led to a similar loss 
neuroprotective properties of this compound following 6-OHDA lesion induction. This was 
evident in the levels of striatal dopamine, where a significant depletion in the striatal 
dopamine content in the lesioned hemisphere was observed which was even more 
pronounced than  the loss of  striatal dopamine in the lesioned hemisphere in the vehicle 
treated animals (Drug treated lesioned: 4.62 ±2.47 (ng/mg), vehicle treated-lesioned: 7.23 ± 
1.55 (ng/mg), p>0.05). Dopamine metabolites, DOPAC and HVA were also significantly 
depleted by ~85% and 83% respectively following pioglitazone withdrawal for 7 days in 6-
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OHDA lesioned animals; however dopamine turn over in these animals did not increase 
(Table 5.3). 
Hence, continuous presence GW855266X and pioglitazone was vital through out the 
time course of the study after 6-OHDA lesion induction in order to protect dopaminergic 
neurons and preserve dopamine concentration in the striatum.  
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Fig 5.8 Loss of protective effect of pioglitazone and GW855266X on the nigrostriatal 
functionality following withdrawal of the treatments for 7 days after 6-OHDA lesion 
induction. 6-OHDA lesion induction in the lesioned hemisphere compared to the 
lesioned hemisphere in vehicle treated animals. Graph demonstrates the concentration 
of striatal dopamine ng/mg in different groups of treatment off drug. 
In vehicle treated animals the striatal dopamine content was significantly decreased in the 
lesioned hemisphere compared to the unlesioned hemisphere following 6-OHDA lesion 
induction. Withdrawal of   treatment with pioglitazone (20mg/kg)  and GW855266X 
(5mg/kg) for 7 days led to a significant depletion of the dopamine content in the striatum in 
the lesioned hemisphere that represented the same levels dopamine compared to the  
lesioned hemisphere in the vehicle treated 6-OHDA lesioned animals. Results are presented 
as mean striatal dopamine ng/mg of wet tissue weight ±SEM. * p<0.5 ** p<0.01, *** p< 
0.001, ns= not significant. Number of animals was 6/group per treatment group. Treatment 
regime: 
 
 
 
Day 9 
7 days PPAR-γ agonists 
treatment p.o.b.i.d 
 
Day2 
 PPAR agonists 
treatment p.o.b.i.d 
Day 16 
 
 6-OHDA lesion 
 induction 
culling 
Withdrawal of  PPAR-γ 
agonists for 7 days 
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DOPAC (ng/mg) HVA (ng/mg)
Dopamine turnover 
(pmol/mg) 
     Vehicle 
Lesion:      0.81 ± 0.47 
Unlesion:   1.8 ± 0.11 
             p<0.5 
Lesion:     0.13± 0.05 
Unlesion: 0.32 ± 0.02 
          p<0.5 
Lesion:    32.15 ± 4.46 
Unlesion: 17.41 ± 2.43 
             p<0.1 
GW855266X 
   (5mg/kg) 
Lesion:      0.41 ± 0.18 
Unlesion:   1.02 ± 0.08 
            p<0.5 
Lesion:    0.10 ± 0.04 
Unlesion: 0.23 ± 0.02 
        p<0.5 
Lesion:     5.29 ± 1.56 
Unlesion:  8.44 ± 2.42 
                p>0.5 
Pioglitazone 
  (20mg/kg) 
Lesion:     0.29± 0.20 
Unlesion: 2.22 ± 0.64 
             p<0.5 
Lesion:    0.05 ± 0.02 
Unlesion: 0.30± 0.03 
            p<0.5 
Lesion:    5.66 ± 3.68 
Unlesion: 18.65 ± 4.07 
               p>0.5 
 
Table 5.3 Withdrawal of treatment with pioglitazone and GW855266X administered 
for 7 days post 6-OHDA lesion induction led to depletion of the mean concentration of 
striatal dopamine metabolites: DOPAC and HVA that was very similar to the vehicle 
treated group. Dopamine turnover did not change significantly following the 
withdrawal of treatment in the 6-OHDA lesioned hemisphere compared to the 
unlesioned hemisphere in drug treated and lesioned hemisphere in the vehicle treated 
animals. 
Table shows that in the vehicle treated animals striatal levels of dopamine metabolites, 
DOPAC and HVA were significantly decreased in the 6-OHDA lesioned hemisphere 
compared to the unlesioned hemisphere. In addition in these animals following 6-OHDA 
lesion induction striatal dopamine turn over increased significantly in the lesioned 
hemisphere compared to the unlesioned hemisphere. Withdrawal of treatment with 
GW855266X (5mg/kg) and pioglitazone (20mg/kg) for 7 days led to a significant depletion 
of both DOPAC and HVA in the 6-OHDA lesioned hemisphere compared to the unlesioned 
hemisphere. However, normalisation of striatal dopamine turn over in the 6-OHDA lesioned 
hemisphere was still observed after withdrawal of the treatments compared to the 
unlesioned hemisphere. Concentration of striatal dopamine metabolites are shown as ng/mg 
of wet tissue weight ±SEM. Mean striatal monoamine turnover ratio was calculated using 
the expression ((DOPAC+HVA)/DA). Number of animals was 6/group per treatment group. 
p<0.5 was considered significant. 
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5.3.6.2 The effects of withdrawal of GW855266X (5mg/kg) and pioglitazone (20mg/kg) 
after 7 days of treatment on the number of TH+ve dopaminergic neurons in the SNc 
following 6-OHDA lesion induction 
 
To evaluate whether the effect of treatment with of GW855266X (5mg/kg) and 
pioglitazone was long lasting, the treatments were administered starting 2 days after 6-
OHDA lesion induction p.o.b.i.d. for 7 consecutive days. Thereafter, drugs were withdrawn 
for 7 days and brains were collected on day 16 after 6-OHDA lesioning. Cell counts in the 
SNc on day 16 revealed that in vehicle treated animals a significant number of TH+ve 
dopaminergic neurons were lost in lesioned hemisphere compared to the control unlesioned 
hemisphere following 6-OHDA lesion induction (lesioned: 37.25  ± 3.20, unlesioned: 72.5 
± 6.53, p<0.001) (Fig. 5.9) Withdrawal of treatment with GW855266X (5mg/kg) for 7 days 
following 6-OHDA lesion induction led to the loss of observed neuroprotective properties 
of this compound in the SNc. Nigral TH+ve dopaminergic cell counts revealed that the 
extent of TH+ve dopaminergic neuronal loss in these animals reached the level of loss 
observed in the lesioned hemisphere of the vehicle treated group (Drug treated- lesioned: 
30.0± 4.30, vehicle treated -lesioned: 37.25 ± 3.20, p>0.05) (Fig 5.9).  
  
This observation further indicated that the neuroprotective effects of GW855266X 
were not long lasting after drug withdrawal and continuous presence of this compound is 
necessary to maintain neuroprotection. In parallel, TH+ve cell counts in the SNc revealed 
that after pioglitazone withdrawal for 7 consecutive days, a significant number of TH+ve 
dopaminergic neurons were lost following 6-OHDA lesioning. The degree of cells death 
was similar to the loss seen in the lesioned hemisphere of the vehicle treated animals (Drug 
treated lesioned: 38.2 ±7.59, vehicle treated-lesioned: 37.25 ± 3.20, p>0.05) (Fig 5.9). 
Taken together, our findings suggested that continuous presence of GW855266X 
and pioglitazone is necessary for their neuroprotective properties in the SNc and 
preservation of dopamine and its metabolites in the striatum following 6-OHDA lesion 
induction. 
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Fig 5.9 Loss of neuroprotective effect of pioglitazone and GW855266X when 
withdrawn for 7 days after therapy for 7 days post 6-OHDA lesion induction. The 
extent of nigral TH+ve dopaminergic neuronal loss in the lesioned hemisphere was 
similar to the lesioned hemisphere in the vehicle treated animals. Graph demonstrates 
the number mean number of TH+ve dopaminergic neurons in the SNc of different 
treatment groups 
In vehicle treated animals the number of TH+ve dopaminergic neurons significantly 
decreased in the lesioned hemisphere compared to the unlesioned hemisphere following 6-
OHDA lesion induction. Withdrawal of treatment with both pioglitazone (20mg/kg) and 
GW855266X (5mg/kg) for 7 days after lesion induction led to a significant decrease in 
TH+ve dopaminergic neuronal cell number in the lesioned hemisphere similar  to the 
lesioned hemisphere in vehicle treated 6-OHDA lesioned animals. Results are presented as 
mean number of cells ±SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant. 
Number of animals was 6/group per treatment group. 
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5.3.7 Continuous presence of GW855266X and pioglitazone was necessary for the 
exertion of anti-inflammatory properties 
5.3.7.1 Withdrawal of GW855266X (5mg/kg) and pioglitazone (20mg/kg) for 7 days 
led to loss of suppressive effect on the activated OX6+ve and CD68+ve 
microglia/macrophages in the SNc following 6-OHDA lesioning 
 
To evaluate whether continuous presence of GW855266X (5mg/kg) and 
pioglitazone (20mg/kg) was necessary to maintain suppression of inflammation in the SNc 
following 6-OHDA lesion induction, treatments were administered p.o.b.i.d. for 7 
consecutive days starting from day 2 after 6-OHDA lesion induction, thereafter the drugs 
were withdrawn for days and brains were collected on day 16. In the vehicle treated group 
cell counts in the SNc revealed that the number of OX6+ve microglial cells significantly 
increased in the 6-OHDA lesioned hemisphere compared to the unlesioned hemisphere 
(lesioned: 31.50± 7.97, unlesioned: 0.83± 0.30, p<0.001) (Fig 5.10A). OX6+ve microglia 
appeared morphologically active with enlarged somas and thickened processes. These cells 
focally accumulated in the medial and lateral portions of the SNc in the lesioned hemisphere. 
Interestingly, in the drug treated groups withdrawal of GW855266X (5mg/kg) for 7 days led 
to loss of its suppressive effect on OX6+ve microglia. A significant activation of OX6+ve 
microglia, which was characterised by increase in their number and activated phenotype, 
following drug withdrawal was observed in the SNc. The extent and localisation of 
microglial activation in these animals was similar to the lesioned hemisphere in the vehicle 
treated group (Drug treated-lesioned: 21.0± 6.37, vehicle treated-lesioned: 31.50± 7.97, 
p>0.05) (Fig 5.10A). In parallel, in the vehicle treated animals cell counts in the SNc 
revealed that the number of CD68+ve macrophages increased significantly in the lesioned 
hemisphere following 6-OHDA lesioning compared to the unlesioned hemisphere ( lesioned: 
33.63 ±5.15, unlesioned: 0.0. p<0.001). CD68+ve macrophages had an amoeboid 
macrophage-like appearance with accumulation of granular staining in the lysosomal 
membranes indicating phagocytic activity. Localisation of CD68+ve cells was very similar 
to OX6+ve microglia in the lateral and medial portions of the SNc. Withdrawal of 
GW855266X (5mg/kg) for 7 days led to loss of suppressive effect on CD68+ve 
macrophages in the SNc. This was characterised by a significant increase in the number of 
activated CD68+ve macrophages in the SNc in the lesioned hemisphere. In these animals, 
the extent of CD68+ve macrophage activation in the lesioned side reached a similar number 
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as observed in the vehicle treated animals (Drug-treated lesioned: 37.67 ±6.17, vehicle 
treated-lesioned: 33.63 ±5.15, p>0.05) (Fig 5.10B). 
Thus, these data suggest that the continuous treatment with GW855266X was 
essential for the drug to be able to exert significant anti-inflammatory hence neuroprotective 
properties in the SNc.  
Pioglitazone withdrawal for 7 days following 6-OHDA lesion induction also led a 
loss of suppressive effect of this drug on inflammation in the SNc. Following drug 
withdrawal, a significant increase in the number of OX6+ve microglia in the SNc was 
observed. The extent and localisation of microglial activation in the lesioned hemisphere 
was similar to the lesioned hemisphere in the vehicle treated group (Drug treated-lesioned: 
32.60± 6.04, vehicle treated-lesioned: 31.50± 7.97, p>0.05). Concomitantly, cell counts for 
CD68+ve macrophages showed a significant increase the extent of CD68+ve macrophages 
activation that reached a similar proportion to the lesioned hemisphere in vehicle treated 
animals (Drug-treated lesioned: 26.20 ±4.69, vehicle treated-lesioned: 33.63 ±5.15, p>0.05). 
Hence, withdrawal of pioglitazone (20mg/kg) treatment after 6-OHDA lesion induction 
resulted in exacerbation of microglia/macrophage reactivity that was characterised by 
increases in their number and activated morphology. 
Taken together, the continuous presence of GW855266X (5mg/kg) and pioglitazone 
(20mg/kg) was necessary to maintain a suppressive effect on the activated OX6+ve and 
CD68+ve microglia/macrophages in the SNc following 6-OHDA lesion induction. 
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Fig 5.10 Loss of anti-inflammatory effect of treatment with PPAR-γ agonists after 7 days of 
withdrawal of treatments following 6-OHDA lesion induction. This is demonstrated as 
significant increase in the number of OX6+ve and CD68+ve microglia/macrophages in the SNc 
ipsilateral to the 6-OHDA lesioned hemisphere to a similar extent as the lesioned hemisphere 
in the vehicle treated animals. 
Graph A: Shows the number of OX6+ve microglia in the SNc in the vehicle and PPAR-γ agonists 
[pioglitazone (20mg/kg) and GW855266X (5mg/kg)]. Immunohistochemistry was performed with 
OX6 antibody that detects the population of microglial cells expressing MHC II antigens. In the 
vehicle treated animals, the number of OX6+ve microglial cells increased significantly following 6-
OHDA lesion induction. Withdrawal of both pioglitazone (20mg/kg) and GW855266X (5mg/kg),  
after 7 days of treatment,  resulted in a significant increase in the number OX6+ve microglial cells 
in the SNc ipsilateral to 6-OHDA lesion side that reached similar proportion to the lesioned 
hemisphere in vehicle treated animals. Results are presented as mean number of cell± SEM. * p<0.5 
** p<0.01, *** p< 0.001, ns= not significant.  Number of animals was 6/group per time point. 
Graph B: Shows the number of CD68+ve macrophages in the SNc in the vehicle and PPAR-γ 
agonists [pioglitazone (20mg/kg) and GW855266X (5mg/kg)]. Immunohistochemistry was 
performed with CD68 antibody that detects phagocytic macrophages. In the vehicle treated animals 
the number of CD68+ve microglial cells increased significantly following 6-OHDA lesion induction. 
Withdrawal of both pioglitazone (20mg/kg) and GW855266X (5mg/kg),  after 7 days of treatment,  
resulted in a significant increase in the number CD68+ve macrophages in the SNc ipsilateral to 6-
OHDA lesion side that reached a  similar proportion to  the lesioned hemisphere in vehicle treated 
A
B
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animals.  Results are presented as mean number of cell± SEM. * p<0.5 ** p<0.01, *** p< 0.001, 
ns= not significant.  Number of animals was 6/group per time point.  
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5.3.7.1 Withdrawal of GW855266X (5mg/kg) and pioglitazone (20mg/kg) for 7 days led to 
loss of suppressive effect on both MMP-3 and MMP-9 expressing cells in the SNc 
following 6-OHDA lesioning 
  
To assess whether the inhibitory affects of GW855266X (5mg/kg) and pioglitazone 
(20mg/kg) on MMP-3 and 9 +ve cells was reliant on its continuous presence in the brain 
throughout out the duration of the study the animals were treated with GW855266X 
(5mg/kg) and pioglitazone (20mg/kg) p.o.b.i.d. for 7 consecutive days starting from day 2 
after 6-OHDA lesion induction. Thereafter treatments were withdrawn for 7 days after 6-
OHDA lesioning. In vehicle treated animals, cell counts in the SNc on day 16 after lesion 
induction showed a significant increase in the number of MMP-3+ve cells in the 6-OHDA 
lesioned hemisphere compared to the unlesioned hemisphere (lesioned: 25.17 ±2.05, 
unlesioned: 9.0 ± 2.04 , p<0.001 ) (Fig 5.11 A). Interestingly, in the GW855266X (5mg/kg) 
treated group drug withdrawal for 7 days following 6-OHDA lesion induction led to loss of 
inhibitory effect of GW855266X on the number of MMP-3 expressing cells. The  number 
of MMP-3+ve cells significantly increased in the SNc on the side of the lesion that reached 
similar levels to the lesioned hemisphere in the vehicle treated group following drug 
withdrawal (Drug treated-lesioned: 23.33 ± 1.74, vehicle treated-lesioned: 25.17 ±2.05, 
p>0.5) (Fig 5.11A). A similar effect was also observed following withdrawal of 
pioglitazone (20mg/kg) for 7 days after 6-OHDA lesion induction. In  pioglitazone 
(20mg/kg) treated group drug withdrawal led to a significant increase in the number of 
MMP-3+ve cells in the SNc on the side of the 6-OHDA  lesion, the number of these cells 
reached similar levels to the lesioned hemisphere in the vehicle treated animals (Drug 
treated-lesioned: 20.00 ± 1.29, vehicle treated-lesioned: 25.17 ±2.05, p>0.5) (Fig 5.11A). 
 In parallel, in vehicle treated animals, MMP-9+ve cells increased in number 
significantly on the side of the lesion compared to the unlesioned side following 6-OHDA 
lesion induction  (lesioned: 25.82 ± 2.57, unlesioned:  10.64 ±1.01, p<0.001) (Fig 5.11B). 
Not surprisingly, in GW855266X (5mg/kg) treated group drug withdrawal for 7 days 
following 6-OHDA lesion induction resulted in a significant increase in the number of 
MMP-9+ve cells in the SNc on the side of the lesion that reached similar levels to the 
lesioned hemisphere in the vehicle treated animals (Drug treated-lesioned: 23.29 ± 2.74, 
vehicle treated-lesioned: 25.82 ± 2.57, p>0.5) (Fig 5.11B).  Similarly in pioglitazone 
(20mg/kg) treated group drug withdrawal for 7 consecutive days following 6-OHDA lesion 
induction resulted in a significant increase in the number of MMP-9+ve cells in the SNc in 
the lesioned hemisphere that reached similar levels to the lesioned hemisphere in the vehicle 
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treated group (Drug treated-lesioned: 24.50 ± 2.14, vehicle treated-lesioned: 25.82 ± 2.57, 
p>0.5) (Fig 5.11B).    
 
Taken together, our data demonstrated that continuous presence of GW855266X and 
pioglitazone after 6-OHDA lesion induction was crucial for the anti-inflammatory and 
neuroprotective properties of these compounds in the SNc and the striatum.  
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Fig 5.11 Loss of inhibitory effect on MMP-3 and MMP-9 expressing cell after 
withdrawal of PPAR-γ agonists for 7 days starting 2 days after 6-OHDA lesion 
induction leads to significant reduction in the number of both MMP-3+ve and MMP-
9+ve cells in the SNc in the lesioned hemisphere compared to the lesioned hemisphere 
in vehicle treated animals.  
Graph A: Shows the number of MMP-3+ve cells in the SNc in the vehicle and PPAR-γ 
agonists [pioglitazone (20mg/kg) and GW855266X (5mg/kg)] treated animals. 
Immunohistochemistry was performed with MMP-3 antibody that detects the expression of 
the active form of MMP-3 in cells. In the vehicle treated animals the number of MMP-3+ve 
cells increased significantly following 6-OHDA lesion induction. Treatment with both 
pioglitazone (20mg/kg) and GW855266X (5mg/kg) resulted in a significant decrease in the 
number MMP-3+ve cells in the SNc ipsilateral to 6-OHDA lesion side compared to the 
lesioned hemisphere in vehicle treated animals. Results are presented as mean number of 
cell± SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant.  Number of animals was 
6/group per time point. Graph B: Shows the number of MMP-9+ve cells in the SNc in the 
vehicle and PPAR-γ agonists [pioglitazone (20mg/kg) and GW855266X (5mg/kg)] treated 
B
A
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animals. Immunohistochemistry was performed with MMP-9 antibody that detects the 
expression of the active form of MMP-9 in cells. In the vehicle treated animals the number 
of MMP-9+ve cells increased significantly following 6-OHDA lesion induction. Treatment 
with both pioglitazone (20mg/kg) and GW855266X (5mg/kg) resulted in a significant 
decrease in the number MMP-9+ve cells in the SNc ipsilateral to 6-OHDA lesion side 
compared to the lesioned hemisphere in vehicle treated animals. Results are presented as 
mean number of cell± SEM. * p<0.5 ** p<0.01, *** p< 0.001, ns= not significant.  Number 
of animals was 6/group per time point.  
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5.4 Discussion 
 
To elucidate the significance of the inflammatory response in the SNc, this study 
was designed to explore the effects of modulation of glial activity via activation of   PPAR-
γ sub-type following 6-OHDA induced lesion into the MFB.  Therefore, 6-OHDA lesioned 
male SD rats were treated with two PPAR-γ agonists and for comparison purposes, one 
PPAR-δ agonist using different treatment regimes. The first compound studied, 
GW855266X, was developed by GSK and was administered with an effective dose of 
(5mg/kg), recommended by GSK from their internal in vitro studies.  The next compound 
was pioglitazone that belongs to the family of TZDs and is a clinically prescribed drug for 
treatment of type 2 diabetes. Pioglitazone was used as a reference compound in our study. 
The final compound that was a PPAR-δ agonist (GW610742X) also developed by GSK was 
administered with a dose of (10mg/kg), recommended by GSK from their internal in vitro 
studies.   
Our initial study was designed to determine whether the compounds exert 
neuroprotective and anti-inflammatory effects in the 6-OHDA model of PD. Since very 
little is known about the time course of action of these compounds  our study was designed  
to treat the animals with each of the compounds for 7 days prior to 6-OHDA lesion 
induction and continue for 7 day afterwards. As demonstrated in preceding chapters 
activated microglial cells are present in the SNc from day 2 after 6-OHDA lesion induction 
and increase in a time dependent manner. Therefore, in this study we tested whether 
presence of GW855266X and pioglitazone prior to 6-OHDA lesioning and continued for 
further 7 days after 6-OHDA lesion induction would halt inflammation hence yield 
neuroprotection. 
Treatment with GW855266X and pioglitazone before and after 6-OHDA lesion 
induction preserved striatal dopamine and protected dopaminergic neurons in the SNc. 
Indicating that continuous presence of GW855266X or pioglitazone before and after 6-
OHDA lesion induction exerted significant neuroprotective effect with preservation of the 
functionality of the nigrostriatal tract. Concomitantly, the number OX6 and CD68+ve 
microglia/macrophages decreased significantly yet partially following treatments before and 
after 6-OHDA lesion induction. However, treatment with PPAR-δ agonist did not show any 
preservation of dopamine concentration in the striatum, hence it was not protective 
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following 6-OHDA lesioning; confirming the effect of PPAR agonists is via the γ receptor 
sub-type.  It is noteworthy however that a recent study demonstrating that a PPAR-δ 
selective agonists exerted neuroprotective effects in MPTP mouse model of PD when it was 
focally injected into the brain’s ventricles (Iwashita et al., 2007). This could indicate that 
the PPAR-δ agonist we tested had poor BBB permeability. These preliminary findings led 
us to study GW855266X and pioglitazone in a more clinically relevant treatment regime 
where treatments were administered p.o.b.i.d 2 days after 6-OHDA lesion induction for 7 
consecutive days. The findings from this study are discussed in the following sections.  
5.4.1 Continuous treatment with GW855266X or pioglitazone starting 2 days after 
6-OHDA lesion induction was neuroprotective and anti-inflammatory 
 
The choice of treating the animals on day 2 after 6-OHDA lesion induction was 
made because as described in the previous chapters glial response in the SNc is detectable 
from day 2 after 6-OHDA lesion induction. Therefore, to achieve beneficial effects it is 
feasible to aim for modulation of glial activity upon their activation. The experiment was 
terminated on day 9 after lesioning because on day 9 significant loss of TH+ve 
dopaminergic neurons started to manifest in the SNc and dopamine depletion in striatum 
was also significant. 
As demonstrated in our results, treatment with GW855266X and pioglitazone 
starting 2 days after 6-OHDA lesion induction for 7 consecutive days attenuated TH+ve 
dopaminergic neuronal cell death in the SNc, hence protected the integrity of dopaminergic 
neurons in this area. This was concomitant with prevention of dopamine depletion in the 
striatum following 6-OHDA lesion induction. This observation further indicated that PPAR-
γ agonists (GW855266X and pioglitazone) preserved the functional activity of the 
nigrostriatal tract and protected dopaminergic neuronal terminals in the striatum on day 9 
after lesion induction compared to vehicle treated group. 
In parallel, our data demonstrated that treatment with GW855266X and pioglitazone 
2 days after 6-OHDA lesion induction significantly decreased the glial response in the SNc. 
The glial response as mentioned in the previous chapters was characterised by increase in 
the number of activated OX6 and CD68+ve microglia/macrophage as well as their 
immunophenotypic changes in the SNc. As discussed in Chapter 3 (see section 3.5.1) 
activated microglia/macrophages undergo morphological changes and transform from a 
resting ramified morphology to an amoeboid morphology with short and thick processes 
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(Kreutzberg, 1996). Presence of OX6+ve microglia indicated that this sub-population of 
activated microglia underwent immunological changes acquiring the ability to process and 
present antigens. Treatment with GW855266X (5mg/kg) or pioglitazone (20mg/kg) for 7 
days led to significant and partial decrease in the number of activated OX6+ve microglia in 
the medial and lateral portions of the SNc. This supports the significance of microglial 
activation and their association with dopaminergic neuronal cell death following 6-OHDA 
lesion induction. Indeed, other studies have shown that oral treatment with the PPAR-γ 
agonist pioglitazone reduced OX6+ve microglial cell number in the SNc and protected 
dopaminergic neurons in the SNc following LPS injection into the striatum (Hunter et al., 
2007). In addition, several other studies have shown that oral administration of PPAR-
γ agonists partially protected dopaminergic neurons against MPTP administration and this 
was associated with inhibition of glial response in the SNc (Teismann and Ferger 2001; 
Breidert et al. 2002; Feng et al. 2002; Dehmer et al. 2004). ). In our study partial inhibition 
of microglial activation was associated with a significant protection of dopaminergic 
neurons and preserved striatal dopamine content. Indicating that reactive gliosis could be   
damaging if microglia are over- activated (Streit et al., 1999). 
 
GW855266X and pioglitazone treatment after 6-OHDA lesion induction, not only 
affected the number of OX6+ve microglia but there was also a total inhibition of CD68+ve 
macrophages in the SNc following GW855266X treatment. The amount of CD68 
expression in a single cell can be correlated to phagocytic activity of the respective cell type 
(Damoiseaux et al., 1994). One possible explanation for the absence/ reduction of CD68 
expressing phagocytic macrophages in the SNc following treatment with GW855266X and 
pioglitazone could be the almost total protection of dopaminergic neurons in the SNc where 
no cell debris or apoptotic neurons were present to stimulate phagocytic activity and 
clearance. In addition, PPAR-γ agonists might have inhibited the phenotypic conversion of 
monocytes to macrophages in the SNc (Ricote et al., 1998). PPAR-γ is expressed on cells of 
monocyte/macrophage lineage including brain resident microglia (Ricote et al., 1998; 
Bernardo et al., 2002). Evidence suggests that PPAR-γ receptor stimulation inhibits the 
activation of macrophages by interfering with the transcriptional induction of genes 
involved in their differentiation, such as MMP-9 which is up regulated during macrophage 
activation and contributes to tissue damage in acute and chronic inflammation (Welgus, 
1990; Matrisian, 1992) and iNOS (Ricote et al., 1998).  Differentiation of the bone marrow 
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derived monocytes into OX6 and CD68+ve microglia/macrophages in the SNc following  
MPTP administration (Rodriguez et al., 2007) was blocked by  PPAR-γ agonists that has 
been shown to be a negative regulator of microglia/ macrophage activation and 
differentiation, ( Ricote et al., 1998). PPAR  agonists were also found to inhibit production 
of inflammatory cytokines such as TNF-α in monocytes (Jiang et al., 1998). 
In line with these findings, our data further demonstrated that concurrent with a 
reduction in the microglial response, treatment with GW855266X and pioglitazone led to 
decrease in the number of MMP-3 and MMP-9+ve cells in the SNc. As demonstrated in 
Chapter 4 neuronal MMP-3 and 9 expressions increased significantly prior to dopaminergic 
neuronal loss and was associated with microglial activation (see Chapter 4, section 4.3.1). 
A decrease in the number of both MMP-3 and 9+ve cells following GW855266X or 
pioglitazone treatment reflects their role in the local activation of microglia. However, the 
number of MMP-3 and MMP-9+ve cells was not entirely eliminated by GW855266X and 
pioglitazone. Evidence suggests that MMPs are involved in microglial activation and 
differentiation in the SNc (Kim et al., 2005; Kim et al., 2007). Hence, partial inhibition of 
MMP-3 and 9 by GW855266X and pioglitazone could be one possible explanation for 
partial inhibition of 6-OHDA induced OX6+ve activated microglia in the SNc. The 
mechanism by which MMPs specifically MMP-3 and MMP-9 leads to microglial activation 
is not yet fully understood. Indeed, ECM molecules such as laminin and fibronectin, are 
substrates for MMPs being modified or cleaved by MMPs to release their soluble forms 
which regulate microglia/macrophages function (Chamak and Mallat, 1991; Tate et al., 
2007). In support of our findings, a recent study has demonstrated that neuroprotection and 
reduction in the infarct size in a model of stroke was associated with decreased MMP-9 
expression following treatments with a non TZD PPAR-γ agonist (Pereira et al., 2005). 
Treatment with GW855266X and pioglitazone after 6-OHDA lesion induction 
protected > 90% of dopaminergic neurons in the SNc however, activated microglial cells 
namely OX6+ve microglia were only partially inhibited by ~68%. Interestingly, even partial 
inhibition of activated microglia protected dopaminergic neurons from 6-OHDA toxicity 
further emphasising the detrimental effects of microglial response in the SNc.  Alternatively, 
there may also be a direct protective effect of GW855266X and pioglitazone on 
dopaminergic nerve cells leading secondary reduction in MMP-3 and 9 expressions and 
microglial activation. Pioglitazone is currently used as an antidiabetic agent that enhances 
basal glucose uptake by regulation of glucose transporters in peripheral tissue (Smith et al., 
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2001). In neuronal tissue, the effects of pioglitazone and other members of 
thiazolidinediones on glucose homeostasis has not yet been investigated. However, 
following 6-OHDA lesion induction, reduced glucose metabolism has been observed on the 
lesioned side of the brain (Carlson et al., 1999; Casteels et al., 2008). Therefore, it is 
feasible to suggest that GW855266X and pioglitazone could induce an increase in glucose 
uptake which could  partially protect dopaminergic neurons from death inducing effects of 
hypoglycemia (For review see, Suh et al., 2007). Such effects could be investigated in vitro 
studies.  
It is beyond the scope of this thesis to explore these mechanisms in detail. However , 
PPAR-γ activation  leads to regulation of gene expression by heterodimerization  with 
another nuclear receptor, the retinoid X receptor α (RXR), and this complex binds to 
specific DNA sequence elements termed peroxisome proliferator response elements (PPREs) 
on target genes, leading to responsive gene expression (Kleiwer et al., 1992). On the other 
hand, PPARs also act to inhibit pro-inflammatory gene expression and do so through 
mechanisms which are not reliant upon their DNA binding ability. Through various 
mechanisms, PPARs can suppress the activities of many distinct families of transcription 
factor. In most cases, agonist-induced activation of the PPAR is required for effective 
transrepression to occur, regardless of the specific controlling mechanism that is being 
induced.  
Ghisletti and colleagues (2007) have recently described a novel mechanism of 
PPAR-γ mediated transrepression of NFκB regulated inflammatory genes.  NFκB-regulated 
inflammatory genes are maintained in a repressed state through their association with 
nuclear receptor co repressor (N-CoR) containing complexes. Upon exposure to pro-
inflammatory stimuli this complex is dissociated and gene expression initiated. If PPAR-γ 
agonists are present they bind to the PPAR-γ and this ligand–receptor complex is then 
modified by the addition of a Small Ubiquitin-related Modifier (SUMO) moiety. This 
modified receptor then binds to N-CoR complexes that are resident on the promoters of 
NFκB-regulated genes and prevents the dismissal of the co repressor complex, thus 
preventing inflammatory gene expression (Pascual et al., 2005). This proposed mechanism 
is supported by in vivo studies in the MPTP model of PD, where an increase in expression 
of the inhibitory protein-kappa-B alpha (IκBα) and inhibition of translocation of the NFκB 
subunit p65 to the nucleus in dopaminergic neurons, glial cells and astrocytes correlates 
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with the protective effects of pioglitazone via blockade of NFκB activation and iNOS 
induction (Dehmer et al., 2004).  
Despite the substantial amount of data, including our study, that demonstrate the 
anti-inflammatory effects of PPAR-γ agonists being the main property of these compounds 
that leads to neuroprotection, other mechanisms of neuroprotection could not be ruled out. 
Indeed a recent study demonstrated that PPAR-γ agonist rosiglitazone protected 
hippocampal and dorsal root ganglion neurons by a mechanism involving Bcl-2 up-
regulation and  inhibition of neuronal apoptosis (Fuenzalida et al., 2007). As demonstrated 
in chapter 3 (see section 3.4.5.1) Caspase-3+ve apoptotic neurons were present in the SNc 
following 6-OHDA lesioning. In addition, PPAR-γ agonists might modulate excitotoxic 
effects of excess glutamate in the SNc, by increasing the expression of GLT1/EAAT2, 
glutamate transporter in the SNc hence, removing excess extracellular glutamate and protect 
neurons from excitotoxicity and death (Romera et al., 2007). 
Taken together, continuous treatment with GW855266X (5mg/kg) and pioglitazone 
(20mg/kg) starting 2 days after 6-OHDA lesion induction protected dopaminergic neurons 
in the SNc and preserved dopamine content in the striatum. The observed neuroprotective 
properties were at least partly mediated via inhibition of the inflammatory response 
following 6-OHDA lesion induction.  
 
 5.4.2 Continuous treatment with GW855266X or pioglitazone was crucial for the 
treatments to be neuroprotective and anti-inflammatory 
 
In order to address the question whether the effects observed with either 
pioglitazone or GW855266X treatment were long lasting, animals were treated with 
GW855266X (5mg/kg) or pioglitazone (20mg/kg) starting 2 days after 6-OHDA lesion 
induction for 7 consecutive days. The treatments were withdrawn for further 7 consecutive 
days and the brains were collected on day 16 after 6-OHDA lesioning. This study mainly 
demonstrated that withdrawal of treatment with pioglitazone and GW855266X after 6-
OHDA lesion induction led to a return of significant dopaminergic neuronal cell death in 
the SNc and a depletion of dopamine in the striatum. However, unlike the vehicle treated 
group in these animals, dopamine turnover did not increase on day 16 after 6-OHDA 
lesioning. The reason for this is not clear in our study but could be due to direct effect of 
PPAR-γ agonists on dopamine itself, further studies in which treatments are given on their 
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without 6-OHDA lesion would be useful in determining the effects of PPAR-γ agonists on 
dopamine and its metabolites. The extent of neuronal cell loss and dopamine depletion 
reached similar levels observed in the vehicle treated animals suggesting that the effects of 
GW855266X and pioglitazone completely negated after 7 days of treatment withdrawal. In 
addition,  withdrawal  of treatment for 7 consecutive days led to an increase in the number 
of activated OX6 and CD68+ve macrophages in the SNc after 6-OHDA administration  that 
were morphologically active. OX6 and CD68+ve microglia/macrophages had hypertrophied 
cell bodies and thickened processes. The extent of microglial activation reached similar 
levels to that observed in the vehicle treated animals 16 days after 6-OHDA suggesting that 
the anti-inflammatory effects of GW855266X and pioglitazone were not long lasting when 
the compounds were withdrawn.  These findings were also reflected in the significant 
increase in the number MMP-3 and MMP-9+ve cells in the SNc, indicating that 
inflammation in the SNc following 6-OHDA lesion induction is an ongoing process and 
continuous presence of PPAR-γ agonist is essential in order to maintain its anti-
inflammatory and hence neuroprotective properties. Time course studies in Chapter 3 and 4 
indicate that on day 15  after 6-OHDA lesion induction active microglia are still present in 
the SNc and further studies in which PPAR-γ agonist treatment is extended past this 
window may be more beneficial in halting microglial activation. Our data indirectly 
supports the mode of action of PPAR-γ agonists that are ligand dependent nuclear receptors 
and continuous presence of the ligand is necessary to evoke cellular changes. Therefore, 
treatment with PPAR-γ agonists relies on adequate presence of its ligand in order to be 
beneficial and maintain its anti-inflammatory and neuroprotective effect.   
Thus, oral administration of PPAR-γ agonists activates a cascade of events involving 
PPAR-γ activation, inhibition of NFκB and iNOS expression in microglia resulting in the 
reduction of active gliosis that leads to protection of dopaminergic neurons in the SNc and 
protects the integrity of the nigrostriatal tract.  
 
Conclusions 
 
This study provides robust evidence that inflammation plays a significant role in the 
initiation and progression of damage to dopaminergic neurons. This was mirrored in the 
neuroprotective and anti-inflammatory effects of PPAR-γ agonists, GW855266X and 
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pioglitazone, in the SNc, following 6-OHDA lesion induction. This study further supports 
potential therapeutic benefits of manipulation of inflammation in PD.  
  
 198
 
Chapter 6 -General Discussion and Future work 
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6.1 A brief overview of the project 
 
 
One of the most challenging and unmet need in PD is to understand the events 
leading to neuronal degeneration. Such information could lead to the development of 
novel drugs that could possibly slow down or even arrest the neurodegenerative process 
in PD. Post-mortem studies have revealed some useful information and insight into the 
pathogenesis of PD, indeed they have demonstrated an association of an innate 
inflammatory response with the neurodegenerative process. Our knowledge of factors 
contributing to the neurodegenerative process is hampered to some degree by the fact 
that donated human tissue for research is often from advanced PD patients, thus 
precluding the examination of factors in the early phases of neurodegeneration. 
Consequently, it is very difficult to judge the true role in the neurodegenerative process 
of factors e.g. microglial activation, found in the terminal stage of the disease. Therefore, 
this project utilized an animal model of PD, namely the 6-OHDA model, to examine the 
role of the innate inflammatory response during initiation and progression of damage to 
dopaminergic neurons. In light of knowledge gained from the time course of the 
inflammatory response in relation to dopaminergic neuronal cell death this project 
further investigated whether manipulation of the inflammatory cascade with anti-
inflammatory agents would be neuroprotective and lead to preservation of dopamine 
content in striatum.  
 
6.2 The summary of the key findings presented in this thesis 
 
1- Activation of microglia/macrophages, characterised by their morphological 
and immunophenotypic transformation, preceded dopaminergic neuronal cell death in 
the SNc following unilateral 6-OHDA lesion induction into the MFB. Activated 
microglia/macrophages were in close vicinity or attached to dopaminergic neurons in 
the SNc from day 3 following lesioning with significant dopaminergic neuronal cell loss  
only occurring from day 9 after 6-OHDA lesion induction concomitant with depletion 
of striatal dopamine. This suggests an active involvement by microglia in the initiation 
and progression of dopaminergic neuronal cell death in the SNc. Furthermore, our data 
demonstrated early phagocytosis of apoptotic neurons by CD68+ve macrophages 
preventing a potential recovery of these neurons. Dopaminergic neuronal cell death was 
  
 200
observed up to day 15 after 6-OHDA lesion induction and was associated with an 
increased numbers of CD68+ve phagocytic macrophages. However, MHC II expressing 
microglia decreased in number from day 9 onwards. This result indicates that the 
microglial response might be self limiting phenomenon that activates a pro-
inflammatory cascade leading to further dopaminergic neuronal death in the SNc. Hence, 
future studies would be necessary to investigate longer survival time points even up to 6 
months. 
2- Up-regulation of MMP-3 and MMP-9 following 6-OHDA lesion induction 
was concomitant with microglia/macrophage activation in the SNc prior to 
dopaminergic neuronal cell death. The time course of MMP-3 up-regulation was similar 
to the appearance of MHC II expressing microglia and decreased by day 15 after lesion 
induction. However, up-regulation of MMP-9 expressing cells was maintained up to day 
15 after lesioning. It is possible that MM-9 might act as a trigger for further pro-
inflammatory changes in the SNc leading to the progression of dopaminergic neuronal 
cell death. Indeed, the interaction between the ECM and neurons plus neuron-glia 
interactions play an important role in microglial activation. This was evident in our 
findings that demonstrated a temporal relationship between neuronal expression of both 
MMP-3 and MMP-9 and microglial activation prior to dopaminergic neuronal cell death 
after 6-OHDA lesioning. These observations were concomitant with up-regulation of 
CD200R expression, further suggesting that once the ECM  is challenged and neurons 
are damaged, signalling factors are released that are rapidly recognised by microglia 
leading to their  activation and consequently neuronal damage and eventually death. 
3- The significance of inflammatory response following 6-OHDA lesion 
induction was evident when treatment with Pioglitazone and PPAR-γ agonist 
(GW855266X) either before or after lesion induction led to the down regulation of 
microglial response and protection of dopaminergic neurons in the SNc with 
preservation of striatal dopamine content.  Indeed, down regulation of both MMP-3 and 
MMP-9 concomitant with inhibition of microglial response was indicative of their 
signalling role in microglial activation. Furthermore, to maintain the neuroprotective 
properties of PPAR-γ agonists their continuous presence was vital as once the drug were 
withdrawn for 7 days the neuroprotective /anti-inflammatory effect were not maintained. 
Taken together, this study for the first time demonstrated that in the 6-OHDA 
model of PD, inflammation that is at least partly triggered by activation of MMP-3 and 
MMP-9 prior to dopaminergic neuronal cell death, is deleterious to dopaminergic 
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neurons. In parallel, the neuron-microglia interaction that keeps microglia quiescence 
was disturbed leading to decreased inhibitory effect of neurons on microglial response 
following 6-OHDA lesioning. This was characterised by a time dependent increase in 
the number of CD200R+ve cells that under normal condition are bound to their ligand 
the CD200 glycoprotein present on neurons. Furthermore, for the first time we 
demonstrated that inhibition of microglial response via activation of the anti-
inflammatory PPAR-γ sub-type, using a novel agonist (GW855266X) and pioglitazone 
as a reference compound, leads to robust neuroprotection in the SNc with preservation 
of dopamine in the striatum.  
The findings presented herein are of significant interest, especially since they are 
in vivo; however it is noteworthy that these data must be interpreted in the context of 
some methodological considerations related to the experimental model of PD employed 
in the current study, which are discussed in the following sections.  
 
 
6.3 Reappraisal of the 6-OHDA model employed in this study and 
some methodological considerations 
 In humans, PD has a slow and progressive nature, whereas the 6-OHDA-lesion 
models may promote rapid cell death. Therefore, different 6-OHDA-lesion rat models 
of PD have been developed to study different stages of PD. 6-OHDA injections into the 
SNc, MFB or striatum have been widely used as methods of inducing degeneration of 
dopaminergic neurons in the nigrostriatal pathway. Nevertheless, depending on the 
location of the injection site, animals present different time courses of progression and 
severity of lesion (Emborg et al., 2004; Deumens et al., 2002; Kirik et al., 1998). The 
model employed in this project was created by injection of 6-OHDA into the MFB in 
order to promote a time dependent partial retrograde loss of dopaminergic neurons in 
the SNc and partial depletion of striatal dopamine. The partial and time dependent 
progression of lesion of the nigrostriatal system represented the early stages of 
idiopathic PD in humans. In the current study, in order to ensure that a partial lesion of 
the nigrostriatal system was generated such that the lesion size may be closer in scale to 
that observed in early stage PD, use of the noradrenalin uptake inhibitor desipramine 
was not employed. Desipramine administration prior to 6-OHDA, leads to an almost 
total destruction of nigrostriatal axons and cell bodies. Desipramine, by preventing 
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uptake and sequestration of 6-OHDA into noradrenergic neurones may result in 
dopaminergic neurons being exposed to a higher concentration of 6-OHDA.  This is 
important, since clearly it would be preferable to investigate the role of inflammation in 
initiation and progression of lesion in the nigrostriatal system and assess the potential 
neuroprotective effects of putative neuroprotective agents in a model system which 
mimics this clinical situation, where some of the nigrostriatal system is still preserved 
and may serve as a substrate for functional regeneration or neuroprotection. It is worth 
noting that toxin injection into the MFB induces dopaminergic cell death retrogradely. 
Thus, this model may provide a more prolonged temporal window for neuroprotective 
effects relative to 6-OHDA injection into the SNc, which probably causes a more rapid 
and dramatic cell death. However, this model did not demonstrate the progressive nature 
of PD as observed in humans. The size of lesion in the SNc did not show any sigficant 
progression after day 9 following 6-OHDA lesioning. This observation could be an 
indication that the 6-OHDA model used in this project, reflects the acute phase of 
dopaminergic cell death and gliosis in the SNc. Therefore, future studies are needed to 
examine long term effects of 6-OHDA on microglial activation and doapminergic 
neuronal cell death in the SNc ( see section 6.5). 
Injection of 6-OHDA to other regions, such as the SN or the striatum was not 
suitable for studying the time course of inflammatory events in association with 
dopaminergic neuronal loss for the following reasons. Studies have demonstrated that 
injection of 6-OHDA into the SNc can promote profound lesions with high degree of 
dopaminergic cell loss (Kondoh et al., 2005) that might mimic the late stages of 
idiopathic PD in humans. Also direction administration of 6-OHDA into the SNc would 
cause additional mechanical damage in the SNc, thus complicating the interpretation of 
the results. Furthermore, single 6-OHDA administration into the striatum only produces 
a mild and regional loss of dopaminergic cells in the SNc. Thus, to obtain the extent of 
cell loss present in newly diagnosed cases of PD it is required to administer  6-OHDA  
into several sites in the striatum, inducing major mechanical damage which would again 
complicate any results obtained. Hence, it was deemed for this study a 6-OHDA lesion 
to the mfb was most suitable. Indeed, there is no perfect animal model that replicates all 
the pathological features of human idiopathic PD, some of the limitations of the 6-
OHDA model employed in this study are discussed below. 
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The clinical and widespread neuropathological alterations seen in PD patients 
are not entirely replicated by intra-cerebral injection of 6-OHDA in rodents. Although 
6-OHDA induces significant decrease of dopamine and dopaminergic fibres in the 
striatum and leads to degeneration of dopaminergic neurons in the SN with preservation 
of non-dopaminergic neurons, it does not affect other brain regions that are affected in 
human PD such as:  anterior olfactory structures, lower brain stem areas or the locus 
coeruleus (Betarbet et al., 2002). In addition, formation of cytoplasmic inclusion bodies, 
known as Lewy bodies, that are hallmarks of PD pathology are not observed in 6-
OHDA lesioned animals. However, in vivo 6-OHDA partial lesion model has been used 
routinely for the purpose of screening potential therapeutic (Lundblad et al., 2002; Asin 
et al., 1995) and neuroprotective drugs (Datla et al., 2003). 6-OHDA robustly mimics 
and reflects many of the molecular changes observed in human PD including oxidative 
stress, altered iron metabolism, mitochondrial dysfunction etc. and it is a suitable model 
for studying the underlying mechanisms involved in the processes that leads to 
dopaminergic neuronal loss including the involvement and role of inflammation 
(Cicchetti et al., 2002; Depino et al., 2003). Despite the mentioned limitations of this 
model it is one the most reliable, reproducible and widely used models of PD. To 
compliment our findings, in future studies it may be informative to carry out similar 
experiments in other experimental models of Parkinsonism. For example, chronic 
treatment of rodents with the pesticide Rotenone (Betarbet et al, 2000a) or the 
proteasome inhibitors such as lactacystin and MG-132 (McKnaught et al, 2002; 2004) 
or Z-Ile-Glu(OtBu)-Ala-Leu-al (PSI) (Zeng et al, 2006), both of which appear to 
replicate the classical neuropathology of PD, but importantly are associated with 
neuropathological changes in other brain nuclei affected in PD and with the formation 
of Lewy body-like inclusions in vivo. 
An additional methodological consideration of the current study may be related 
to the cell counting methodology employed. Indeed, this methodology may potentially 
lead to over or under estimation of cell numbers (neurons and glia). In the current study, 
the numbers of cells were quantified manually in a blind fashion throughout the rostral 
to caudal extent of the SNc. As the cell counting was not performed at pre-determined 
distance intervals as is the case in unbiased stereological methods (Hedreen et al., 1999; 
Baddely et al., 2001) coupled with the thickness of the tissue sections on which 
immunostaining and cell counting was performed (20 µM-thick) the possibility exists 
that the same cells may be present in two sections, leading to possible over estimation 
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of cell numbers. Therefore, our results could be confirmed using unbiased stereological 
methods of cell counting as described by others (Luquin et al., 2006; Aguirre et al., 
2001). However, it is important to note that the approach used to cell counting has been 
employed in previously published studies to ensure that comparable rostral to caudal 
levels of the SNc are sampled between animals. Importantly, this approach provides 
robust and accurate quantification of nigral cell loss (Iravani et al., 2002,2005) and 
neuroprotection (Datla et al., 2001, 2004; Vernon et al., 2005; 2007). Moreover, the 
counting was performed blind to the treatment group and verified by a second operator, 
also blind to the treatment group.  
   
6.4 General discussion of the main findings and possible future 
directions 
 
Following a 6-OHDA challenge to the MFB activated microglia started to 
migrate and proliferate in the SNc in a time dependent manner prior to dopaminergic 
neuronal cell death in the SNc. The local proliferation of activated microglia was 
evident by expression of the Ki67 mitotic marker co-localised with the MHC II 
expressing microglia and their migration was observed by their relocation from the 
medial portion of the SNc to the ventrolateral portion in a time dependent manner. In 
the SNc, OX6+ve microglia appeared earlier than those labelled with CD68. Moreover, 
it was found throughout all time points of our study that the number of OX6+ve 
microglia was slightly greater than that of CD68+ve microglia suggesting that a vast 
proportion of the OX6 +ve cells may acquire a phagocytic phenotype. In fact, it has 
been demonstrated that significant proportion of OX6+ve microglial cells are CD68+ve 
at the site of neurodegeneration after MFB transection (Cho et al., 2003, Cho et al., 
2007). It would be interesting in the future studies to assess the presence of activated 
microglia/macrophages at the actual site of lesion in the MFB and to determine the time 
course of their activation in this region and comparing it to the SNc. This may be useful 
in the assessment of dynamics of the microglial response in the MFB compared to the 
SNc. Our findings clearly demonstrated that following 6-OHDA lesion induction a 
significant increase in microglia/macrophages occurs in the SNc. However, whether this 
is a direct effect of 6-OHDA on microglia or whether it is indirectly induced via other 
cells, remains to be elucidated. Indeed, studies on rat primary mesencephalic cultures, 
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demonstrated that cell death observed following 6-OHDA exposures could be due to 
different factors.  Namely the synergestic effect of 6-OHDA auto-oxidation derived 
ROS and the inhibition of the mitochondrial respiratory chain with early microglial 
activation followed by further  increase in the amounts NADPHoxidase derived ROS 
constitute a relevant and early component of the 6-OHDA-induced neuronal  death 
(Rodriguez-Pallares et al., 2007). These findings are in line with our studies presented 
in this thesis. However, the effect of 6-OHDA on microglial cells per se is not yet 
known, therefore in vitro studies using glial cell cultures on their own would be 
informative to establish whether the effect of 6-OHDA on the activation of glia mainly 
microglia is a direct effect or it requires the presence of neurons or other cells such as 
astrocytes in the culture. In addition, further studies are needed to investigate the origins 
of the microglia /macrophages in our model. This study would address the question of 
what proportion of activated microglia in the SNc are the resident macrophages in the 
brain and to what extent do peripheral blood derived monocytes participate in this 
process and mature to OX6 or CD68 expressing microglia/macrophages in the brain 
parenchyma. Interestingly, a study by Rodriguez et al., (2007) demonstrated that the 
migration of peripheral bone-marrow-derived cells (BMDCs) takes place to the brain 
occurs in the chronic MPTP model of PD. They demonstrated that BMDCs expressing 
enhanced green fluorescent protein (GFP) were present in the SNc before dopaminergic 
neuronal cell death and were mainly microglial cells of a peripheral origin that matured 
to OX6 and CD68 expressing microglia/macrophages in the SNc. Therefore, this study 
provides evidence of increased penetration of BMDC into brain areas before and during 
dopaminergic cell death. The differentiation of BMDC into microglia suggests that cells 
crossing the BBB may participate in the neurodegeneration process (Rodriguez et al., 
2007). Furthermore, these findings imply that the transformation of microglia to antigen 
presenting cells, expressing MHC II antigens, that precedes their transformation to 
phagocytic cells, could be initiated from both the local resident population of microglia 
and some invading BMD cells. However, which one of these processes precedes the 
other is another missing link which needs to be addressed in future studies.  Indeed, 
studies by Carvey, et al (2005) demonstrated that unilateral injections of 6-OHDA into 
the striatum or the MFB produced increased leakage in the BBB in the SNc and striatum, 
as assessed by the leakage of FITC-labelled albumin or horseradish peroxidase from the 
vasculature into the brain parenchyma.  
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The time dependent functional and morphological transformation of microglia in the 
SNc in parallel to dopaminergic cell death, indicates that when dopaminergic cell death 
occurs, the number of phagocytic macrophages also increase to clean up the debris. 
which on its own could be neuroprotective.  Indeed initial activation of 
microglia/macrophages  could be an attempt to protect neurons, importantly the exent 
and the duration of their activation are crucial factors determining the role of glia in the 
CNS following an insult. One of  the  most compelling evidence supporting a critical 
role of microglia in neuroprotection comes from acute axonal injury in rodents. 
Axotomy of facial motoneurons in the periphery triggers a microglial response in the 
facial nucleus almost immediately after the injury has occurred. Within a few days, 
axotomized perikarya are surrounded by activated microglial cells which tightly 
ensheath the injured neurons with their cytoplasmic processes. The number of activated 
microglia in the facial nucleus increases dramatically and suddenly through a 
proliferative burst that lasts from about day 2 to day 4 post-axotomy (Graeber et al, 
1988). In addition production of transforming growth factor-b1 (TGF-β1) mRNA is 
increased in the facial nucleus during the first week post-axotomy and this growth factor 
has been localized to activated microglial cells (Lehrmann et al, 1998). Indeed, it likely 
that many other intercellular communication processes are mediated by the close 
physical apposition of microglia and neurons. Microglia   constantly monitore  the 
neuronal state of viability, which undoubtedly involves many complex signaling events 
(Nimmerjahn et al, 2005). In fact, it is even conceivable that upon early recognition of 
non-viability, microglia may actively hasten the neuron's demise through production of 
toxic molecules, facilitating speedy removal of a non-functional cell (Streit et al, 2002). 
On the other hand, the  over-activation of microglia, as observed in our study, could 
lead to further damage and apoptosis. Apoptotic cells trigger the recruitment of 
phagocytic cells, so as to quickly and effectively remove the dead neurons. Such dying 
cells release chemoattractants, such as fractalkine, a chemokine that is predominantly 
expressed in the brain (Chapman et al., 2000) or the phospholipid 
lysophosphatidylcholine (Lauber et al., 2003) which promotes chemotaxis of primary 
microglia and monocytes. In the early phases of neuronal injury microglia express 
numerous molecules with important immune functions and may stimulate functions 
such as the adaptive removal of synapses from injured neurons (Graeber et al., 1993). 
The loss of synapses, axons and neurons following 6-OHDA lesion induction may 
exacerbate the inflammatory response within the central nervous system towards the site 
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of injury leading to progressive neuronal cell death (Hirsch et al., 1998). In a more 
clinical point of view, similar activation could be elicited by neuronal inclusions, Lewy 
bodies, plaques or viral/bacterial antigens in humans. Microglia, acquire a macrophage 
phenotype and take on the role of removing degenerating synaptic terminals and 
neuronal debris. The inflammatory response around damaged neurons or neurites could 
induce an indiscriminate response similar to chronic inflammation in the cartilage or 
myelin, as observed during autoimmune disease such as rheumatoid arthritis or multiple 
sclerosis (Vowinckel et al., 1997; Banati et al., 1999). This response may result in 
exacerbation of neuronal injury. Activated microglia could participate in the 
neurodegenerative process by releasing soluble factors and enzymes such as TNFα, 
PGE2 ,  INF-γ, reactive nitrogen species ,proteases, ROS, eicosanoids and excitatory 
amino acids which are toxic to neurons (Block and Hong ,2005; Liu and Hong, 2003). 
Among these microglial derived neurotoxic factors, ROS and their downstream 
products have been shown by us and others to contribute significantly to neuronal cell 
loss in PD (Dexter et al., 1987, Dexter et al., 1994, Koutsilieri et al., 2002). It is highly 
likely that microglia-derived neurotoxic factors act in concert, exacerbating their effects. 
For example, TNFα induces the expression of inducible nitric oxide synthase (iNOS) in 
glia, thus amplifying the NO-mediated neuronal loss. Additionally, aging is shown to 
provide a pro-inflammatory environment in the brain and is another factor that amplifies 
the microglial response (Godbout et al., 2005).  Microarray studies on post-mortem 
brain tissue from parkinsonian patients and controls demonstrated an  increased 
expression of genes encoding pro-inflammatory cytokines including, the  TNF receptor 
gene, TNF receptor super family, member 21, and the mitochondrial complex I gene, 
and subunits of the mitochondrial electron transport chain with decreased expression of 
several glutathione related genes in the SNc suggesting a molecular basis for 
inflammatory and oxidative damage to neurons in parkinsonian cases compared to 
controls (Duke et al., 2007). These findings, despite reflecting the end stage of the 
disease, provide clues for future studies on the involvement of inflammation in PD 
pathogenesis.  
This project, for the first time established a potential trigger for activation of 
microglia/macrophage in the SNc following 6-OHDA lesion induction. We 
demonstrated that the microglia response, could to be at least partly mediated by 
expression of different matrix metalloproteinases as signalling molecules. Neuronal 
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expression of MMP-3 and MMP-9 showed a temporal relationship with microglial 
activation and dopaminergic neuronal cell death. The exact cellular and molecular 
events that trigger the release of MMP-3 and MMP-9 enzymes in our model are to be 
investigated in future studies. In addition, the full chemotaxis leading to the focal up-
regulation of MMP-3 and MMP-9 in the SNc, followed by focal activation of microglia, 
remains to be investigated. It seems likely that pre-apoptotic neurons, which were 
detected by the expression of the apoptotic marker caspase-3, release significant 
amounts of MMP-3 and MMP-9. Up-regulation of these enzymes could destabilise the 
ECM that alerts and eventually activates microglial cells. Up-regulation of CD200R, 
which is predominantly expressed on microglia and under homeostasis conditions, is 
engaged with its ligand CD200 on neurons, is a further indication of a disrupted ECM 
and up-regulation of microglia. At this stage, neuronal inhibition of microglia is reduced 
or even lost as consequence of the neurons being pre-apoptotic, hence leading to 
microglial activation.  Additional evidence for MMP-3 release from apoptotic neuronal 
cells was evident in studies by Kim et al., (2007) where MMP-3 was identified in 
degenerating primary mouse mesencephalic cultures treated with MPP+. Furthermore, in 
such studies the inhibition of TNF-α release from activated microglia by the specific 
MMP-3 inhibitor NNGH led to neuroprotection. Up-regulation of MMP-3 and MMP-9   
may contribute to changes in BBB permeability with the ingress of plasma components, 
which contribute in some part to microglial activation (Madena et al., 2000). The 
cascade of events leading to the glial response and cell death in PD following an insult, 
could be further investigated by examining the up-stream mechanisms that induces 
MMP activation in the 6-OHDA model. A search for MMP inducing factors in tumour 
cells has led to the identification of the extracellular matrix metalloproteinase inducer 
(EMMPRIN) molecule (Kataoka et al., 1993; Biswas et al., 1995). EMMPRIN is a cell 
surface glycoprotein composed of two Ig domains in the extracellular region. 
Depending on the cell system, EMMPRIN can stimulate production of MMP-1, -2, -3, 
and 9 (Gabison et al., 2005; Yan et al., 2005). Therefore, studies looking into the gene 
expression profile of this molecule and its expression following 6-OHDA lesion 
induction would be of interest as it could be a new target for therapy in PD that might 
lead to inhibition of inflammation before its initiation.  
The interpretation of our findings in a clinically relevant scenario so far indicates 
that the process of dopaminergic neuronal degeneration in the SNc is initiated following 
the expression of both MMP-3 and MMP-9 with subsequent microglial activation. This 
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process not only enhances death of the damaged dopaminergic neurons but also cause 
apoptosis of the neighbouring dopaminergic neurons. This cycle may create a 
progressive, self-perpetuating degeneration of the dopaminergic neurons in the SNc. 
The progressive nature of PD is best shown in previously mentioned reports in humans 
who had self-administered MPTP 10 to 12 years prior to death. As mentioned in the 
preceding chapters, post-mortem analysis in these subjects revealed activated microglial 
surrounding dopaminergic neurons in the SNc (Langston et al., 1999). Therefore, the 
final part of this project given the significance of the inflammatory response in the SNc, 
explored the effects of modulation of glial activity via activation of   PPAR-γ sub-type 
following 6-OHDA induced lesion into the MFB.   
Our data presented herein demonstrated that a microglial response was evident 
from 2-3 days after 6-OHDA lesion induction. Hence, this is a rapid process and 
considering the progressive dopaminergic neuronal cell death that followed, the glial 
response is most likely to be more damaging than protective. Therefore, we 
hypothesised that inhibition or down-regulation of microglial cells could serve as a 
neuroprotective strategy in PD. To examine this hypothesis we used a novel PPAR-
γ agonist GW855266X (licensed by GSK) and pioglitazone as a reference compound. 
Our data provided robust evidence that oral treatment with GW855266X and 
pioglitazone, either before 6-OHDA lesion induction and continued for 7 days post 
lesion or administered 2 days after 6-OHDA lesion induction continued for further 7 
days, significantly reduced the microglial response in addition to both MMP-3 and 
MMP-9 expression. This was accompanied by a significant protection of dopaminergic 
neurons in the SNc. The nigrostriatal functionality was also preserved indicated by 
normal levels of striatal dopamine and its metabolites. However, continuing presence of 
PPAR-γ agonists was vital for the neuroprotective and anti-inflammatory effects of 
these compounds. As presented in our data withdrawal from this compound led to 
dopaminergic neuronal death and activation of microglia to the same level as the vehicle 
treated animals.  
The exact mechanism of action of PPAR-γ agonists is not yet fully understood in 
the 6-OHDA model. Our drug withdrawal data indirectly supports the known mode of 
action of PPAR-γ agonists, which stimulate nuclear receptors and continuous presence 
of the ligand is necessary to evoke cellular changes. Therefore, treatment with PPAR-
γ agonists relies on adequate presence of its ligand in order to be beneficial and maintain 
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its anti-inflammatory and neuroprotective effect.  Our knowledge regarding the anti-
inflammatory role of PPAR-γ would potentially be aided greatly by comparative 
evaluation of normal and mutant mice that lack PPAR-γ subtypes. However, complete 
elimination of a functional PPAR-γ gene results in embryonic lethality, therefore 
PPAR-γ heterozygote knockout mice (PPARγ+/–) with 50% reduction in PPAR-γ were 
developed. Such mice exhibit resistance to high-fat diet–induced obesity and insulin 
resistance (Kubota et al., 1999; Kadowaki et al., 2000). PPAR-γ mutant permits us to 
investigate the physiological role of PPAR-γ in the immune system that will aid in the 
development of better drug targets. Evidence suggests that PPAR-γ receptor stimulation 
inhibits the activation of macrophages by interfering with the transcriptional induction 
of genes involved in their differentiation, such as MMP-9 which is up regulated during 
macrophage activation and contributes to tissue damage in acute and chronic 
inflammation (Welgus, 1990; Matrisian, 1992) and iNOS (Ricote et al., 1998) (Fig 6.1).  
Differentiation of the bone marrow derived monocytes into OX6 and CD68+ve 
microglia/macrophages in the SNc following  MPTP administration (Rodriguez et al., 
2007) was blocked by PPAR-γ agonists which have been shown to be a negative 
regulator of microglia/ macrophage activation and differentiation, ( Ricote et al., 1998). 
PPAR  agonists were also found to inhibit production of inflammatory cytokines such 
as TNF-α in monocytes (Jiang et al., 1998) (Fig 6.1). 
Despite all this encouraging in vivo evidence, it is noteworthy that almost all putative 
neuroprotective drugs, which have shown promising neuroprotection in vitro and in vivo 
experimental models of PD, have failed to show neuroprotective or disease modifying 
effects in humans. This may reflect limitations of current experimental models of this 
disease (Schapira et al., 2004). One other major problem is the fact that despite evidence 
to suggest that inflammation, excitotoxicity, oxidative stress and UPS defects may all be 
potential pathogenic mechanisms in PD; we still do not know what triggers 
neurodegeneration in the SNc or indeed, any of the other brain regions affected in PD 
(Jenner and Olanow, 2006). Additionally, increasing evidence suggests that PD is not 
simply a single disease, but may in fact be a syndrome associated with different 
aetiologies, that may vary in complexity between individuals (Jenner and Olanow, 2006; 
Langston et al., 2006; Carvey,  et al., 2006). It is apparent, that different signs and 
symptoms of PD manifest at different time points in different individual patients, 
suggesting that the involvement of pathogenic factors may also vary between individual 
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patients which points to the heterogeneity of PD aetiology (Jenner and Olanow, 2006). 
Thus, the possibility that PD is a syndrome, in which different patients may be 
undergoing different pathogenic mechanisms at different times and in different brain 
regions, it is perhaps not surprising that many neuroprotective strategies which are 
aimed at a specific pathogenic event or pathway implicated in PD may fail (Jenner and 
Olanow, 2006). Additionally, to imply anti-inflammatory/neuroprotective therapy for 
PD one major issue is to be able to diagnose PD before the symptoms appear. Because 
once symptoms are present already ~80% of dopaminergic neurons are lost hence 
neuroprotective strategies might not be beneficial due to the profound loss of 
dopaminergic neurons.. This is where biomarkers that specifically reflect onset of 
pathology, directly or indirectly, may have a profound impact on diagnosis making in 
the future. Biomarkers can also be used to determine the efficacy of novel 
neuroprotective strategies and for monitoring the progress of the disease. Research into 
finding the most relevant biomarkers that are indicative of early PD before the 
symptoms occur is a growing field and still there is no definite marker for this disease. 
Studies in this area are ongoing, for example one study using a high field strength MRI 
demonstrated increase of iron in the lateral portion of the SNc in early PD ( Martin et al., 
2008). Other possible biomarkers include biochemical markers where antibodies found 
in the CSF or blood of patients against certain molecules, such as α-synuclein and 
neuromelanin antibodies, oxidative stress and mitochondrial deficit markers. In addition, 
alteration in the ratio of T regulatory cells in the blood may reflect an immune reaction 
before any symptoms of the disease manifest (Baba et al., 2005). On the basis of 
findings of McGeer et al., (2004) who demonstrated immune reactions associated with 
cell death in the SN occur several years before the onset of symptomatic PD, it is 
interesting to note a study which reported PD patients rarely have a cold with high fever 
requiring bed rest, not only during the course of their illness but also before 
symptomatic disease onset (Kawaguchi et al., 1998). This observation indicates that a 
series of peripheral immune alterations might precede the occurrence of immune 
reaction-related inflammation in the brain that could be used as immune related 
biomarkers for PD. Thus, until these issues are resolved or we are able to identify 
specific subsets of PD patients with specific aetiologies and treat them accordingly to 
the pathogenic cascade underlying their disease, a possible useful approach to PD 
treatment may be the use of multi-functional or a cocktail of drugs which are able to 
protect neurones against multiple toxic insults (Jenner and Olanow, 2006). Indeed, 
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support for this idea comes from the development of novel iron chelators which are also 
monoamine oxidase B inhibitors and sequester free radicals result in significantly 
greater neuroprotection in experimental models of PD than compounds with these 
individual activities alone (Zheng et al, 2005; Gal et al, 2005). These data suggest that a 
drug with at least two mechanisms of action, targeting at multiple pathogenic 
mechanisms of the same disease, may offer more therapeutic benefit compared with a 
drug that only targets one disease aetiology (Van der Schyf et al., 2006). To this end, 
treatment with PPAR-γ agonist in our model targets multiple factors involved in the 
pathogenesis of PD. For example, as mentioned earlier the reduction in both MMP-3 
and MMP-9 could stabilise the BBB, hence limiting the invasion of activated blood-
derived leukocytes into the brain (Leppert  et al., 2001; Avolio et al., 2003), plus the 
down regulation of microglia/macrophage activation in the SNc leading to the ultimate 
protection of dopaminergic neurons. In addition, other studies have demonstrated that 
PPAR-γ agonists inhibit neuronal apoptosis (Fuenzalida et al., 2007), modulate 
excitotoxic effects of excess glutamate in the SNc, thus protecting neurons from 
excitotoxicity (Romera et al., 2007), blockade of NFκB activation and iNOS induction 
(Dehmer et al., 2004). PPAR-γ agonists were also found to inhibit production of 
inflammatory cytokines such as TNF-α in monocytes (Jiang et al., 1998).  Therefore, 
PPAR-γ agonists may be promising compounds in modifying PD in future. (Figure 6.2 
shows a simplified schematic diagram of how inflammatory pathway effects 
dopaminergic neurons).  
 
6.5 Future directions 
 
The main findings of this project could be taken further to expand our 
knowledge on the role of immune responses in PD and to identify potential key 
molecules as new drug targets for neuroprotective therapy in PD. The main findings 
presented in this thesis demonstrated that microglial response triggered by expression of 
neuronal MMP-3 and MMP-9 enzymes precedes dopaminergic neuronal loss in PD. 
Furthermore modulation of microglial response concomitant with down regulation of 
MMP-3 and MMP-9 by PPAR-γ agonists reduced the inflammatory response and 
protected dopaminergic neurons in the SNc and restored functional activity of the 
nigrostriatal tract. 
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   To take our studies further and gain more insight into the role of inflammation in 
PD pathogenesis in our model, later time points could be investigated to elucidate later 
phases of microglial activation and changes in signalling molecules both in the SNc and 
striatum and their association with progression of dopaminergic neuronal loss. 
In addition, we could further investigate additional factors that are involved in 
dopaminergic neuronal cell death in the SNc following microglial activation, such as the 
expression profile of pro and anti-inflammatory cytokines at different time points in the 
SNc and striatum, following 6-OHDA lesion induction needs to be assessed. For 
example: Groups of animals (n=6) will be sacrificed at 1,3,5,7,9,11,13,15,21,28, 35 and 
50 days post 6-OHDA lesion induction for changes in cytokine expression profiles in 
the SNc and the striatum.  Cytokines that can be investigated utilising SearchLight 
(ThermoFisher Scientific) cytokine/chemokine rat Arrays (sandwich ELISA) include, 
the anti-inflammatory cytokines (IL-4, IL-6, IL-10, IL-11, 1L-13 and TGF-Β) and pro-
inflammatory cytokines (IL-1β, IL-1α, IL-2, IFNγ, TNFα and MCP-1). In addition, to 
gain more information on degeneration of dopaminergic neurons Fluoro-Jade C 
immunoreactivity which has been utilised as an early marker of degenerating neurons 
could also be employed to see whether the neurons are showing signs of 
neurodegeneration prior to the loss of TH or NeuN expression. In light of data gained 
from the above mentioned studies key molecules in the activation of microglia and the 
neurodegenerative process could be identified and used as targets for neuroprotective 
therapy in PD. To test whether these molecules represent suitable drug targets for 
neuroprotection proof of concept neuroprotective studies utilizing the 6-OHDA model 
would be used. However, knowing that no animal model truly represents all of the 
features of PD hence it is essential to pre-clinically test potential neuroprotective 
compounds in a variety of models displaying different features of PD so as to support 
their use in the clinic. This approach will also enable us to study the nature of innate 
immune response in different models. Therefore in addition to   the 6-OHDA the 
lactacysteine proteasome inhibitor rat models and the MPTP mouse model should also 
be employed. One example of a molecule used as a target for therapy would be the 
expansion of our pilot studies using PPARγ agonist. As demonstrated (see Chapter 5) a 
single dose of PPAR γ agonist in the 6-OHDA model have shown a robust 
neuroprotective effect associated with inhibition of microglial activation after 7 days of 
treatment when animals were killed on drug. Neuroprotection was observed when the 
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PPARγ  agonist was given both as a pre and post 6-OHDA treatment; however this 
neuroprotection was lost in animals where the drug had been withdrawn after 7 days of 
treatment. Therefore, future studies on this compound would be to carry out a dose 
response study in the 6-OHDA model and to investigate whether longer treatment 
results in a long lasting neuroprotection. Two days after the 6-OHDA lesioning, PPAR 
γ agonist (5, 10 or 20mg/kg) or drug vehicle will be administered twice daily by gavage 
for 15 days. 50% of the animals will be killed at the end of the 15 days treatment whilst 
the remainder will be killed after a further 7 days off drug. This aims to investigate 
whether the effect of PPAR-γ agonist would be long lasting after the microglial 
response is down regulated day 15. Similar to this study other potential targets that play 
an active role in the inflammatory/neurodegenerative process in PD could be used. 
However, it is important to carry out the pre-clinical studies on different models of PD 
such as the recent partial lesion model of MPTP in marmosets (Iravani et al., 2005). 
6.6 Conclusion 
 
Microglial activation triggered by expression of MMP-3 and MMP-9 preceded 
dopaminergic neuronal demise in the SNc and was associated with the initiation and the 
process of cell death in the 6-OHDA rat model of PD. Early modulation of glial 
response with PPAR-γ agonists (GW855266X- licensed by GSK) and pioglitazone 
down-regulated the glial response and protected dopaminergic neurons in the SNc with 
preservation of the functional integrity of the nigrostriatal tract. Hence, inflammation 
does play a deleterious role in PD pathogenesis and modulation of microglial response 
could serve as a neuroprotective strategy in this disease. 
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Fig 6.1 After ligand binding (A), PPARs form a PPAR–RXR heterodimeric complex, capable 
of binding to specific response elements, termed PPREs, located in the promoter region of target 
genes. In the absence of ligand, the PPAR–RXR heterodimer is associated with a 
multicomponent corepressor complex, which contains histone deacetylase activity and thus 
maintains the chromatin in an inactive state. Binding of the ligand to PPAR physically 
destabilizes the co-repressor complex and leads to the recruitment of a multicomponent 
coactivator complex, which induces chromatin remodeling by histone acetylation and activates 
the basal transcription machinery resulting in gene activation. PPARs may repress gene 
transcription by a mechanism that is independent of DNA binding (B). This mechanism 
includes interference by PPARs with other transcription factor pathways such as those involving 
NF B, STAT, C/EBP, and AP-1, which modulate the expression of genes involved in 
inflammation pathways. This repression mechanism occurs by interference at different levels of 
these signal transduction pathways: via protein–protein interaction between PPARs and 
transcription factors, leading to the formation of inactive complexes; via competition with, and 
sequestration of, cofactors; via induction of the inhibitor of NF B (I B); and via 
downregulation of gene transcription of membrane receptors of inflammatory cytokines and 
activators.  
Abbreviations: ABCA-1, ATP-binding cassette A1; AP-1, activator protein 1; Apo, 
apolipoprotein; C/EBP, CAAT enhancer binding protein; COX-2, cyclooxygenase type 2; CPT-
I, carnitine palmitoyltransferase I; CRP, C-reactive protein; ET-1, endothelin 1; FABP; 
adipocyte fatty acid binding protein; FAT, fatty acid translocase; FATP, fatty acid transport 
protein; ICAM-1, intercellular adhesion molecule 1; IL-1, interleukin 1; IL-6, interleukin 6; 
LPL, lipoprotein lipase; MCP-1, monocyte chemoattractant protein 1; MMP-9, matrix 
metalloproteinase 9; NF B, nuclear factor B; PPAR, peroxisome proliferator-activated 
receptor; PPRE, peroxisome proliferative response element; RXR, retinoic X receptor; SR-B1, 
scavenger receptor class B1; STAT, signal transducer and activator of transcription; TNF, tumor 
necrosis factor; VCAM-1, vascular cell adhesion molecule. Adapted from:  Gervois P et al. 
(2007) Drug Insight: mechanisms of action and therapeutic applications for agonists of 
peroxisome proliferator-activated receptors Nat Clin Pract Endocrinol Metab 3: 145–156  
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Fig 6.2 Simplified schimatic showing the inflammatory pathways 
contributing to dopaminergic neurodegeneration in PD. 
 Activated microglia releases cytotoxic compounds such as cytokines, TNF-α, 
IFN-γ and IL-1β.  Cytokines have a direct effect on the dopaminergic neurons 
by activating transduction pathways that lead to apoptosis or by inducing the 
expression of iNOS within glial cells and the subsequent formation of NO.  NO 
is membrane permeable and can diffuse into neighbouring dopaminergic 
neurons.  If the neighbouring cell has elevated levels of superoxide, there is 
increased probability that superoxide will react with NO to form the 
peroxynitrite (ONOO-), which can damage lipids, proteins and DNA, which 
ultimately leads to the death of the neurons.  Astrocytes may have a 
neuroprotective effect acting to reduce the numbers of superoxides and 
neurotoxins. The inflammatory response could modulated by PPAR-γ agonists 
that act to inhibit different components of the inflammatory cascade leading 
dopaminergic neuronal cell death  (The diagram was adapted from Schulz et al, 
2004). 
 
 
 
 
 
 
 
 
 PPAR-γ 
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